UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM
10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended May 31, 2017

2020
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Transition Period From
To
.

COMMISSION FILE NUMBER
0-17988

NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

MICHIGAN
 
38-2367843

(State orof other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices, including zip code)

517-372-9200

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE

Title of each Class
Trading
Symbol(s)
Name of each exchange
on which registered
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

COMMON STOCK, $0.16 par value per share

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    
Yes
   No  

Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  
    No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of RegulationS-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  
   No  

Indicate by check mark if disclosure of delinquent filerswhether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to ItemRule 405 of RegulationS-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III
S-T
(§ 232.405 of this Form10-K or any amendmentchapter) during the preceding 12 months (or for such shorter period that the registrant was required to this Form10-K.submit such files).    
Yes
☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or anon-accelerated filer.an emerging growth company. See definitionthe definitions of “accelerated filer and large“large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule
12b-2
of the Exchange Act.

(Check one):

Large accelerated filer  

 
Accelerated filer  
 
Non-accelerated
 filer  
 
Smaller reporting company  

Emerging growth company  

   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Act).    Yes  
    No  

Based on the closing sale price on November 30, 20162019 the aggregate market value of the voting stock held by
non-affiliates
of the registrant was $2,403,000,000.$3,489,079,000. For these purposes, the registrant considers its Directors and executive officers to be its only affiliates.

The number of outstanding shares of the registrant’s Common Stock was 38,211,87352,963,988 on June 30, 2017.


2020.

DOCUMENTS INCORPORATED BY REFERENCE

The Registrant’s

Certain portions of the registrant’s definitive proxy statement to be prepared pursuant to Regulation 14a and filed in connection with solicitation of proxies for its October 5, 20178, 2020 annual meeting of shareholders isare incorporated by reference into part III of thisthe Form
10-K.


TABLE OF CONTENTS

 
ITEM 1.BUSINESS
  4
ITEM 1.
3
 
ITEM 1A.
14
ITEM 1A. 
ITEM 1B.
19
ITEM 2.
19
ITEM 3.
20
ITEM 4.
20
  13 
ITEM 1B.UNRESOLVED STAFF COMMENTS17
ITEM 2.PROPERTIES17
ITEM 3.LEGAL PROCEEDINGS17
ITEM 4.MINE SAFETY DISCLOSURES18
PART II
ITEM 5.
20
  
18
ITEM 6.
22
 
ITEM 6.SELECTED FINANCIAL DATA20
ITEM 7.
23
  21
ITEM 7A.
34
  31
ITEM 8.
34
  31
ITEM 9.
34
ITEM 9A.
34
ITEM 9B.
36
  31
 
ITEM 10.
36
ITEM 9A.CONTROLS AND PROCEDURES  
31
ITEM 11.
38
 
ITEM 9B.OTHER INFORMATION33
PART III
ITEM 10.DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE33
ITEM 11.EXECUTIVE COMPENSATION35
ITEM 12.
38
  35
ITEM 13.
38
  35
ITEM 14.
38
  35 
PART IV
ITEM 15.
38
  
35
ITEM 16.
38
 
40
SIGNATURES37 
F-1
Subsidiaries
  F-1 
Subsidiaries
Consent of independent registered public accounting firm — BDO USA, LLP
 
Section 302 Certification of Principal Executive Officer
 
Section 302 Certification of Principal Financial Officer
 
Section 1350 Certification pursuant to Section 906
 

1

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Annual Report on Form
10-K,
including statements relating to management’s expectations regarding new product introductions; the adequacy of the Company’sour sources for certain components, raw materials and finished products; and the Company’sour ability to utilize certain inventory. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, effects of the ongoing
COVID-19
pandemic on our business, results of operations, liquidity, financial condition, and stock price, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed in item 1A. RISK FACTORS in this Form
10-K
and from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in ITEM 1A. RISK FACTORS and under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Critical Accounting Policies and Estimates,” and “Future Operating Results.”

statements.

In addition, any forward-looking statements represent management’s views only as of the day this Annual Report on Form
10-K
was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

As used in this Annual Report on Form
10-K,
the terms “Neogen,” “the Company,” “we,” “us,” and “our” refer to Neogen Corporation and, where appropriate, its consolidated subsidiaries, unless the context indicates otherwise.
2

PART I

ITEM 1.
BUSINESS

Neogen Corporation and subsidiaries (Neogen or the Company) develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. The Company’sOur Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., dehydrated culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant
by-products,
meat speciation, drug residues, pesticide residues and general sanitation concerns. TheOur diagnostic test kits are generally less expensive, easier to use and provide greater accuracy and speed than conventional diagnostic methods. The majority of the teststest kits are disposable,
single-use,
immunoassay and DNA detection products that rely on the Company’sour proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. The Company’sOur expanding line of food safety products also includes bioluminescence-basedgenomics-based diagnostic technology.

technology, and advanced software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Neogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through a network of nationalveterinarians, retailers, livestock producers and international distributors, as well as a number of large farm supply retail chains in the United States and Canada. The Company’sanimal health product distributors. Our USDA-licensed facility in Lansing, Michigan, produces immunostimulant products for horses and dogs, and a unique equine botulism vaccine. The Company’sOur line of drug detection products is sold worldwide for the detection of abused and therapeutic drugs in animals and animal products, and has expanded into the workplace and human forensic market.

markets.

Neogen’s products are marketed by Companyour sales personnel in the U.S., Canada, Mexico, Central America, Brazil, Argentina, Uruguay, Chile, the United Kingdom and other parts of Europe, Brazil, China, India and Australia, and by distributors throughout the rest of the world.

Neogen’s

Our mission is to be the leading company in the development and marketing of solutions for food and animal safety. To meet this vision,mission, a growth strategy consisting of the following elements has been developed: (i) increasing sales of existing products; (ii) introducing new products and product lines;services; (iii) expandinggrowing international sales; and (iv) acquiring businesses and forming strategic alliances. The Company hasWe have historically been successful at increasing product sales organically, including international growth, and maintainsmaintain an active acquisition program to identify and capitalize on opportunities to acquire new products, and/businesses, or businesses.

technology.

Neogen Corporation was formed as a Michigan corporation in June 1981 and actual operations began in 1982. The Company’sOur principal executive offices are located at 620 Lesher Place, Lansing, Michigan 48912-1595 and itsour telephone number is
(517) 372-9200.

Neogen’s Annual Report on Form
10-K,
Quarterly Reports on Form
10-Q,
Current Reports on Form
8-K,
and amendments to those reports are available free of charge via our website (
www.neogen.com
) as soon as reasonably practicable after such information is filed with, or furnished to, the United States Securities and Exchange Commission.

The content of our website or the website of any third party that may be noted herein is not incorporated by reference in this Form

10-K.
PRODUCTS

Product trademarks and registered trademarks owned by Neogen include:
CORPORATE:
Neogen
®
, Neogen flask logo(logo)
®
, Neogen and flask (logo)
®
;
FOOD SAFETY:
AccuClean
®
, AccuPoint
®
, AccuScan
®
, Acumedia
®
, Agri-Screen
®
, Alert
®
, ANSR
®
, BetaStar
®
, BioLumix
®
, Colitag
, F.A.S.T.
®
, GeneQuence
®
, GENE-TRAK
®
, HarlequinTM
®
,
ISO-GRID
®
, Lab M
®
,
Listeria
Right Now
, NeoCare™MPNPlate
, NeoColumn™MPNTray
, NeoCare
, NeoColumn
, NeoFilm
®
, NeoNet™NeoNet
®
, NeoSeek™NeoSeek
,
NEO-GRID
®
, Penzyme
®
, Raptor™Raptor
®
, Reveal
®
, Soleris
®
, µPREP
®
, Veratox
®
, Simple. Accurate. Supported. Food Safety Solutions
SM
;
LIFE SCIENCES:
Alert
®
,
K-Blue
®
,
K-Blue
Substrate
®
,
K-Gold
®
, NeoSal
®
;
ANIMAL SAFETY:Acid-A-Foam™, Aero-ssault™,Ag-Tek®
Acid-A-Foam
, AluShield™Aero-ssault
,
Ag-Tek
®
, AluShield
, AquaPrime
®
, Assault
®
, Barnstorm™Barnstorm
®
, BioCres™ BioCres
50, BioPhene™BioPhene
, BioQuat™BioQuat
, BotVax
®
, Breeder-Sleeve
®, Bromethalin One Meal Is All It Takes(design)®
, Calf Eze™Eze
, Chem-Tech, Ltd.
, Chem-Tech’s CT logo (with circle)
,Chlor-A-Foam™, COMPANION™
Chlor-A-Foam
, Cowboy SyringeCOMPANION
,
CT-511
®,CT-511®
, Cykill™Cykill
, D3™ D3
Needles, DC&R
®
, DeciMax
®
,
Di-Kill
®
, Dr. Frank’s
®
,
Dy-Fly
®
,
Dyne-O-Might
®
, Earth City Resources (design)
®
, ElectroJac
®
, ELISA Technologies (design)
®
, EqStim
®
, EquiSleeve
®
,
E-Z Bond™
Bond
,
E-Z
Catch
®
, Farm-Foam
, Farmphene
®
,
Final-Fly-T
®
,
Fly-Die Defense™
Defense
,
Fly-Die
Ultra
, Fura-Zone
®
, GenQuat™GenQuat
, Horse Sense
®
, Ideal
®
, ImmunoRegulin
®
, Insectrin
®
, Insight™Insight
, Iodis
®
, Jolt
®
,
LD-44
®
,LD-44T™
LD-44T
,
Maxi Sleeve
®
, MaxKlor
®
, MegaShot™MegaShot
, MycAseptic™MycAseptic
, NeedleGard™NeedleGard
, NFZ™Neogen
®
Viroxide Super
, Neogen
®
Viroxide Super and flask (design)
, NFZ
, Nu Dyne
®
, PanaKare™PanaKare
, Pantek™Pantek
, ParlorMint™ParlorMint
, Parvosol
®
, Peraside
, Place Pack
®
, PolyPetite™PolyPetite
, PolyShield™PolyShield
, PolySleeve
®
, Preserve™Preserve
®
, Preserve International™International
®
, Preserve International(design)
®
, Prima
®
, Prima Marc™Marc
, Prima®Prima-Shot
, Prima Tech
®
, Prima Tech logo
®
,
Pro-Fix
®
,
Pro-Flex
®
, Promar™Promar
,Pro-Shot™
Pro-Shot
,
PRO-TECT
6 MIL
®,PRO-TECT 6 MIL logo®
, Prozap
®
, Prozap (stylized mark w/fancy Z)
,PY-75™, Quat-Chem™
PY-75
, Ramik
®
, Rat &
Mouse-A-Rest
II
®
, RenaKare™RenaKare
, Rodent Elimination Station™
3

Station
, Rodex™Rodex
,Rot-Not™
Rot-Not
,
Safe-T-Flex™, Siloxycide®
Safe-T-Flex
, Spectrasol™Siloxycide
®
, Spec-Tuss™Spectrasol
, Spec-Tuss
, Squire
®
, Starlicide
®
,
Stress-Dex
®
, SureBond
®
, SureKill
®
,Swine-O-Dyne™
Swine-O-Dyne
®
,
Synergize
®
, SyrVet
®
, Tetrabase™Tetrabase
®
, Tetracid
®,Tetradyne™
, ThyroKare™Tetradyne
®
, TopHoof™ThyroKare
, TopHoof
,
Tri-Hist
®
,Tri-Seal™
Tri-Seal
,
Tryad
®
, Turbocide
®
, Turbocide Gold
®
, Uniprim
®
, UriKare™UriKare
,VAP-5™
VAP-5
,VAP-20™
VAP-20
,Vet-Tie™
Vet-Tie
,Vita-15™
Vita-15
,
War Paint
®
,
X-185
, We keep ‘em movin’Zipcide
®
;
GENOMICS:
Deoxi
,X-185™, Zipcide®;GENOMICS: Deoxi™ Envigor
, GeneSeek
®
, Genomic Profiler™Profiler
, Genomic Insight for Personalized Care
, Genomic Solutions for Food Security
®
, Igenity
®
, SeekGain™SeekGain
, SeekSire™SeekSire
, SeekTrace™SeekTrace
,
Tru-Polled
®
;LOGOTYPES:
LOGOTYPES:
BioSentry barn logo
®
, BioSentry chicken logo
®
, BioSentry pig logo
®
, Circular design
®
, TurboCide
®
(stylized), D3 color mark – red
.

Neogen operates in two business areas: the Food Safety and the Animal Safety segments. See Notes to Consolidated Financial Statements elsewhere in this Form
10-K
for financial information about the Company’sour business segments and international operations.

FOOD SAFETY SEGMENT

Neogen’s Food Safety segment is primarily engaged in the production and marketing of diagnostic test kits and complementary products marketed to food and feed producers and processors to detect dangerous and/or unintended substances in food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant
by-products,
meat speciation, drug residues, pesticide residues and general sanitation concerns.

Our test kits are used to detect potential hazards or unintended substances in food and animal feed by testers ranging from small local grain elevators to the largest, best-known food and feed processors in the world, and numerous regulatory agencies. Neogen’s products include tests for:

Mycotoxins.
Grain producers and processors of all types and sizes use the Company’sour Veratox, Agri-Screen, Reveal, Reveal Q+ and Reveal Q+ MAX tests to detect the presence of mycotoxins, including aflatoxin, aflatoxin M1, deoxynivalenol, fumonisin, ochratoxin, zearalenone,
T-2/HT-2
toxin andT-2/HT-2 toxin, ergot alkaloid, to help ensure product safety and quality in food and animal feed.

Food allergens.
The world’s largest producers of cookies, crackers, candy, ice cream and many other processed foods use the Company’sour Veratox, Alert, Reveal, Reveal
3-D
and BioKits testing products for food allergens to help protect their food-allergic customers from the inadvertent contamination of products with food allergens, such asincluding but not limited to peanut, milk, egg, almond, gliadin (gluten), soy, hazelnut and hazelnutcoconut residues.

Dairy antibiotics. Dairies
Dairy processors are the primary users of Neogen’s BetaStar S, BetaStar Combo,Advanced and BetaStar 4D and Penzyme diagnostic tests to detect the presence of beta-lactam and tetracyclineveterinary antibiotics in milk. The presence of these drugs above a certain level in milk is a public health hazard and an economic risk to processorsproducers as it limits the milk’s further processing.

Foodborne pathogens.
Meat and poultry processors, seafood processors, fruit and vegetable producers and many other market segments are the primary users of Neogen’s ANSR and Reveal tests for foodborne bacteria, including
E. coli
O157:H7,
Salmonella
,
Listeria
and
Campylobacter
. Neogen’s ANSR pathogen detection system is an isothermal amplification reaction test method which exponentially amplifies the DNA of any bacteria present in food and environmental samples to detectable levels in 10 minutes. Combined with ANSR’s single enrichment step, Neogen’s pathogen detection method provides
DNA-definitive
results in a fraction of the time of other molecular detection methods. Our
Listeria
Right Now test detects the pathogen in less than 60 minutes without sample enrichment. Reveal’s lateral flow device combines an immunoassay with chromatography for a rapid and accurate
one-step
result.

Spoilage microorganisms.
Neogen’s Soleris and BioLumix products are used by food processors to identify the presence of spoilage organisms (e.g., yeast and mold) and other microbiological contamination in food. The systems measure microbial growth by monitoring biochemical reactions that generate a color change in the media as microorganisms grow. The sensitivity of the system allows detection in a fraction of the time needed for traditional methods, with less labor and handling time.

Our NeoSeek genomics services utilize a novel application of 16s metagenomics to determine all bacteria in a sample, without introducing biases from culture media, and without the need to generate a bacterial isolate for each possible microbe in a sample.

Sanitation monitoring.
Neogen manufactures and markets itsour AccuPoint Advanced rapid sanitation test forto detect the presence of adenosine triphosphate (ATP), a chemical found in all living cells. This
easy-to-use
and inexpensive test uses bioluminescence to quickly determine if a contact surface has been completely sanitized. When ATP comes into contact with the reagents contained in the test device, a reaction takes place that produces light. More light is indicative of higher levels of ATP and a need for more thorough sanitation. The Company’sOur worldwide customer base for its ATP sanitation testing products includes food and beverage processors, the food service and healthcare industries, as well as many other users.

Dehydrated culture media.Neogen’s Acumedia and Lab M products offer dehydrated culture media for varied purposes, including traditional bacterial testing and the growth of beneficial bacteria, such as cultures for sausages and beer. The Company’s customers for dehydrated culture media also include commercial and research laboratories and producers of pharmaceuticals, cosmetics and veterinary vaccines.

Seafood contaminants.
Neogen’s specialty products for the seafood market include tests for histamine, a highly allergenic substance that occurs when certain species of fish begin to decay; chloramphenicol, a banned antibiotic in most of the world, but still used by some shrimp farmers to improve the yield of their products; sulfite, an effective but potentially allergenic shrimp preservative; and shellfish toxins.

Neogen’s Reveal lateral flow tests for shellfish toxins include rapid tests to detect the toxins that cause amnesic shellfish poisoning (ASP), diarrhetic shellfish poisoning (DSP) and paralytic shellfish poisoning (PSP).

4

Waterborne microorganisms.
Neogen offers the food and beverage industries, including water companies, several platforms for performing the microbial analysis of water. This includes Neogen’s filter tests, which are a combination of Neogen Filter membrane filtration and Neogen Culture Media ampouled media, and
easy-to-use
Colitag product. With Colitag, after an incubation period, the sample changes color in the presence of coliforms and fluoresces in the presence of
E. coli
.
Neogen’s Food Safety group also offers:
Culture media.
Neogen Culture Media, formerly Neogen’s Acumedia and Lab M products, offers culture media and prepared media for varied purposes, including traditional bacterial testing and the growth of beneficial bacteria, such as cultures for sausages and beer. Our customers for culture media also include commercial and research laboratories and producers of pharmaceuticals, cosmetics and veterinary vaccines.
Laboratory services.
Neogen offers food safety analysis services in the U.S., United Kingdom (U.K.) and India. These ISO accredited laboratories offer a variety of fee for service tests for the food and feed industry.
The majority of Neogen’s food safety test kits use immunoassay technology to rapidly detect target substances. The Company’sOur ability to produce high quality antibodies sets itsour products apart from immunoassay test kits produced and sold by other companies. The Company’sOur kits are available in microwell formats, which allow for automated and rapid processing of a large number of samples, and lateral flow and other similar devices that provide distinct visual results. Typically, test kits use antibody-coated test devices and chemical reagents to indicate a positive or negative result for the presence of a target substance in a test sample; the simplicity of the tests makes them accessible to all levels of food producers, processors and handlers. Neogen also offers other test methods and products to complement its immunoassay tests.

The Company’s

Our test kits are generally based on internally developed technology, licensed technology, or technology that is acquired in connection with acquisitions. In fiscal 2017,2020, the Food Safety segment incurred royalty expense totaling $1,710,000$2,040,000 for licenses and royalties for licensed technology used in the Company’sour products, including expense of $863,000$822,000 for allergen products, $199,000$426,000 for the pathogen product line and $375,000 for licenses$257,000 related to the dairy antibiotics product line. Generally, the Company’s royalty rates are in the range of 2% to 10% of revenues on products containing the licensed technology. Some licenses involve technology that is exclusive to Neogen’s use, while others are
non-exclusive
and involve technology licensed to multiple licensees.

Neogen’s international operations in the United Kingdom,U.K., Mexico, Brazil, China and India originally focused on the Company’s Food Safetyfood safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer the Company’sour complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management at our international operations, and are reportedreport through the Food Safety segment.

Revenues from Neogen’s Food Safety segment accounted for 47.4%50.9%, 45.6%51.5%, and 46.5%48.9% of the Company’sour total revenues for fiscal years ended May 31, 2017, 20162020, 2019 and 2015,2018, respectively.

ANIMAL SAFETY SEGMENT

Neogen’s Animal Safety segment is primarily engaged in the development, manufacture, marketing and marketingdistribution of veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, a full suite of agricultural biosecurity products such as rodenticides, cleaners, disinfectants and insecticides, and genomics services.

Veterinary instruments.
Neogen markets a broad line of veterinary instruments and animal health delivery systems under the Ideal brand name. Approximately 250 different products are offered, many of which are used to deliver animal health products, such as antibiotics and vaccines. Ideal’s D3 Needles are stronger than conventional veterinary needles and are uniquely detectable by metal detectors at meat processing facilities — a potential market advantage in the safety-conscious beef and swine industries. Neogen’s Prima Tech product line consists of highly accurate devices used by farmers, ranchers and veterinarians to inject animals, provide topical applications and to use for oral administration. Prima Tech is also a supplier of products used in artificial insemination in the swine industry. Other products include animal identification and handling equipment.

Veterinary pharmaceuticals.
Animal Safety’s NeogenVet product line provides innovative, value-added, high quality products to the veterinary market. Top NeogenVet products include PanaKare, a digestive aid that serves as a replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency; Natural Vitamin
E-AD,
which aids in the prevention and treatment of vitamin deficiencies in swine, cattle and sheep; and RenaKare, a supplement for potassium deficiency in cats and dogs. Other products sold under the NeogenVet brand include
Vita-15
and Liver 7, which are used in the treatment and prevention of nutritional deficiencies. The CompanyWe also manufacturesmanufacture and marketsmarket Uniprim, a leading veterinary antibiotic.

Veterinary biologics.
Neogen’s BotVax B vaccine has successfully protected thousands of high-value horses and foals against Type B botulism, commonly known as Shaker Foal Syndrome. The Company’sOur product is the only USDA-approved vaccine for the prevention of Type B botulism in horses. Years of research and
5

many thousands of doses have proven Neogen’s EqStim immunostimulant to be safe and effective as a veterinarian-administered adjunct to conventional treatment of equine bacterial and viral respiratory infections. The Company’sOur ImmunoRegulin product uses similar immunostimulant technology to aid in the treatment of pyoderma (a bacterial skin inflammation) in dogs.

Veterinary OTC products.
Animal Safety products offered by Neogen to the retail
over-the-counter
(OTC) market include Ideal brand veterinary instruments packaged for the retail market. OTC products also include
Stress-Dex,
an oral electrolyte replacer for performance horses, and Fura-Zone, for the prevention and treatment of surface bacterial infections in wounds, burns and cutaneous ulcers.Ag-Tek and other hoof Hoof care, disposables and artificial insemination supplies are marketed to the dairy and veterinary industries.

Rodenticides.
Neogen’s comprehensive line of proven rodenticides, sold under brand names such as Ramik and Havoc, effectively address rodent problems of any size and serve as a critical component of an overall biosecurity plan for animal protein production operations. Neogen offers several rodenticide active ingredients including diphacinone, bromethalin, brodifacoum, and zinc phosphide formulated with food grade ingredients to generate the highest acceptance and most palatable bait possible.

Cleaners and disinfectants.
Used in animal and food production facilities, Neogen’s cleaners and disinfectants, including DC&R, 904 Disinfectant,
Acid-A-Foam, Preserve, Tetradyne
Synergize, BioPhene, Neogen Viroxide Super and FarmFluid S, can stop a disease outbreak before it starts. The products are also are used in the veterinary clinic market to maintain sanitary conditions and limit the potential hazards of bacteria, fungi and viruses.

Neogen’s water line cleaner and disinfectant products, including Peraside, NeoKlor, AquaPrime and Siloxycide, clean water lines, and provide continuous disinfection of a livestock facility’s water supply.

Insecticides.
Neogen’s highly effective insecticides utilize environmentally friendly technical formulas, and several are approved for use in food establishments.establishments and by pest control professionals in a wide range of environments. The company’sCompany’s Prozap insecticide brand is well knownused in the large animal production industry, particularly with dairy and equine producers.

Neogen’s SureKill line of products is used by professionals to control a variety of insects.

Animal genomics services. Neogen’s animal genomics businesses,
Neogen Genomics, formerly known as GeneSeek, and Igenity, provideprovides value-added services to leading agricultural genetics providers, large national cattle associations, companion animal breed registries and direct to consumer canine genetic test providers, university researchers, and numerous commercial beef and dairy cattle, swine, sheep and poultry producers. With
state-of-the-art genetics
genomics laboratories and the comprehensive bioinformatics to interpret geneticgenomics test results, Neogen Genomics offers identity and trait determination and analysis. GeneSeek’sOur technology employs high-resolutionhigh-density DNA genotyping and genomic sequencing for identity and trait analysis in a variety of important animal and agricultural plant species. Igenity’sOur extensive bioinformatics database identifies and predicts an animal’s positive or negative traits based on DNA test results. This information has helped livestock producers make significant improvementsincrease the speed of genetic improvement in the genomic makeuptheir herds and overall performance and quality of their animals.

Life sciences.
Neogen’s line of approximately 100 drug detection immunoassay test kits is sold worldwide for the detection of approximately 300 abused and therapeutic drugs in farm animals and racing animals, and for the detection of drug residues in meat and meat products. The test kits are also used for human forensic toxicology drug screening applications. This line includes tests for narcotics, analgesics, stimulants, depressants, tranquilizers, anesthetics, steroids and diuretics. Neogen also has several products used by researchers for the detection of biologically active substances.

Many of the products and services in the Animal Safety segment use licensed technology. In fiscal year 2020, Animal Safety incurred royalty expense totaling $949,000$484,000 for licenses and royalties in fiscal 2017 for licensed technology used in the segment’sour products and services, including expense of $410,000 for licenses$213,000 related to the genomics services line.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, our Australian operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.
Revenues from Neogen’s Animal Safety segment accounted for 52.6%49.1%, 54.4%48.5%, and 53.5%51.1% of the Company’sour total revenues for fiscal years ended May 31, 2017, 20162020, 2019 and 2015,2018, respectively.

GENERAL SALES AND MARKETING

Neogen is organized under two segments — Food Safety and Animal Safety. Within these segments, the Company’sour sales efforts are generally organized by specific markets, rather than by products or geography. During the fiscal year that ended May 31, 2017, the Company2020, we had approximately 23,00028,000 customers for itsour products. Since many of our customers for animal safety products are distributors, and certain animal safety products are offered to the general retail market, the total number of end users of the Company’sour products is considerably greater than 23,000.28,000. As of May 31, 2017,2020, a total of 375379 employees were assigned to sales and marketing functions, within the Company, compared to 348359 at the end of May 2016.2019. During the fiscal years ended May 31, 2017, 20162020, 2019 and 2015,2018, no single customer or distributor accounted for 10% or more of the Company’sour revenues.

6

DOMESTIC SALES AND MARKETING

FOOD SAFETY

To reach each customer and prospect with expertise and experience, Neogen has a staff of specialized food safety sales and technical service representatives assigned to specific markets. This staff sells Companyour products directly to end users, and also handles technical support issues that arise with customers in the United States and Canada.

States.

Neogen’s food safety markets are primarily comprised of: milling
Milling and grain
, including grain elevators, feed mills, pet food manufacturers, and grain inspection companies; meat
Meat and poultry
, including meat and poultry processors, producers of
ready-to-eat
meat and poultry products, and the USDA’s Food Safety Inspection Service (FSIS); grocery products,
Prepared foods and ingredients
, including flour millers, malters, bakeries, candy and confection manufacturers, manufacturers of prepared meals, nuts, spices, cookies, crackers and other snack foods; fruits
Fruits and vegetables
, including growers and processors of juice and packaged fresh cut grocery items; seafood,
Seafood
, including harvesters and processors of a wide variety of seafood products; dairy,
Dairy
, including milk and yogurt processors; beverage,
Beverage
, including soft drink bottlers and beer and wine producers; healthcare,
Water,
including food producers, water bottlers and municipal water departments;
Healthcare
, including hospitals and distributors to the healthcare industry; traditional
Traditional culture media markets
, including commercial and research laboratories and producers of pharmaceuticals, cosmetics and veterinary vaccines; food
Food service
, including fast food service establishments and retail grocery market chains,chains; and nutraceuticals,
Nutraceuticals
, including producers and marketers of a wide variety of nutritional and holistic consumer products.

ANIMAL SAFETY

Neogen markets a broad range

Neogen’s staff of pharmaceuticals, vitamin injectables, wound carespecialized animal safety sales, marketing, customer and technical service representatives sell our products topicals, instruments, genomicsand services directly to consumers, dealers, veterinarians, distributors and biologicals to the veterinary market. The product range is focused on the food (e.g., cattle, swineother manufacturers and poultry) and companion (e.g., horses, dogs and cats) animal markets. Neogen’s sales group works directly with veterinarians, clinics and universities, and markets through established ethical distributors by supporting the efforts of over 1,000also handle domestic distributor sales representatives calling on 35,000 plus veterinarians.technical support issues. Neogen further supports its veterinary distribution channelchannels through product training, field support, promotions and technical service.

The Company believes the animal health market offers growth opportunities for Neogen and its products. Neogen offers a broad range of products including well-recognized brands of rodenticides, cleaners and disinfectants, insecticides, instruments and horse care products. To reach the OTC market, Neogen’s sales team works with a large network of animal health distributors including marketing groups, traditionaltwo-step distributors, catalogers and large retail chains. Support includes product training, field support, planogram solutions,various promotions and advertising.

As

Neogen’s animal safety markets are primarily comprised of:
Companion animal veterinarians.
Neogen has a commercial laboratory, GeneSeek providesdedicated sales group that sells and technically supports the Company’s animal care, biosecurity and disposable products to the companion animal veterinary market.
Livestock producers, veterinarians and breed associations.
Neogen has a dedicated group of sales professionals that sells the Company’s comprehensive suite of biosecurity and husbandry products and genomics services directdirectly to large-herd beeflivestock producers, and livestock veterinarians and veterinary clinics.
Distributors.
To expand the reach of its animal safety OTC and veterinary products, Neogen has a dedicated sales team that sells the Company’s products to animal health product distributors.
Retailers.
Neogen offers select animal care and biosecurity products directly to large farm and ranch retailers for sale to consumers.
Breeding and genetics companies.
Neogen has sales professionals who sell directly to the large dairy cattle, swine,artificial insemination providers, poultry and sheep producers, universitiesswine genetics companies and the aquaculture industry.
Diagnostic labs and universities.
Neogen has a dedicated lab, manufacturing, sales and technical service group that call on large commercial and forensic testing laboratories and universities.
Other manufacturers and government agencies.
Neogen has an experienced group of professionals who work directly with other research organizations,manufacturers and various livestockgovernment agencies to provide custom solution products and canine breed associations.

services for their needs.

7

INTERNATIONAL SALES AND MARKETING

Neogen maintains 1015 Company-owned locations outside of the United States to provide a direct presence in regions of particular importance to the Company, and maintainsus; we maintain an extensive network of distributors to reach countries where the Company doeswe do not have a direct presence.

Neogen Europe.Europe and subsidiaries.
Neogen Europe, Ltd., located in Ayr, Scotland, provides the Company access to the European Union (E.U.), and sells products and services to itsour network of customers and distributors throughout the E.U.United Kingdom (U.K.), Europe, the Middle East and Africa. Customers in the United Kingdom,U.K., France, Germany, Italy and the Netherlands are served by Companyour employees. In other European regions, customers are generally serviced by distributors managed by Neogen Europe personnel. Neogen Europe’s research and development team continues to be a strong asset in the development of products tailored to meet the unique requirements of the European market.
Neogen Europe management is also responsible for sales and marketing for the Company’s England-based Neogen’s other Europe-based operations, which include:
Lab M and Quat-Chem businesses. In August 2015, Neogen acquired the stock of Lab M Holdings (Lab M)Ltd., a developer, manufacturer and supplier of microbiological culture media and diagnostic systems located in Heywood, England. Lab M’sEngland, which manufactures an extensive range of microbiological culture media, supplements and immunomagnetic separation techniques andtechniques; its proficiency testing systems are used in laboratories around the world. In December 2016, Neogen acquired
Quat-Chem Ltd., a Rochdale, England-based chemical company specializingthat specializes in the development, manufacture and sale of agricultural, industrial, and food processing biocidal hygiene products, including cleaners and disinfectants. Quat-Chem sells its products on a global basis, with a focus on markets in the United Kingdom, European Union,U.K., E.U., Middle East and Asia.

Neogen Latinoamérica. The Company’s subsidiaryItalia, a Milan, Italy-based business acquired in Mexico, January 2020, directly markets and sells Neogen’s products in Italy.
Abtek (Biologicals) Ltd., acquired in February 2020, a developer and supplier of culture media supplements and microbiology technologies. With the acquisition, Abtek’s Liverpool operations became Neogen’s third global microbiology manufacturing facility, joining locations in Lansing and Heywood.
Neogen
Latinoam
é
rica
.
Neogen Latinoamérica is headquartered near Mexico City and distributes Neogen’s products throughout Mexico and Central America. Neogen Latinoamérica manages the Company’sour business activities throughout the region by marketing to animal and crop producers and food processors, utilizing itsour direct sales representatives to sell Food Safety products and genomics services, while marketing cleaners, disinfectants and other Animal Safety products primarily through distributors.

Neogen Argentina, Neogen Uruguay and Neogen Chile.
In January 2020, Neogen acquired Productos Quimicos Magiar and Lakenord S.A. (Magiar Uruguay), distributors of Neogen’s food safety diagnostics products for the previous 20 years, with operations in Argentina and Uruguay, respectively. In March 2020, Neogen acquired the assets of Chile-based Magiar Chilena, a distributor of food, animal, and plant diagnostics, including Neogen products. With the acquisitions, the former Magiar operations remain in the three countries and provide Neogen with a physical presence in the important agricultural Southern Cone region of South America, which has large beef and dairy populations with significant export markets. The operations are managed through Neogen’s Latin American operations and offer direct sales of Neogen food safety, animal safety and genomics products into Argentina, Uruguay and Chile.
Neogen do Brasil.
Neogen do Brasil, (translated as Neogen of Brazil), headquartered near São Paulo, distributes Neogen’s products throughout Brazil. Brazil is one of the world leaders in the export of numerous food commodities, including beef, poultry, soybeans, coffee, sugar and orange juice, and this operation gives the Companyus direct sales representation to these important markets. Neogen do Brasil management is also responsible for sales and marketing for the Company’sBrazil-based Deoxi and Rogama, businesses. Neogen owns Deoxi Biotecnologia Ltda,located in Pindamonhangaba, Brazil. This company operates a genomics testing laboratory located in Aracatuba, Brazil, which it purchased in April 2016. In December 2016, Neogen acquiredBrazil-based Rogama Indústria e Comércio Ltda., a company which(formerly named Deoxi) and develops, manufactures and markets rodenticides and insecticides. Rogama was founded in 1979 and offers more than 70 registered pest control products to Brazil’s agronomic, professional and retail markets.

Neogen China. Neogen’s
Our Chinese subsidiary, with officeslocated in Shanghai, and Beijing, employs sales representatives who sell directly to Chinese customers. China’s burgeoning middle class, with its rapidly growing demand for higher quality meat and dairy products, makes the country a substantial growth opportunity for NeogenNeogen’s products and services — both for animal production on the country’s farms, and in processing plants throughout China’s food production and distribution channels. The Company utilizesWe utilize both direct sales representatives and distributors to market itssell our complete portfolio.

portfolio in this growing market.

Neogen India. In June 2015, Neogen acquired the assets of Sterling Test House, a leading commercial food testing
This business operates an accredited laboratory based in southwest India, to serve as a base for the Company’s operations in India. Sterling Test House was incorporated in 1990, and its business includeswhich performs food safety and water quality testing for food producers, major hotels and restaurants in its home region, as well as safety and quality analysis for the country’s expanding nutraceutical market, and growing food export businesses. The laboratory is located in Kochi, in the state of Kerala, which is India’s leading region for the export of spices, tea, and fresh fruits and vegetables. Neogen India is also responsible for sales of our food safety and animal safety products to customers and distributors in India and nearby countries.
8

Neogen Australasia.
Neogen Australasia operates a genomics testing laboratory, focusing on the sheep and cattle markets in Australia and New Zealand, and also markets and sells our animal safety products in those countries. In late fiscal 2016,February 2020, the Company acquired the assets of Cell BioSciences, an Australian distributor of food safety and industrial microbiology products. This acquisition has given Neogen transferreda direct sales responsibilitypresence across Australasia for its Food Safety products directly to sales representatives at Neogen India.

entire product portfolio.

Neogen Canada.
In September 2015,January 2019, Neogen openedacquired the assets of the Edmonton-based Delta Genomics Centre, a Canadian locationmajor animal genomics laboratory in Guelph, Ontario. Currently, this office is used forCanada. With the acquisition, Delta’s laboratory operations were renamed Neogen Canada, and became Neogen’s sixth animal genomics sales and sample reception, and reports throughlaboratory, joining locations in the Animal Safety segment.

Dairy antibiotics distributor. Neogen’s dairy antibiotics diagnostic products are marketed directly to customers in North America,U.S., Scotland, Brazil, and China and distributed elsewhere internationally by Denmark based Chr. Hansen, an international supplier of natural ingredient solutions for the food, health and nutritional industries.

Australia.

Other distributor partners.
Outside of the Companyour physical locations, and dairy antibiotics distributor mentioned above, Neogen uses itsour own sales managers in both the Food Safety and Animal Safety segments to work closely with and coordinate the efforts of a network of approximately 150200 distributors in more than 100 countries. The distributors provide local training and technical support, perform market research and promote Company products within designated countries around the world.

Sales to customers outside the United States accounted for 35.8%39.4%, 33.5%40.1%, and 36.7%37.6% of the Company’sour total revenues for fiscal years ended May 31, 2017, 20162020, 2019 and 2015,2018, respectively.

No individual foreign country contributed 10% or more of our revenues for those same periods.

RESEARCH AND DEVELOPMENT

Management maintains a strong commitment to Neogen’s research and development activities. The Company’sOur product development efforts are focused on the enhancement of existing products and in the development of new products that fit itsour business strategy. As of May 31, 2017, the Company2020, we employed 9289 individuals in itsour worldwide research and development group, including immunologists, chemists and microbiologists. Research and development costs were approximately $10.4$14.8 million, $9.9$12.8 million, and $9.6$10.9 million representing 2.9%3.5%, 3.1%, and 3.4%2.7% of total revenues in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. Management currently expects the Company’sour future research and development expenditures to approximate 3% to 4% of total revenues.

revenues annually.

Neogen has ongoing development projects for a number ofseveral new and improved diagnostic tests, readers and other complementary products for both the food safetyFood Safety and animal safetyAnimal Safety markets. Management expects that a number of these products will be commercially available at various times during fiscal years 2018 to 2020.

2021 and 2022.

Portions of certain technologies utilized in some products manufactured and marketed by Neogen were acquired from or developed in collaboration with affiliated partnerships,partners, independent scientists, governmental units, universities and other third parties. The Company hasWe have entered into agreements with these parties that provide for the payment of license fees and royalties based upon sales of products that utilize the pertinent licensed technology. License fees and royalties,Royalties, expensed to sales and marketing, under these agreements amounted to $2,659,000, $1,969,000$2,524,000, $2,795,000, and $2,189,000$2,876,000 in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively.

PROPRIETARY PROTECTION AND APPROVALS

Neogen uses trade secrets as proprietary protection in many of its food and animal safety products. In many cases, the Company haswe have developed unique antibodies capable of detecting microorganisms and residues at minute levels. The supply of these antibodies, and the proprietary techniques utilized for their development, may offer better protection than the filing of patents. Such proprietary reagents are maintained in secure facilities and stored in more than one location to reduce exposure to complete destruction by natural disaster or other means.

Patent and trademark applications are submitted whenever appropriate. Since its inception, Neogen has acquired and received numerous patents and trademarks, and has several pending patents and trademarks. The patents expire at various times over the next 2223 years.

9

A summary of patents by product categories follows:

   USA   International   Expiration 

Natural Toxins, Allergens, & Drug Residues

   6    31    2018-2038 

Bacterial & General Sanitation

   17    18    2017-2030 

Life Sciences

   0    7    2024 

Veterinary Instruments & Other

   14    32    2017-2039 

Genomics Services

   7    1    2021-2029 

The Company does

   
USA
   
International
   
Expiration
 
Natural Toxins, Allergens, & Drug Residues
   21    33    2021-2026 
Bacterial & General Sanitation
   5    0    2021-2022 
Life Sciences
   0    4    2024 
Vaccine
   1    0    2028 
Veterinary Instruments & Other
   13    44    2020-2042 
Genomics Services
   18    4    2021-2029 
We do not expect the near-term expiration of any single patent to have a significant effect on future results of operations.

Management believes that Neogen has adequate protection regarding proprietary rights for itsour products. However, it iswe are aware that substantial research has taken place at universities, governmental agencies and other companies throughout the world and that numerous patents have been applied for and issued for technologies which may be used in the Company’sour products. To the extent some of the Company’sour products may now, or in the future, embody technologies protected by patents, copyrights or trade secrets of others, we may need to obtain licenses to use such technologies may need to be obtained in order to continue to sell the products. These licenses may not be available on commercially reasonable terms. Failure to obtain any such licenses may delay or prevent the sale of certain new or existing products. In addition, patent litigation is not uncommon. Accordingly, there can be no assurance that the Company’sour existing patents will be sufficient to completely protect itsour proprietary rights.

One of the major areas affecting the success of biotechnology development involves the time, cost and uncertainty surrounding regulatory approvals. Neogen products requiring regulatory approval, which the Companywe currently hashave in place, include BotVax B, EqStim, ImmunoRegulin, Uniprim and BetaStar. The Company’sOur general strategy is to select technical and proprietary products that do not require mandatory approval by regulatory bodies to be marketed. Neogen’s rodenticide, disinfectant and insecticide products are subject to registration in the United States and internationally.

Neogen utilizes third-party validations on many of itsour disposable test kits as a marketing tool to provide itsour customers with assurances that the Company’sour products perform to specified levels. These include validation by the AOAC International, independently administered third-party, multi-laboratory collaborative studies and approvals by the U.S. Federal Grain Inspection Service and the USDA Food Safety Inspection Service for the use of Companyour products in their operations.

PRODUCTION AND SUPPLY

Neogen manufactures itsour products in Michigan, Kentucky, Wisconsin, North Carolina, Iowa, Tennessee, California, the United Kingdom and Brazil and provides genomics services in Nebraska, Scotland, Brazil, Australia, China and Brazil.Canada. As of May 31, 2017,2020, there were approximately 680965 full-time employees assigned to manufacturing and providing of services in these locations, operating on one or two shifts; with occasional 24/7 production during high demand periods. Future demand increases could be accommodated by adding shifts. Management believes itwe could increase the current output of itsour primary product lines by more than 50% using the current space available; however, to do so would require investment in additional capital equipment.

Food safety diagnostics.
Manufacturing of diagnostic tests for the detection of natural toxins, pathogens, food allergens, dairy antibiotics, spoilage organisms and pesticides, final kit assembly, quality assurance and shipping takes place in the Company’sat our facilities in Lansing, Michigan. Proprietary monoclonal and polyclonal antibodies for Neogen’s diagnostic kits are produced on a regular schedule in the Company’sour immunology laboratories in Lansing. Generally, final assembly and shipment of diagnostic test kits to customers in Europe is performed in the Company’sour Ayr, Scotland facility. Assembly and shipmentMost of electronic readers and disposablesingle-use samplers takes place in the Company’s facilities in Lansing. Solerisfood safety diagnostic instruments and BioLumix instrument readers are produced by third partythird-party vendors to the Company’sour specifications, quality tested in Lansing, and then shipped to customers. Dehydrated cultureCulture media products are manufactured in aFDA-registeredan
ISO-approved
facility in Lansing and also in Heywood and Liverpool, England. Products are blended following strict formulations or custom blended to customer specificationspecifications and shipped directly to customers from Lansing and Heywood.

the United Kingdom. The Heywood location produces prepared media plates, sterile liquid media, and other related products in ready to use format for the food testing laboratories across the U.K. and western Europe.

Animal health products.
Manufacturing of animal health products, pharmacological diagnostic test kits and test kits for drug residues takes place in the Company’sour
FDA-registered
facilities in Lexington, Kentucky. In general, manufacturing operations including reagent manufacturing, quality assurance, final kit assembly and packaging are performed by Neogen personnel. Certain animal health products and veterinary instruments that are purchased finished or that are toll manufactured by third party vendors are warehoused and shipped from the Company’sour Lexington facilities. Other veterinary instruments are produced in the Company’sour facilities in Lansing, and are generally then shipped to Lexington for distribution to customers. Manufacturing and shipment of devices used for animal injections, topical applications and oral administration takes place in a Company-owned facilityoccurs in Kenansville, North Carolina.

10

Veterinary biologics.
Neogen maintains a Lansing-based USDA-approved manufacturing facility devoted to the production of the biologic products EqStim and ImmunoRegulin.P. acnes
P.acnes
seed cultures are added to media and then subjected to several stages of further processing resulting in a finished product that is filled and packaged within the facility. The Company’sOur BotVax B vaccine is also produced in the Lansing facility utilizing Type B botulism seed cultures and a traditional fermentation process. All completed biologic products are then shipped to Neogen’s Lexington facilities for inventory andwhere they are inventoried prior to distribution to customers.

Agricultural genomics services.
Neogen offers agricultural genomics laboratory services and bioinformatics at itsour locations in Lincoln, Nebraska; Ayr, Scotland;Nebraska, Scotland, Brazil, Australia, China and Aracatuba, Brazil.Canada. Through itsour laboratory services and bioinformatics (primarily in beef and dairy cattle, pigs, sheep, poultry, horses and dogs), GeneSeek empowers itsNeogen Genomics allows our customers to speed genetic improvement efforts, as well as identify economically important diseases. In fiscal 2016, the Company added to its processing capabilities in Scotland, while also purchasing a genomics business in Brazil to enhance its presence there.

Cleaners, disinfectants and rodenticides.
Manufacturing of rodenticides and/or cleaners and disinfectants takes place in the following locations: Randolph, Wisconsin; Memphis, Tennessee; Turlock, California; Rochdale, England; and Pindamonhangaba, Brazil. Manufacturing of rodenticides consists of blending technical material (active ingredient) with bait consisting principally of various grains. Certain cleaners and disinfectants are manufactured in Neogen facilities, while others are purchased from other manufacturers for resale, or toll manufactured by third parties.

Pesticides.

Insecticides.
Neogen manufactures insecticides and other pesticides at its facilities in Pleasantville, Iowa and Pindamonhangaba, Brazil.

Neogen purchases component parts and raw materials from more than 9001,000 suppliers. Though many of these items are purchased from a single source in order to achieve the greatest volume discounts, the Company believes it haswe believe we have identified acceptable alternative suppliers for most of itsour key components and raw materials where it is economically feasible to do so. There can be no assurance that the Companywe would avoid a disruption of supply in the event a supplier discontinues shipment of product. Shipments of products are generally accomplished within a
48-hour
turnaround time. As a resultBecause of this quick response time, Neogen’sour backlog of unshipped orders at any given time has historically not been significant.

COMPETITION

Although competitors vary in individual markets, management knows of no competitor that is pursuing Neogen’s fundamental strategy of developing and marketing a broad line of products, ranging from disposable tests and dehydrated culture media to veterinary pharmaceuticals and instruments for a large number of food safety and animal safety concerns. For each of itsour individual products the Company facesor product lines, we face intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the Company. Neogen competesNeogen. We compete primarily on the basis of ease of use, speed, accuracy and other similar performance characteristics of itsour products. The breadth of the Company’sour product line, the effectiveness of itsour sales and customer service organizations, and pricing are also components in management’s competitive plan.

strategy.

Future competition may become even more intense, and could result from the development of new technologies, which could affect the marketability and profitability of Neogen’s products. The Company’sOur competitive position will also depend on management’sour ability to continue to develop proprietary products, attract and retain qualified scientific and other personnel, develop and implement production and marketing plans and obtain patent protection.protection for new products. Additionally, the Companywe must continue to generate or have access to adequate capital resources to execute itsour strategy.

FOOD SAFETY:

With a large professional sales organization offering a comprehensive catalog of food safety solutions, management believes the Company maintainswe maintain a general advantage over competitors offering only limited product lines. In most cases, Neogen sales and technical service personnel can offer unique insight into a customer’s numerous safety and quality challenges, and offer testing and other solutions to help the customer overcome those challenges.

Competition for pathogen detection products includes traditional methods and antibody and genetic-based platforms; competition for natural toxins and allergen detection products include instrumentation and antibody-based tests. While the Company’sour offerings will not always compete on all platforms in all markets, the products that are offeredwe offer provide tests that can be utilized by most customers to meet their testing needs.

Besides its

In addition to our extensive product offerings and robust distribution network, the Company focuses itswe focus our competitive advantage in the areas of customer service, product performance, speed, and ease of use of itsour products. Additionally, by aggressively maintaining itselfNeogen as a
low-cost
producer, Neogen believeswe believe that itwe can be competitive with new market entrants that may choose a low pricing strategy in an attempt to gain market share.

11

ANIMAL SAFETY:

Neogen’s Animal Safety segment faces no one competitor across the products and markets it serves.we serve. In the racing industry market, the Company believes it holdswe believe we hold a leading market share position. In the life sciences and forensicforensics markets, the Company competeswe compete against several other diagnostic and reagent companies with similar product offerings.

In the veterinary market, Neogen markets BotVax B, the only USDA-approved vaccine for the prevention of botulism Type B in horses. The Company competesWe compete on other key products through differentiated product performance and superior customer and technical support. With some of itsour products, the Company provideswe provide solutions as a lower cost alternative and offersalso offer a private label option for itsour distributors.

Competition in the rodenticide market includes several companies of comparable size that offer products into similar market segments. The retail rodenticide market is not dominated by a single brand. While the technical materials used by competing companies are similar, Neogen uses manufacturing and bait formula techniques which the Company believeswe believe may better attract rodents to the product and thereby improves overall product performance.

Within the insecticide market, the Company’sChem-Tech products specifically focus on the area of insect control for food and animal safety applications. There are several competitors offering similar products, however, the Company haswe have a proprietary formulation chemistry that optimizes the delivery and safe application of insecticides at the customer’s location. These products are currently only sold in the U.S. through a combination of direct sales and distributors.

Numerous companies, including a number of large multinationals, compete for sales in the cleaner and disinfectant product segment. Neogen’s broad line of products are sold through itsour distributor network around the world, primarily to assist in the cleaning and disinfecting of animal production facilities.

In addition to the Company’sour extensive portfolio of Animal Safety products, Neogen also competes in the retail market by providing solutions to common retail problems, such as stock outs, wasted floor space and inconsistent brand identity. The Company differentiates itselfWe differentiate ourselves by offering planograms and convenient reordering systems to maximize turns and profitability for itsour retail customers.

GeneSeek,

Neogen Genomics, which includes the leading commercial agricultural genomics laboratory in the U.S., employs cutting-edge technology in the area of genomics. The result of this technology allows the acceleration of natural selection through selective breeding of traits such as disease resistance, yield improvement and meat quality. Competition comes mainly from a number of service providers, whose primary focus are the human and pharmaceutical industries,some significantly larger than us, as well as several smaller companies offering genomics services. GeneSeekNeogen Genomics is not involved in cloning or the development of transgenic animals.

GOVERNMENT REGULATION

A significant portion of Neogen’s products and revenues are affected by the regulations of various domestic and foreign government agencies, including the U.S. Department of Agriculture (USDA), the Environmental Protection Agency (EPA), and the U.S. Food and Drug Administration (FDA). Changes in these regulations could affect revenues and/or costs of production and distribution.

Neogen’s development and manufacturing processes involve the use of certain hazardous materials, chemicals and compounds. Management believes that the Company’sour safety procedures for handling and disposing of such commodities comply with the standards prescribed by federal, state and local regulations; however, changes in such regulations or rules could involve significant costs to the Companyus and could be materially adverse to itsour business.

The rodenticides, insecticides, cleaners, disinfectants and sanitizers manufactured and distributed by Neogen are subject to EPA and various state regulations. In general, any international sale of the productour products must also comply with similar regulatory requirements in the country of destination. Each country has its own individual regulatory construct with specific requirements (e.g., label in the language of the importing country). To the best of the Company’sour knowledge, Neogen products are in compliance with applicable regulations in the countries where such products are sold.

Dairy diagnostic products used in National Conference on Interstate Milk Shipments (NCIMS), a cooperative program involving FDA, state governments and other milk monitoring programs are regulated by the FDA.industry, must first be approved. Before products requiring FDANCIMS approval can be sold in the U.S., extensive product performance data must be submitted in accordance with the
FDA-approved
protocol administered by the AOAC Research Institute (AOAC RI). Following approval of a product by the FDA,NCIMS, the product must also be approvedreviewed by NCIMS, an oversight body that includes federal, state and industry representatives. The Company’sthe FDA. Our BetaStar Advanced U.S. dairy antibiotic residue testing product has been reviewed and/or approved by the FDA, NCIMS, and AOAC RI. While some foreign countries accept AOAC RI approval as part of theirappropriate regulatory approval processes, many countries have their own regulatory requirements.

bodies.

12

Many of the food safety diagnostic products to detect allergens and spoilage organisms do not require direct government approval. However, the Company haswe have pursued AOAC approval for manya number of these products to enhance their marketability. Products for mycotoxin detection, which are used by federal inspectors, must be approved by the USDA. Neogen has obtained and retained the necessary approvals to conduct its current operations.

Neogen’s veterinary vaccine products and some pharmaceutical products require government approval to allow for lawful sales. The vaccine products are approved by the U.S. Department of Agriculture, Center for Veterinary Biologics
(USDA-CVB)
and the pharmaceutical products are approved by the FDA. The products, and the facilities in which they are manufactured, are in a position of good standing with both agencies. The Company has hadWe have no warning letters based on any review of these products or facility inspection, no recalls on any of these products, and knowsare not aware of noany reason why itwe could not manufacture and market such products in the future.

Other animal safety and food safety products generally do not require additional registrations or approvals. However, Neogen’s regulatory staff routinely monitors amendments to current regulatory requirements to ensure compliance.

EMPLOYEES

As of May 31, 2017, the Company2020, we employed 1,4131,764 full-time persons worldwide. None of the employees are covered by collective bargaining agreements. There have been no work stoppages or slowdowns due to labor-related problems, and management believes that itsour relationship with itsour employees is generally good. Employees havingwith access to proprietary information have executed confidentiality agreements with the Company.

Neogen.

13

ITEM 1A.
RISK FACTORS

An investment in Neogen Corporation’s common shares involves a high degree of risk. The risks described below are not the only ones that an investor faces. Additional risks that are not yet known to us or that we currently think are immaterial could also impair our business, financial condition or results of operations. If any of the following risks actually occurs, our business, financial condition or results of operations could be adversely affected.

Risks Relating to Our Business

The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, could adversely affect our business, results of operations and financial condition.
We could be negatively impacted by the widespread outbreak of an illness or any other communicable disease, or any other public health crisis that results in economic and trade disruptions, including the disruption of global supply chains. In December 2019, an outbreak of a new strain of coronavirus
(“COVID-19”)
began in Wuhan, Hubei Province, China. In March 2020, the World Health Organization declared
COVID-19
a pandemic. The
COVID-19
pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. The extent of the impact of the
COVID-19
pandemic on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend on many factors outside our control, including, without limitation, the timing, extent, trajectory and duration of the pandemic, related restrictions on travel and transports, the development and availability of effective treatments and vaccines, the imposition of protective public safety measures, and the impact of the pandemic on the global economy and consumer demand. Additional future impacts to us may include, but are not limited to, material adverse effects on: demand for our products and services; our supply chain, and sales and distribution channels; and our profitability and cost structure. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, and financial condition. The situation is changing rapidly and future impacts may materialize that are not yet known. To the extent the
COVID-19
pandemic adversely affects our business, results of operations, financial condition and stock price, it may also have the effect of heightening many of the other risks described in this section.
Our business strategy is dependent on successfully promoting internal growth and identifying and integrating acquisitions.

Our business has grown significantly over the past several years as a result of both internal growth and acquisitions of existing businesses and their products. Management initiatives may be attempted to augment internal growth, such as strengthening our presence in select markets, reallocating research and development funds to higher growth potential products, development of new applications for our technologies, enhancing our service offerings, continuing key customer efforts, and finding new markets for our products. Failure of these management initiatives may have a material adverse effect on our operating results and financial condition.

Identifying and pursuing acquisition opportunities, integrating these acquisitions into our business and managing their growth requires a significant amount of management’s time and skill. We cannot assure that we will be effective in identifying, integrating or managing future acquisition targets. Our failure to successfully integrate and manage a future acquisition may have a material adverse effect on our operating results and financial condition.

In addition, if we continue to experience growth in our business, such growth could place a significant strain on our management, customer service, operations, sales and administrative personnel, and other resources. To serve the needs of our existing and future customers we will be required to recruit, train, motivate and manage qualified employees. We have incurred and will continue to incur significant costs to retain qualified management, sales and marketing, engineering, production, manufacturing and administrative personnel, as well as expenses for marketing and promotional activities. Our ability to manage our planned growth depends upon our success in expanding our operating, management, information and financial systems, which might significantly increase our operating expenses.

We may not be able to effectively manage our future growth, and if we fail to do so, our business, financial condition and results of operations could be adversely affected.

We rely significantly on our information systemssystems’ infrastructure to support our operations and a failure of these systems and infrastructure and/or a security breach of the Company’sour information systems could damage the Company’sour reputation and have an adverse effect on operations and results.

We rely on our information systemssystems’ infrastructure to integrate departments and functions, to enhance our ability to service customers, to improve our control environment and to manage our cost reduction initiatives. If a security breach or cyberattack of our IT networks and systems occurs, our operations could be interrupted. Any issues involving our critical business applications and infrastructure may adversely impact our ability to manage our operations and the customers we serve. Although we have controls and security measures in place to prevent such attacks, experienced computer
14

hackers are increasingly organized and sophisticated. Malicious attack efforts operate on a large-scale and sometimes offer targeted attacks as a
paid-for
service. In addition, if the Company’stechniques used to access or sabotage networks change frequently and generally are not recognized until launched against a target.
We rely on several information systems throughout our company, as well as those of our third-party business partners, to provide access to our
web-based
products and services, keep financial records, analyze results of operations, process customer orders, manage inventory, process shipments to customers, store confidential or proprietary information and operate other critical functions. Although Neogen employs system backup measures and engages in information system redundancy planning and processes, such measures, as well as our current disaster recovery plan, may be ineffective or inadequate to address all vulnerabilities. Further, our information systems and our business partners’ and suppliers’ information systems may be vulnerable to attacks by hackers and other security breaches, including computer viruses and malware, through the Internet (including via devices and applications connected to the Internet), email attachments and persons with access to these information systems, such as our employees or third parties with whom we do business. As information systems and the use of software and related applications by us, our business partners, suppliers, and customers become more cloud-based, there has been an increase in global cybersecurity vulnerabilities and threats, including more sophisticated and targeted cyber-related attacks that pose a risk to the security of our information systems and networks and the confidentiality, availability and integrity of data and information.
While we have implemented network security and internal control measures, especially for the purpose of protecting our connected products and services from cyberattacks, and invested in our data and information technology infrastructure, there can be no assurance that these efforts will prevent a system disruption, attack, or security breach and, as such, the risk of system disruptions and security breaches from a cyberattack remains.
If our security and information systems are compromised, or employees fail to comply with the applicable laws and regulations, andor this information is obtained by unauthorized persons or used inappropriately, it could adversely affect the Company’sour reputation, as well as results of operations, and could result in litigation, the imposition of penalties, or significant expenditures to remediate any damage to persons whose personal information has been compromised.

In addition,
COVID-19
may have an adverse impact on our information technology systems, including telecommuting issues associated with the rapid and broad-based shift in our employee population working remotely, which creates inherent productivity, connectivity and oversight challenges.
Disruption of our manufacturing and service operations could have an adverse effect on our financial condition and results of operations.

We manufacture our products at several manufacturing facilities located in the following locations: Lansing, Michigan; Lexington, Kentucky; Randolph, Wisconsin; Kenansville, North Carolina; Pleasantville, Iowa; Memphis, Tennessee; Turlock, California; Heywood, England; Liverpool, England; Ayr, Scotland; Rochdale, England; and Pindamonhangaba, Brazil. We offer genomics services from facilities located in: Lincoln, Nebraska; Ayr, Scotland; Pindamonhangaba, Brazil; Edmonton, Canada; Shanghai, China; and Aracatuba, Brazil.Gatton, Australia. These facilities and our distribution systems are subject to catastrophic loss due to fire, flood, terrorism or other natural or
man-made
disasters. If any of these facilities were to experience a catastrophic loss, it could disrupt our operations, delay production, shipments and revenue and result in significant expenses to repair or replace the facility and/or distribution system. If such a disruption were to occur, we could breach agreements, our reputation could be harmed, and our business and operating results could be adversely affected. Although we carry insurance for property damage and business interruption, we do not carry insurance or have financial reserves for interruptions or potential losses arising from terrorism. Economic conditions and uncertainties in global markets may adversely affect the cost and other terms upon which we are able to obtain third party insurance. If our third partywe are unable to obtain sufficient and cost-effective third-party insurance coverage, is adversely affected, or to the extent we have elected to self-insure, we may be at greater risk that our operations will be harmed by a catastrophic loss.

Our dependence on suppliers could limit our ability to sell certain products or negatively affect our operating results.

We rely on third partythird-party suppliers to provide raw materials and other components in our products, manufacture products that we do not manufacture ourselves and perform services that we do not provide ourselves, including package delivery services.ourselves. Because these suppliers are independent third parties with their own financial objectives, actions taken by them could have a negative effect on our results of operations. The risks of relying on suppliers include our inability to enter into contracts with third party suppliers on reasonable terms, inconsistent or inadequate quality control, relocation of supplier facilities, supplier work stoppages and suppliers’ failure to comply with their contractual obligations. In addition, we currently purchase some raw materials and products from sole or single sources. Some of the products that we purchase from these sources are proprietary and, therefore, cannot be readily or easily replaced by alternative sources. Problems with suppliers could negatively impact our ability to supply the market, substantially decrease sales, lead to higher costs or damage our reputation with our customers.

15

We rely heavily on third partythird-party package delivery services, and a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.

We ship a significant portion of our products to our customers through independent package delivery companies, such as UPS, Federal Express and DHL. We also ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third partythird-party package delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with some of our customers could be adversely affected. In addition, if one or more of our third partythird-party package delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments inwithin our delivery network, our profitability could be adversely affected.

Our business sells many products through distributors, which present risks that could negatively affect our operating results.

We sell many of our products, both within and outside of the U.S., through distributors. As a result, we are dependent on these distributors to sell our products and assist us in promoting and creating a demand for our products. Our distributors sometimes offer products from several different companies, and those distributors may carry our competitors’ products and promote our competitors’ products over our own. We have limited ability, if any, to cause our distributors to devote adequate resources to promoting, marketing, selling and supporting our products. We cannot assure that we will be successful in maintaining and strengthening our relationships with our distributors or establishing relationships with new distributors who have the ability to market, sell and support our products effectively. We may rely on one or more key distributors for a product or region, and the loss of one or more of these distributors could reduce our revenue. Distributors may face financial difficulties, including bankruptcy, which could harmimpact our collection ofability to collect our accounts receivable and negatively impact our financial results. In addition, violations of anti-corruption laws or similar laws by our distributors could have a material impact on our business, and any termination of a distributor relationship may result in increased competition in the applicable jurisdiction. Failing to manage the risks associated with our use of distributors may reduce sales, increase expenses and weaken our competitive position, which could have a negative impact on our operating results.

The development of new products entails substantial risk of failure due to the production of
non-viable
products, lack of properly identifying market potential, and competitors better serving the marketplace.

Our growth strategy includes significant investment in and expenditures for product development. To execute this strategy, we are continually developing new products for which we believe there should be significant market demand. We cannot assure that we will successfully develop commercially viable products, that the products will be developed on a timely basis to meet market demand or that the relevant market will be properly identified. Our competitors may also adapt more quickly, and deliver superior technologies, price and/or service to better fit our customers’ requirements. If we expend substantial resources in developing an unsuccessful product, whether that lack of success is the result of our production of a
non-viable
product, a misidentified market, or a competitor’s superior ability to meet our customers’ requirements, operating results could be adversely affected.

Our international operations are subject to different product standards as well as other operational risks.

In fiscal 2017, sales to customers outside of the U.S. accounted for 35.8% of the Company’s total revenue. We expect that our international business will continue to account for a significant portion of our total revenue. Foreign regulatory bodies may establish product standards different from those in the U.S. and with which the Company’s current products do not comply. Our potential inability to design products that comply with foreign standards could have a material adverse effect on our future growth. Other risks related to our sales to customers outside of the U.S. include possible disruptions in transportation, difficulties in building and managing foreign distribution, fluctuation in the value of foreign currencies, changes in import duties and quotas and unexpected economic and political changes in foreign markets. These factors could adversely affect international sales and our overall financial performance.

The markets for our products are extremely competitive, and our competitors may be able to utilize existing resource advantages to our detriment.

The markets in which the Company competeswe compete are subject to rapid and substantial changes in technology and are characterized by extensive research and development and intense competition. Many of ourOur competitors and potential competitors may have greater financial, technical, manufacturing, marketing, research and development and management resources than we do. These competitors might be able to use their resources, reputations and ability to leverage existing customer relationships to give them a competitive advantage over us. They might also succeed in developing products that are more reliable and effective than our products, make additional measurements, are less costly than our products or provide alternatives to our products.

We are dependent on the agricultural marketplace, which is affected by factors beyond our control.

Our primary customers are in the agricultural and food production industries. Economic conditions affecting agricultural industries are cyclical and are dependent upon many factors outside of our control, including weather conditions, changes in consumption patterns or commodity prices. Any of these factors in the agricultural marketplace could affect our sales and overall financial performance.

Our quarterly operating results are subject to significant fluctuations.

We have experienced, and may experience in the future, significant fluctuations in our quarterly operating results. The mix of products sold and the acceptance of new products, in addition to other factors, could contribute to this quarterly variability. We operate with relatively little backlog and have few long-term customer contracts. Substantially all of our product revenue in each quarter results from orders received in that quarter. In addition, our expense levels are based, in part, on our expectation of future revenue levels. A shortfall in expected revenue could, therefore, result in a disproportionate decrease in our net income.

16

Our success is highly dependent on our ability to obtain protection for the intellectual property utilized in our products.

Our success and ability to compete depends in part upon our ability to obtain protection in the United StatesU.S. and other countries for our products by establishing and maintaining intellectual property rights relating to or incorporated into our technology and products. Patent applications filed by the Companyus may not result in the issuance of patents or, if issued, may not be issued in a form that will be commercially advantageous to us. Even if issued, patents may be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing similar products or limit the length of time we may have patent protection for our products. We also cannot assure that our nondisclosure agreements, together with trade secrets and other common law rights, will provide meaningful protection for the Company’sour trade secrets and other proprietary information. Moreover, the laws of some foreign jurisdictions may not protect intellectual property rights to the same extent as in the United States,U.S., and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights domestically or in foreign jurisdictions, we may incur substantial costs and our business, including our business prospects, could be substantially harmed.

From time to time, the Company haswe have received notices alleging that the Company’sour products infringe third partythird-party proprietary rights. Whether the manufacture, sale or use of current products, or whether any products under development would, upon commercialization, infringe any patent claim will not be known with certainty unless and until a court interprets the patent claim in the context of litigation. When an infringement allegation is made against us, we may seek to invalidate the asserted patent claim and/or to allege
non-infringement
of the asserted patent claim. In order forFor us to invalidate a U.S. patent claim, we would need to rebut the presumption of validity afforded to issued patents in the United StatesU.S. with clear and convincing evidence of invalidity, which is a high burden of proof. The outcome of infringement litigation is subject to substantial uncertainties, and also the testimony of experts as to technical facts upon which experts may reasonably disagree. Our defense of an infringement litigation lawsuit could result in significant expense. Regardless of the outcome, infringement litigation could significantly disrupt our marketing, development and commercialization efforts, divert management’s attention and consume our financial resources. In the event that we are found to infringe any valid claim in a patent held by a third party, we may, among other things, be required to:

Pay damages, including up to treble damages and the other party’s attorneys’ fees, which may be substantial;

Cease the development, manufacture, importation, use and sale of products that infringe the patent rights of others, through a court-imposed injunction;

Expend significant resources to redesign our technology so that it does not infringe others’ patent rights, or develop or acquire
non-infringing
intellectual property, which may not be possible;

Discontinue manufacturing or other processes incorporating infringing technology; and/or

Obtain licenses to the infringed intellectual property, which may not be available to us on acceptable terms, or at all.

Any development or acquisition of
non-infringing
products, technology or licenses could require the expenditure of substantial time and other resources and could have a material adverse effect on our business and financial results. If we are required to, but cannot, obtain a license to valid patent rights held by a third party, we would likely be prevented from commercializing the relevant product, or from further manufacture, sale or use of the relevant product.

We are subject to substantial governmental regulation.

A portion of our products and facilities are regulated by various domestic and foreign government agencies including, but not limited to, the U.S. Department of Agriculture, the U.S. Food and Drug Administration and the Environmental Protection Agency. A significant portion of our revenue is derived from products used to monitor and detect the presence of residues that are regulated by various government agencies. Furthermore, the Company’sour growth may be adversely affected by the implementation of new regulations. The Company is not aware of any failures to comply with applicable laws and regulations; the costs of compliance or failure to comply with any obligations related to these laws or regulations could adversely impact theour business.

We are dependent on key employees.

Our success depends, in large part, on members of our management team. Our loss of any of these, or other key employees could have a material adverse effect on the Company.us. We maintain certain incentive plans for key employees, and most of these employees have been with the Company in excess of five years. However, we have not executed long-term employment agreements with any of these employees and do not expect to do so in the foreseeable future. Our success depends, significantly, on our ability to continue to attract and retain such personnel. We cannot assure that we will be able to retain our existing personnel or attract additional qualified persons when required and on acceptable terms.

Our business may be subject to product or services liability claims.

The manufacturing and distribution of the Company’sour products involveor performance of our services involves an inherent risk of product liability claims being asserted against us. Regardless of whether we are ultimately determined to be liable or our products are determined to be defective, we might incur significant legal expenses not covered by insurance. In addition, product liability litigation could damage our reputation and impair our ability to market our products, regardless of the outcome. Litigation could also impair our ability to retain product liability insurance or make our insurance more expensive.
17

Although the Companywe currently maintainsmaintain liability insurance, we cannot assure that we will be able to continue to obtain such insurance on acceptable terms, or that such insurance will provide adequate coverage against all potential claims. If we are subject to an uninsured or inadequately insured product or services liability claim, our business, financial condition and results of operations could be adversely affected.

Market prices for securities of technology companies are highly volatile.

The market prices for securities of technology companies have been volatile in the past and could continue to be volatile in the future. Fluctuations in our financial performance from period to period could have a significant impact on the market price of our common shares.

Operating

Our international operations are subject to different product standards as well as other operational risks.
In fiscal 2020, sales to customers outside of the U.S. accounted for 39.4% of our total revenue. We expect that our international business will continue to account for a significant portion of our total sales. Foreign regulatory bodies may establish product standards different from those in the U.S. and with which our current products do not comply. Our potential inability to design products that comply with foreign standards could have a material adverse effect on our future growth. Other risks related to sales to customers outside of the U.S. include possible disruptions in transportation, difficulties in building and managing foreign distribution, fluctuation in the value of foreign currencies, changes in import duties and quotas and unexpected economic and political changes in foreign markets. These factors could negatively impact our competitiveness in these markets or otherwise adversely impact our business results or financial condition. Moreover, discriminatory or conflicting fiscal or trade policies in different countries, including potential changes to tariffs and existing trade policies and agreements, could be negatively impacted by economic,adversely affect our results.
Changing political or other developmentsconditions could adversely impact our business and financial results.
Changes in countriesthe political conditions in markets in which we do business.

Future operatingmanufacture, sell or distribute our products may be difficult to predict and may adversely affect our business and financial results. For example, the U.K.’s decision to leave the European Union has created uncertainty regarding, among other things, the U.K.’s future legal and economic framework and how the U.K. will interact with other countries, including with respect to the free movement of goods, services, capital and people. In addition, results of elections, referendums or other political processes in certain markets in which our products are manufactured, sold or distributed could be negatively impacted by unstable economic, political and social conditions, including but not limited to fluctuations in foreign currency exchange rates, political instability, or changes in the creation or interpretation ofcreate uncertainty regarding how existing governmental policies, laws and regulations or administrative actions in eachmay change, including with respect to sanctions, taxes, the movement of goods, services, capital and people between countries and other matters. The potential implications of such uncertainty, which include, among others, exchange rate fluctuations, trade barriers and market contraction, could adversely affect the Company’s business and financial results.

Tax legislation could materially adversely affect our financial results and tax liabilities.
We are subject to the tax laws and regulations of the countries whereU.S., including state and local governments, as well as foreign jurisdictions. Legislation may be enacted that could materially adversely affect our financial results There can be no assurance that our effective tax rate will not be adversely affected by legislation.
Our tax expense and liabilities may also be affected by other factors, such as changes in our business operations, acquisitions, investments, entry into new businesses and geographies, intercompany transactions, the Company conducts business, including the United States.

These potential negative impacts include, butrelative amount of our foreign earnings, losses incurred in jurisdictions for which we are not limited to: reductionable to realize related tax benefits, changes in our stock price, and changes in our deferred tax assets and liabilities and their valuation. In addition, tax laws and regulations are extremely complex and subject to varying interpretations. For example, the legislation known as the U.S. Tax Cuts and Jobs Act of demand for some2017 (the “U.S. Tax Act”) requires complex computations to be performed that were not previously required by U.S. tax law, significant judgments to be made in interpretation of the provision of the U.S. Tax Act, significant estimates in calculations, and the preparation and analysis of information not previously relevant or regularly produced. The U.S. Treasury Department, the IRS, and other standard-setting bodies will continue to interpret or issue guidance on how provisions of the U.S. Tax Act will be applied or otherwise administered. As future guidance is issued, we may make adjustments to amounts that we have previously recorded that may materially impact our products, increasefinancial statements in the rate of order cancellationsperiod in which the adjustments are made.

Although we believe that our historical tax positions are sound and consistent with applicable laws, regulations and existing precedent, there can be no assurance that our tax positions will not be challenged by relevant tax authorities or delays, increased risk of excess and obsolete inventories, increased pressure on the prices for our products and services, and longer sales cycles and greater difficultythat we would be successful in collecting accounts receivable.

any such challenge. Additionally, the Company operateswe operate in multiple income tax jurisdictions and must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax audits associated with the allocation of income and other complex issues may result in significant income tax adjustments that could negatively impact the Company’sour future operating results.

18

ITEM 1B.
UNRESOLVED STAFF COMMENTS – NONE

ITEM 2.
PROPERTIES

Principal Manufacturing, Distribution and Administrative locations

Location

  Approximate 
Square

Feet
   

Operations

  

Ownership

Lansing, Michigan

   300,000   Corporate, Food Safety, Animal Safety  Owned

Lexington, Kentucky

   210,000   Animal Safety  Owned

Kenansville, North Carolina

   26,00033,500   Animal Safety  Leased, expires 12/20173/2021

St Joseph, Michigan

   7,000   Animal Safety  Leased, month to monthexpires 5/2021

Randolph, Wisconsin

   113,000137,000   Animal Safety  Owned

Pleasantville, Iowa

   59,000   Animal Safety  Leased, expires 12/20182020

Lincoln, Nebraska

   26,00041,000   Animal Safety  Owned

Memphis, Tennessee

   66,100   Animal Safety  Owned

Turlock, California

   29,500   Animal Safety  Leased, expires 9/2022

Guelph, Ontario,

Edmonton, Alberta, Canada

   7004,800   Animal Safety  Leased, expires 7/2019Owned

Ayr, Scotland, United Kingdom

   74,000   Food Safety  Owned

Heywood, England, United Kingdom

   24,80026,800   Food Safety  Owned

Rochdale, England, United Kingdom

   60,000   Food Safety  Owned

Liverpool, England, United Kingdom
4,000Food SafetyLeased, expires 12/2025
Milan, Italy
1,000Food SafetyLeased, expires 12/2020
Indaiatuba, Brazil

   6,800   Food Safety  Leased, expires 5/2021

Aracatuba,

Pindamonhangaba, Brazil

   2,000Food SafetyLeased, expires 10/2017

Pindamonhangaba, Brazil

55,30076,000   Food Safety  Owned

Naucalpan, Mexico

   27,000   Food Safety  Leased, expires 10/20182021

Shanghai, China

Buenos Aires, Argentina
   4,9002,200   Food Safety  Leased, expires 2/20198/2020

Beijing, China

Ciudad de la Costa, Uruguay
   1,100900   Food Safety  Leased, expires 12/201710/2020

Santiago, Chile
2,700Food SafetyLeased, expires 3/2022
Shanghai, China
7,900Food SafetyLeased, expires 10/2021
Kochi, India

   5,500   Food Safety  Leased, expires 4/20182021
Gatton, Australia
4,600Animal SafetyLeased, expires 1/2023

The Company’s

Our corporate headquarters are located in Lansing, Michigan, with administrative, sales, manufacturing and warehousing in other locations domestically and globally. These properties are in good condition, well-maintained, and generally suitable and adequate to carrysupport our business. For those leases expiring within the next 12 months, we believe that we will be able to negotiate agreements to extend such leases on the Company’s business.

similar terms.
19

ITEM 3.
LEGAL PROCEEDINGS

Neogen is subject to certain legal proceedings in the normal course of business that, in the opinion of management, should not have a material effect on itsour future results of operations or financial position.

ITEM 4.
MINE SAFETY DISCLOSURES NOT APPLICABLE

PART II

ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

MARKET INFORMATION:

Market Information
Neogen Common Stock is traded on the NASDAQ Global Select Market under the symbol “NEOG”. The following table sets forth, for the fiscal periods indicated, the high and low sales prices for the Common Stock as reported on the NASDAQ Stock Market.

   High   Low 

Year ended May 31, 2017

    

First Quarter

  $60.56   $49.30 

Second Quarter

  $63.57   $50.53 

Third Quarter

  $69.09   $61.25 

Fourth Quarter

  $68.98   $59.51 

Year ended May 31, 2016

    

First Quarter

  $62.70   $44.90 

Second Quarter

  $59.76   $43.00 

Third Quarter

  $60.38   $45.00 

Fourth Quarter

  $53.02   $43.79 

HOLDERS:

NEOG.

Holders
As of June 30, 2017,2020, there were approximately 281245 stockholders of record of Common Stock and management believes there are a total of approximately 12,00010,000 beneficial holders.

DIVIDENDS:

Dividends
Neogen has never paid cash dividends on its Common Stock and does not anticipate paying cash dividends in the foreseeable future.

20

The graph below matches Neogen Corporation’s cumulative5-year
5-Year
total shareholder return on common stock with the cumulative total returns of the NASDAQ Composite index and the NASDAQ Medical Equipment index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from May 31, 20125/31/2015 to May 31, 2017.

   5/12   5/13   5/14   5/15   5/16   5/17 

Neogen Corporation

   100.00    139.88    145.57    180.05    190.18    243.80 

NASDAQ Composite

   100.00    123.46    155.08    186.71    183.49    231.19 

NASDAQ Medical Equipment

   100.00    110.10    114.40    146.23    155.20    204.07 

5/31/2020.

   
5/15
   
5/16
   
5/17
   
5/18
   
5/19
   
5/20
 
Neogen Corporation
  
 
100.00
 
  
 
105.63
 
  
 
135.41
 
  
 
215.97
 
  
 
160.75
 
  
 
203.17
 
NASDAQ Composite
  
 
100.00
 
  
 
98.82
 
  
 
125.26
 
  
 
152.00
 
  
 
153.87
 
  
 
197.98
 
NASDAQ Medical Equipment
  
 
100.00
 
  
 
105.80
 
  
 
140.72
 
  
 
197.84
 
  
 
194.22
 
  
 
235.57
 
The stock price performance included in this graph is not necessarily indicative of future stock price performance.

Issuer Purchases of Equity Securities

In December 2008, the Board of Directors authorized management to repurchase up to a total of 1,125,000 shares of its common stock in open market transactions. This authorization remains in effect; however, the Company made no purchases of common stock in fiscal years 2017, 2016 and 2015.

21

ITEM 6.
SELECTED FINANCIAL DATA

The following tables set forth selected consolidated financial data of Neogen for the year ended May 31, 2017,2020, and each of the four preceding fiscal years. The selected consolidated financial data presented below have been derived from the Company’sour consolidated financial statements. This financial data should be read in conjunction with the consolidated financial statements, related notes and other financial information appearing elsewhere in this Form
10-K.

   Years Ended May 31 
(in thousands, except per share data)  2017  2016  2015  2014  2013 

Income Statement Data:

      

Food Safety Revenues

  $171,325  $146,421  $131,479  $116,290  $106,158 

Animal Safety Revenues

   190,269   174,854   151,595   131,115   101,370 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total Revenues

   361,594   321,275   283,074   247,405   207,528 

Cost of Revenues

   189,626   168,211   143,389   124,807   98,034 

Sales and Marketing

   62,424   57,599   51,757   46,432   40,791 

General and Administrative

   34,214   29,189   25,233   24,449   20,216 

Research and Development

   10,385   9,890   9,577   8,326   7,781 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Operating Income

   64,945   56,386   53,118   43,391   40,706 

Other Income (Expense)

   1,728   (873  (1,042  (360  435 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income Before Income Taxes

   66,673   55,513   52,076   43,031   41,141 

Provision for Income Taxes

   22,700   18,975   18,500   15,000   14,100 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net Income

   43,973   36,538   33,576   28,031   27,041 

Net (Income) Loss Attibutable toNon-Controlling Interest

   (180  26   (50  127   149 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net Income Attributable to Neogen

  $43,793  $36,564  $33,526  $28,158  $27,190 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net Income per Share (basic) (1)

  $1.16  $0.98  $0.91  $0.77  $0.76 

Net Income per Share (diluted) (1)

  $1.14  $0.97  $0.90  $0.76  $0.75 

Weighted Average Shares Outstanding (diluted) (1)

   38,374   37,875   37,444   37,267   36,491 
   2017  2016  2015  2014  2013 

Balance Sheet Data:

      

Cash and Cash Equivalents and Marketable Securities

  $143,635  $107,796  $114,164  $76,496  $85,369 

Working Capital (2)

   256,959   219,628   205,739   163,779   150,728 

Total Assets

   528,409   449,940   392,181   345,301   290,558 

Long-Term Debt

   —     —     —     —     —   

Total Equity

   471,757   404,161   350,963   306,300   258,287 

   
Year Ended May 31
 
   
2020
   
2019
   
2018
  
2017
  
2016
 
(in thousands, except per share data)
                  
Income Statement Data:
        
Food Safety Revenues
  $212,691   $213,474   $194,477  $170,034  $145,057 
Animal Safety Revenues
   205,479    200,712    203,453   188,243   172,172 
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Total Revenues
   418,170    414,186    397,930   358,277   317,229 
Total Cost of Revenues
   221,891    222,266    211,658   189,353   167,898 
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Gross Margin
   196,279    191,920    186,272   168,924   149,331 
Sales and Marketing
   69,675    70,230    66,929   59,380   53,866 
General and Administrative
   44,331    40,791    38,294   34,214   29,189 
Research and Development
   14,750    12,805    10,855   10,385   9,890 
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Operating Income
   67,523    68,094    70,194   64,945   56,386 
Other Income (Expense)
   4,782    4,865    3,271   1,728   (873
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Income Before Income Taxes
   72,305    72,959    73,465   66,673   55,513 
Provision for Income Taxes
   12,830    12,783    10,250   22,700   18,975 
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Net Income
   59,475    60,176    63,215   43,973   36,538 
Net (Income) Loss Attributable to
Non-controlling
Interest
   —      —      (70  (180  26 
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Net Income Attributable to Neogen
  $59,475   $60,176   $63,145  $43,793  $36,564 
  
 
 
   
 
 
   
 
 
  
 
 
  
 
 
 
Net Income per Share (basic) (1)
  $1.13   $1.16   $1.23  $0.87  $0.73 
Net Income per Share (diluted) (1)
  $1.13   $1.15   $1.21  $0.86  $0.72 
Weighted Average Shares Outstanding (diluted) (1)
   52,860    52,425    52,149   51,165   50,500 
   
Year Ended May 31
 
   
2020
   
2019
   
2018
  
2017
  
2016
 
Balance Sheet Data:
        
Cash and Cash Equivalents and Marketable Securities
  $343,673   $267,524   $210,810  $143,635  $107,796 
Working Capital (2)
   488,917    411,278    337,101   256,959   219,628 
Total Assets
   797,182    695,740    618,009   528,409   449,940 
Long-Term Debt
   —      —      —     —     —   
Total Equity
   725,177    637,899    560,175   471,757   404,161 
(1)
On October 30, 2013,December 29, 2017, the Company paideffected a3-for-2
4-for-3
stock split affected in the formwhereby shareholders of record on December 18, 2017 received a dividend of its common stock.one additional share of stock for each three shares held. All share and per share amounts in this Form
10-K
have been adjusted to reflect the stock split as if it had taken place at the beginning of the period presented.

(2)
Defined as current assets less current liabilities.

22

ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The informationfollowing discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes appearing elsewhere in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen Corporation management does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependenceAnnual Report on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Form

10-K.
In addition, any forward-looking statements represent management’s views only as of the day this Report on Form
10-K
was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While managementwe may elect to update forward-looking statements at some point in the future, itwe specifically disclaimsdisclaim any obligation to do so, even if itsour views change.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The discussion and analysis of the Company’sour financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including but not limited to, those related to receivable allowances, inventories and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Though the impact of the
COVID-19
pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. Actual results may differ from these estimates under different assumptions or conditions.

The following critical accounting policies reflect
policy reflects
management’s more significant judgments and estimates used in the preparation of the consolidated financial statements.

Revenue Recognition

Revenue from products and services is recognized when the product has been shipped or the service performed, the sales price is fixed and determinable, and collection of any receivable is probable. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred and later recognized in the period that all recognition criteria have been met. Customer credits for sales returns, pricing and other disputes, and other related matters (including volume rebates offered to certain distributors as marketing support) represent approximately 3% of reported net revenue for each period presented.

Accounts Receivable Allowance

Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, that amount is charged against the allowance for doubtful accounts.

Inventory

A reserve for obsolete and slow moving inventory has been established and is reviewed at least quarterly based on an analysis of the inventory, taking into account the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or market may be adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenantsnot-to-compete and patents. Amortizable intangible assets are amortized on either an accelerated or a straight-line basis, generally over 5 to 25 years. The Company reviews the carrying amounts of goodwill and othernon-amortizable intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired by performing a quantitative assessment. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is made to operations.

Long-lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.

Equity Compensation Plans

Share options awarded to employees and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company’s stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model using assumptions for inputs such as interest rates, expected dividends, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized.

To value options, several recognized valuation models exist. None of these models can be singled out as being the best or most correct one. The model applied by the Company is able to handle most of the specific features included in the options granted, which is the reason for its use. If a different model were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on the Company’s equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Notes 1 and 5 to the consolidated financial statements.

Income Taxes

The Company accounts

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carry forwardscarryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

The Company’sdetermination of income subject to income tax in each tax paying jurisdiction requires us to apply transfer pricing guidelines for certain intercompany transactions.

Our wholly-owned foreign subsidiaries are comprised of Neogen Europe, Lab M Holdings,Ltd, Quat-Chem Ltd, Abtek (Biologicals) Ltd, Neogen Italia S.r.l., Neogen do Brasil, Rogama Industria e Comercio Ltda, Neogen Latinoamérica, Productos Quimicos Magiar S.A., Neogen Uruguay, Neogen Chile SpA, Neogen
Bio-Scientific
Technology Co (Shanghai), Neogen Food and Animal Security (India), Neogen Canada, Acumedia do Brasil, Deoxi Biotecnologia Ltda, and Rogama Industria e Comercio, Ltda; Neogen owns 90% of Neogen Latinoamerica.Australasia Pty Limited. Based on historical experience, as well as the Company’sour future plans, earnings from these subsidiaries are expected to be
re-invested
indefinitely for future expansion and working capital needs. Furthermore, the Company’sour domestic operations have historically produced sufficient operating cash flow to mitigate the need to remit foreign earnings. On an annual basis, the Company evaluateswe evaluate the current business environment and whether any new events or other external changes might require a
re-evaluation
of the decision to indefinitely
re-invest
foreign earnings. At MayIt is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (U.S. Tax Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a federal corporate tax rate reduced from 35% to 21% for tax years beginning after December 31, 2017, unremitted earningsthe transition of U.S. international taxation from a worldwide tax system to a territorial system, and a
one-time
transition tax on the mandatory deemed repatriation of foreign earnings. The U. S. Tax Act also includes a provision to tax global intangible
low-taxed
income (GILTI) of foreign subsidiaries were $35,281,000.

and a deduction for foreign derived intangible income (FDII), both of which became effective for us beginning June 1, 2018. See Note 6 to the consolidated financial statements for further information.

23

RESULTS OF OPERATIONS

Executive Overview

Total consolidated revenue for Neogen Corporation

Consolidated revenues were $418.2 million in fiscal 2017 was $361.6 million,2020, an increase of 13%1.0% compared to revenue of $321.3$414.2 million in fiscal 2016. Net income attributable to Neogen rose 20% to $43.8 million, or $1.14 per fully diluted share, compared to $36.6 million, or $0.97 per fully diluted share, in fiscal 2016. Cash flow from operations for fiscal 2017 was $60.3 million compared to $35.3 million in fiscal 2016.

The Company’s Food Safety segment revenues were $171.3 million in fiscal 2017, an increase of 17%, and Animal Safety segment revenues were $190.3 million, an increase of 9%, each2019. Organic sales overall increased 0.2% compared to the prior year.

Food Safety segment sales were $212.7 million in fiscal year. Recent2020 compared to $213.5 million in fiscal 2019, a decrease of $800,000, or 0.4%. Organic sales decreased 1.3%, while the Clarus Labs (August 2018) acquisition, the purchase of four former distributors and a small manufacturer (Abtek) completed during the year, contributed $2.0 million in revenues.
Animal Safety segment sales were $205.5 million in fiscal 2020, an increase of 2.4% compared to $200.7 million in fiscal 2019. Organic sales rose 1.9%, with the acquisitions of Lab M (August 2015)Livestock Genetic Services (September 2018), Virbac (December 2015), Deoxi (April 2016), Preserve (May 2016), Quat-Chem (December 2016)Delta Genomics (January 2019) and Rogama (December 2016) contributed $27.7 millionCell BioSciences (March 2020) contributing the remainder of revenue in fiscal 2017; overall organic sales growth was 4%.

the growth.

International sales were $129.3 million39.4% of total sales in fiscal 2017, or 35.8%2020 compared to 40.1% of total revenues,sales in fiscal 2019.
Our effective tax rate was 17.7% in fiscal 2020 compared to $107.7an effective tax rate of 17.5% in fiscal 2019.
Net income was $59.5 million, or 33.5%$1.13 per diluted share, a decrease of total revenues,1% compared to $60.2 million, or $1.15 per share, in the prior year. The increase
Cash generated from operating activities in fiscal 2020 was $85.9 million, compared to $63.8 million in fiscal 2019.
Neogen’s international salesrevenues were $164.7 million in fiscal 2020, compared to $165.9 million in fiscal 2019. Currency translation had a negative impact during the year. In a neutral currency environment, revenues would have been approximately $6.0 million higher on a comparative basis in fiscal 2020, as a percentagethe U.S. dollar (USD) strengthened against all the currencies in the countries in which we conduct business. As financial markets reacted to the global impact of total salesthe
COVID-19
pandemic, currency translations negatively impacted comparative revenues by $3.5 million in the fourth quarter of fiscal 2020. This was primarily due to devaluation of the Brazilian real and the Mexican peso, which were 25% and 18% lower on average, respectively, compared to the fourth quarter of fiscal 2019.
We continue to focus on increasing our presence and market share throughout the world, while also integrating recent international acquisitions into our overall geographic and strengthproduct portfolio. Sales results for fiscal 2020 compared to the prior year are as follows for each of our international locations:
   
Revenue
   
Revenue
 
   
% Increase
   
% Increase
 
   
USD
   
Local Currency
 
Neogen Europe (including Lab M, Quat-Chem & Abtek)
   5%    8% 
Neogen do Brasil (including Rogama)
   (10)%    0% 
Neogen Latinoamerica
   6%    11% 
Neogen China
   22%    26% 
Neogen India
   3%    5% 
Neogen Australasia
   18%    26% 
Neogen Canada
   70%    72% 
The revenue increase in thepre-existing international operations. For the year, revenuesU.S. dollars at Neogen Europe increased 13% (32%was led by a 14% increase in local currency)sales of disinfectant and veterinary products, primarily due primarilyto
COVID-19
related sales of hand sanitizer and disinfectant in the U.K. Sales of genomics services rose 7% in fiscal 2020, on strength to strongthe bovine market. Sales of culture media products increased 5% for the year. Partially offsetting this growth, were lower sales of deoxynivalenol (DON) test kits into France and Germany, due to an outbreak in fiscal 2019, which did not recur in the current year.
Revenues in Brazil declined 10% in USD in fiscal 2020, in large part due to the devaluation of the Brazilian real relative to the U.S. dollar during the year. Sales of our forensic drug test kits, used to test for the presence of prohibited drugs in commercial truck drivers in that country, declined 86%, as a large commercial laboratory switched to an
alternative testing
method in the first quarter of the year. Genomics revenues in Brazil declined 26% during the year, primarily due to a project testing cattle for the Brazilian government in the prior fiscal year which did not recur in fiscal 2020,
24

as well as delays in receiving samples in the fourth quarter due to
COVID-19.
Partially offsetting that decline was strong growth in sales of natural toxins test kits, as we continued to gain significant business from customers testing for the presence of aflatoxin in corn and DON in grains.
Neogen Latinoamerica grew revenues by 6% in USD, with strong growth in sales of diagnostic test kits, which offset lower sales of cleaners, disinfectants and rodenticides in Mexico and Central America due to weakness in the distribution channels in those markets. Growth in China was the result of strong sales of cleaners and disinfectants, including Neogen Viroxide Super, into the porcine market, due to demand resulting from outbreaks of contaminated corn cropsthe Asian swine flu and
COVID-19
outbreak in western Europe, and increasesthat country. Revenue growth in genomics revenues resulting from strong demand for these services in Europe and the addition of anin-house genomics lab in Ayr. Neogen do Brasil revenues increased 65%India was 3% for the year (46% increase in local currency), with sales of forensic and diagnostic test kits leadingbut decreased 16% during the growth. Revenues at Neogen Latinoamerica declined by 7% (6% increase in local currency) due to adverse currency translations and the termination of a distribution agreement for certain of its cleaners and disinfectants in the 4thfourth quarter of fiscal 2017. Neogen China revenues rose 24% (32% increase in local currency) and Neogen India sales increased 67% (70% increase in local currency), each off of small bases.

Service revenue was $55.1 million in fiscal 2017, an increase of $7.4 million, or 15%, compared to fiscal 2016. The increase was primarily due to higher genomics revenues due to continued market penetration in U.S. beef and dairy cattle markets, strong demand in Europe and additional genomics capacity resulting from laboratory facilities constructed at our Scotland-based operation, and incremental ongoing business with a large customer in the poultry industry. Revenues were also enhanced, to a lesser extent, by the April 2016 acquisition of Deoxi Laboratories, an agricultural genomics lab in Brazil.

Gross margin was 47.6% in both fiscal years 2017 and 2016. In the current year, acquisitions of businesses with gross margins which are lower than the Company’s historical average, and the adverse margin impact resulting from currency translation, were entirely offset by favorable product mix shifts on existing products and higher genomics margins, resulting in gross margins that were flat compared to the prior year.

Salesyear, as the country’s economic activity was greatly reduced in that period due to

COVID-19.
Neogen Australasia’s growth was led by a 21% gain in genomics revenue to the sheep market and marketing expenses were $62.4growth in traditional animal safety products for the year, while strong genomics sales in beef and poultry markets in Canada drove their 70% revenue increase, albeit off a small base.
Service revenue, which consists primarily of genomics services to animal protein and companion animal markets, was $82.6 million in fiscal 2020, an increase of $4.8 million, or 8%, compared to the11% over prior fiscal year. Increasesyear sales of $74.7 million. The growth was led by increases in this category were primarily the result of increased personnel related costs such as salaries, commissions and travel; shipping and royalty expenses also rose due to the increased volume. General and administrative expenses were $34.2 million, an increase of $5.0 million, or 17%. Incremental ongoing operating expensessample volumes from the most recent four acquisitions, which continued to operate from their existing locations,global commercial beef, sheep and related amortization expense accounted for $2.6 million of the increase. Other increases in this category resulted from investments in information technology personnelcompanion animal markets, while porcine and infrastructure and increased salary and benefit expenses across the organization. Research and development expenses increased 5% to $10.4 million, primarily due to increased personnel related expenses and new product development activities, partially offset by lower contracted outside services.

Operating margin in fiscal 2017 was 18.0% compared to 17.6% in the prior fiscal year. The improvement in operating margin resulted from the revenue increases, flat gross margins, and growth in operating expenses which was less than the rate of the revenue increase.

Other income of $1.7 million in fiscal 2017 included $838,000 of net interest income, a $660,000 gain recorded as the result of the settlement of a licensing agreement, $171,000 of royalty income, and a loss of $40,000 from currency translations. Fiscal 2016 other expense of $873,000 included a $1,338,000 loss from currency translations, partially offset by interest income of $322,000 and royalty income of $217,000.

The effective income tax rate for fiscal 2017 was 34.0%, compared to 34.2% in the prior fiscal year.

poultry sales were fairly flat.

REVENUES

   Year Ended 

(dollars in thousands)

  May 31, 2017   Increase/
(Decrease)
  May 31, 2016   Increase/
(Decrease)
  May 31, 2015 

Food Safety:

        

Natural Toxins, Allergens & Drug Residues

  $70,926    12 $63,269    4 $60,561 

Bacterial & General Sanitation

   34,706    2  33,899    15  29,492 

Dehydrated Culture Media & Other

   40,658    9  37,285    27  29,423 

Rodenticides, Insecticides & Disinfectants

   13,620    223  4,213    (8%)   4,568 

Genomics Services

   11,415    47  7,755    4  7,435 
  

 

 

    

 

 

    

 

 

 
   171,325    17  146,421    11  131,479 

Animal Safety:

        

Life Sciences

   9,704    24  7,815    (10%)   8,715 

Veterinary Instruments & Disposables

   41,693    (1%)   42,028    1  41,740 

Animal Care & Other

   29,495    (19%)   36,494    32  27,606 

Rodenticides, Insecticides & Disinfectants

   69,825    31  53,490    17  45,857 

Genomics Services

   39,552    13  35,027    27  27,677 
  

 

 

    

 

 

    

 

 

 
   190,269    9  174,854    15  151,595 
  

 

 

    

 

 

    

 

 

 

Total Revenue

  $361,594    13 $321,275    13 $283,074 
  

 

 

    

 

 

    

 

 

 

   
Year Ended
 
       
Increase/
       
Increase/
     
(dollars in thousands)
  
May 31, 2020
   
(Decrease)
   
May 31, 2019
   
(Decrease)
   
May 31, 2018
 
Food Safety:
          
Natural Toxins, Allergens & Drug Residues
  $76,207    (3)%   $78,373    7%   $72,962 
Bacterial & General Sanitation
   41,780    (0)%    41,966    10%    38,156 
Culture Media & Other
   47,847    (4)%    49,857    13%    44,271 
Rodenticides, Insecticides & Disinfectants
   28,890    13%    25,584    7%    23,821 
Genomics Services
   17,967    2%    17,694    16%    15,267 
  
 
 
     
 
 
     
 
 
 
   212,691    (0)%    213,474    10%    194,477 
Animal Safety:
          
Life Sciences
   6,322    (20)%    7,858    (25)%    10,411 
Veterinary Instruments & Disposables
   42,941    (4)%    44,582    (7)%    47,749 
Animal Care & Other
   28,389    (5)%    29,941    (3)%    30,930 
Rodenticides, Insecticides & Disinfectants
   68,815    4%    66,389    (2)%    67,646 
Genomics Services
   59,012    14%    51,942    11%    46,717 
  
 
 
     
 
 
     
 
 
 
   205,479    2%    200,712    (1)%    203,453 
  
 
 
     
 
 
     
 
 
 
Total Revenue
  $418,170    1%   $414,186    4%   $397,930 
  
 
 
     
 
 
     
 
 
 
Year Ended May 31, 20172020 Compared to Year Ended May 31, 2016

The Company’s 2019

Food Safety segment revenuesSafety:
The
COVID-19
pandemic in the second half of fiscal 2017 were $171.3 million compared2020 resulted in difficult operating conditions in many of our key market segments. Shelter in place orders across the U.S. and in a number of our international markets, the closure or reduced output of businesses due to $146.4 millionquarantine, disruption in fiscal 2016, an increase of 17%. Organic growth for the segment was 9%, with the acquisitions of Lab M (August 2015), Deoxi (April 2016), Quat-Chem (December 2016) and Rogama (December 2016) contributing the remainder of the growth. Adverse currency conditions,supply chain resulting from reduction in
end-market
demand, and the strengthinability of the U.S. dollar, reduced overall growth and organic growth within the segment for the comparative period. In a neutral currency environment, overall Food Safety growth for the year was 22% and organic growth was 14%.

some markets to react quickly to these changes, each adversely impacted our revenues.

Natural Toxins, Allergens
 & Drug Residues sales increased by 12% to $70.9 million
Sales in this category were 3% lower in fiscal 2017. Within this category, sales of natural toxin test kits increased 19%, led by sales of test kits and related equipment to detect the mycotoxin deoxynivalenol (DON), due to outbreaks of DON in corn crops in the midwest U.S., Canada and western Europe. Allergen test kit revenues rose 16% for the year, as increases in product recalls relating to allergenic contamination of food continued to expand the market. The largest increases in this product line were test kits to detect milk, gliadin, tree nut, hazelnut and peanut contamination. Partially offsetting these increases, sales of test kits to detect drug residues were down 4%, due primarily to market losses in Europe caused by delays in the launch of new products, and, to a lesser extent, currency translations, as this product is sold in euros, which declined 2% against the dollar in fiscal 2017. A number of new and improved drug residue detection products are expected to be available for sale in the first half of fiscal 2018.

Bacterial & General Sanitation revenues rose 2%,2020 compared to the prior fiscal year, leddriven by a 4% increase30% decline in sales of the Company’s line of automated equipment and consumable vials to detect spoilage microorganisms (e.g. yeast and mold), and an 11% increase in sales ofSalmonelladrug residues test kits, due to lower demand from a large distributor in Europe. In January 2020, we ended our exclusive

25

relationship with this distributor and have begun marketing these products directly into the European market. Partially offsetting the decrease in drug residue testing, the natural toxins and allergens product lines each increased 4% for the year as the Company gained market share with its ANSR product line. These increases wereyear. The natural toxin increase was due to continued new business earned in Brazil for aflatoxin and DON test kits, partially offset by lower sales of a distributed product that the Company discontinued in fiscal 2017. The Company’s line of AccuPoint readers and samplers to monitor environmental sanitation rose 4% for the year, with samplers increasing 7%, while equipment was flat compared to fiscal 2016. Dehydrated Culture Media & Other sales increased 9% in fiscal 2017, aided in part by the acquisition of Lab M; organic sales in this category increased 6%. Within this category, there was a significant increase in sales of forensicDON test kits through the Company’s Brazilian subsidiary. Demand for these kits from commercial labs located in Brazil has increased dramatically due to a new requirement for drug testing of commercial truck drivers. Partially offsetting this increase was an 11% decrease in sales of the Company’s Acumedia line of dehydrated culture media sold into traditional domestic markets; the first half of fiscal 2016 had strong sales resulting from a research project, which did not recur.

Rodenticides, Insecticides & Disinfectants sales into the Company’s Food Safety segment increased 223%, almost entirely due to the acquisitions of Rogama (Brazil), which reports through Neogen do Brasil, and Quat-Chem (U.K.), which reports through Neogen Europe; each was purchased in December 2016. Excluding these acquisitions, growth in this category was 3%, primarily from rodenticide and disinfectant sales into Mexico and Central America by the Company’s Mexican subsidiary. Genomics revenues into Food Safety increased 47%, primarily due to strong demand of genomics testing in Europe and expanded capabilities at the Company’s operation in Ayr, Scotland to better serve the growing European market; the Deoxi acquisition in April 2016 also contributed to the growth.

Revenues for the Company’s Animal Safety segment were $190.3 million in fiscal 2017, an increase of 9% compared to prior year revenues of $174.9 million. The revenue growth resulted from the acquisitions of Virbac (December 2015) and Preserve (May 2016). In the first quarter of fiscal 2017, the Company lost the ability to sell its popular canine thyroid replacement product after the FDA approved a new drug application for a competitor, which gave the competitor exclusive marketing rights to the product. The Company will be unable to sell this product, which had sales of $6.2 million in fiscal 2016, in the U.S. until similar regulatory approval is granted; this approval is currently expected to occur in fiscal 2019. Additionally, in January 2017,and France, the Company’s agreement to distribute certain cleaners and disinfectants was canceled, resulting in the lossresult of $1.3 million of sales in the 4th quarter of fiscal 2017. Excluding these products, this segment had overall organic growth of 5% for the year. Currency translations had minimal effect on revenues in this segment.

Life Sciences sales increased 24% in fiscal 2017, compared to the prior year. This growth was primarily due to increased volume to U.S. commercial labs to meet new requirements for drug testing of commercial truck drivers in Brazil. Veterinary Instruments & Disposables revenues decreased 1%, due to lower sales of disposable syringes, which had increased sales in the prior year due to a competitor’s backorder situation, and marking products. Partially offsetting this were gains in the sales of the Company’s proprietary detectable needles and durable speed needles, with both gains due to strong demand from customers. Animal Care & Other sales decreased 19% due to the loss of the ability to sell the Company’s popular thyroid replacement product, mentioned above. Partially offsetting this was an increase in revenues for vitamin injectable products due to increased market share and price increases.

Rodenticides, Insecticides & Disinfectants revenues increased 31% for the current fiscal year, due to the acquisitions of Virbac (December 2015) and Preserve (May 2016); organic sales in this category were flat. The Preserve acquisition added $15.5 million of revenue in fiscal 2017, primarily to the domestic swine, poultry, dairy and food processing markets. Rodenticide sales increased 1% with strong sales in the custom solutions, retail and distribution markets offset by lower sales in the northwest U.S. after the prior year rodent outbreak subsided. Cleaners and disinfectant sales were 8% lower on an organic basis, due to the early termination of a distribution agreement for certain cleaners and disinfectants in the second half of the fiscal year; it is expected that there will be some offset of these lost revenues in fiscal 2018 by substitution of similar products from the planned transition to the Preserve product line.

Genomics Services revenues reported within the Animal Safety segment increased 13% in fiscal 2017, compared to fiscal 2016. The increase was due primarily to increased market share in the beef and dairy markets from new product offerings and focused sales efforts in these markets; also contributing to the increase was expanded business with a large customer in the poultry market.

Year Ended May 31, 2016 Compared to Year Ended May 31, 2015

The Company’s Food Safety segment revenues were $146.4 million in fiscal 2016, an 11% increase compared to the prior year. The increase, predominantly volume related, from organic sales was 6%, with revenues from the BioLumix (October 2014), Lab M (August 2015) and Deoxi (April 2016) acquisitions contributing the remainder of the growth. Sales of Natural Toxins, Allergens & Drug Residues increased 4% in fiscal 2016 compared to fiscal 2015. Natural toxin sales were flat with a 10% increase in aflatoxin sales offset by a 3% decrease in DON sales, due tomild outbreaks in the prior year which weredid not repeatedrecur in fiscal 2016. Allergen2020. The allergen test kit increase was primarily the result of strong gliadin, milk and coconut allergen test kit sales increased 20%, as increased consumer awareness continuedin the U.S. market, although fourth quarter sales declined 7% due to grow demand for these products, while sales of drug residue test kits decreased 5%, causedlower business with customers supplying restaurants and other food service organizations, which were adversely impacted by currency conversions, as the majority of these sales are invoiced in euros.

COVID-19.
Bacterial
 & General Sanitation revenues increased 15%
Sales in this category were essentially flat in fiscal 2016, aided by $1.9 million in sales from the October 2014 BioLumix acquisition. Excluding BioLumix sales, the organic increase in these products was 9% over2020 compared to the prior year. TheSales of test kits to detect pathogens decreased 2%, as lower sales of ANSR equipment were only partially offset by increases from our
Listeria
Right Now test kit, which grew 24% in fiscal 2020. Sales of our AccuPoint sanitation monitoring product line recorded an increase of 18% due to the continued successful introduction of an improved, next generation product line.increased 6%, on gains in both readers and samplers. Sales of the Soleris and BioLumix product lines, whichproducts to detect spoilage organisms increased 23%in foods decreased 7% in fiscal 2020 on reduced sales of readers and consumable vials during the year, resulting from lower market demand and customer losses.
Culture Media
 & Other –
Sales in this category decreased 4% in fiscal 2020 compared to fiscal 2019. This category includes forensic drug test kits sold within Brazil, which declined significantly as a large commercial lab customer in that country moved to an alternative technology which provided higher throughput. Culture media revenues declined 5%, due to lower end market demand from several large customers in the U.S. Higher shipping revenues, which rose 12% for the year, (5% organic growth), with revenueand lower rebates offered to certain customers, both of which are reported in this category, partially offset the lower forensic and culture media revenues.
Rodenticides, Insecticides
 & Disinfectants –
Revenues of products in this category sold through our Food Safety operations increased 13% in fiscal 2020 compared to fiscal 2019. This category was led by increases in both equipmentsales of cleaners and disposable vials. Pathogendisinfectants to customers in Europe, the Middle East and China, partially offset by a decrease in sales increased 4%of rodenticides in Central America due to lower demand from a large distributor, and reduced demand of cleaners and disinfectants in India, due to a large order in 2019 which did not recur in fiscal 2016 as2020.
Genomics Services –
Sales of genomics services sold through our Food Safety operations increased 2% in fiscal 2020 compared to the prior year, primarily due to anhigher sales in the European bovine and equine markets. Partially offsetting this increase were lower revenues from our genomics operation in Brazil due to a research project with the Brazilian government from 2019 which did not recur in fiscal 2020.
Animal Safety:
A significant proportion of the Animal Safety products are marketed and sold through our veterinary distributor network; this channel has been soft in both fiscal years 2019 and 2020, as difficult market conditions resulting from increased tariffs and political uncertainties in our agricultural and animal protein markets continued. The
COVID-19
pandemic in the second half of fiscal 2020 has exacerbated these market conditions; further, the market uncertainty resulting from
COVID-19
has caused our larger distributor partners to implement working capital improvement programs by lowering inventory levels which resulted in lower sales ofListeria test kits many products in our animal health portfolio. Partially offsetting this weakness in the fourth quarter were higher sales of several of our cleaning and disinfecting products due to demand caused by the
COVID-19
pandemic.
Life Sciences –
Sales in this category decreased 20% in fiscal 2020 compared to the commercial lab market.

Dehydrated Culture Media & Other sales increased 27% in fiscal 2016. This category includes $4.8 million of Lab M revenues, a business which was acquired in August 2015; excluding the impact of these revenues, the organic increase was 10%. Sales of Acumedia products into the food safety market increased 10% while sales into traditional domestic media markets increased 16%. Rodenticides, Insecticides & Disinfectants revenues decreased 8% in U.S. dollars, due to the strength of the dollar, poor economic conditions in a number of international markets and order timing from large distributors. Genomics service revenues in the Company’s international operations increased 4%.

The Company’s Animal Safety segment revenues were $174.9 million in fiscal 2016, a 15% increase, predominantly volume related, over fiscal 2015. Life Sciences sales decreased 10% in fiscal 2016 after a strong 16% increase in 2015. Sales of forensic kits to commercial labs declined as new testing requirements in Brazil for commercial drivers, originally anticipated to go into effect in late fiscal 2015, were delayed until the 4th quarter of fiscal 2016. Veterinary Instruments & Disposables increased 1%, as market share gains in disposable syringes, up 25%, and animal marking products, up 14%, were almost entirely offset by an 8% decrease in detectable needles, due to large orderssame period in the prior year, which did not recur, and an 11%the result of lower forensic drug test kit sales to a large commercial lab in the U.S. serving the Brazilian market, a reduction in sales of products to the U.S. horse racing industry in the U.S. due to a decline in hoofdomestic racing activity, and leg products, due to lower salesthe consolidation of these products to customersseveral state laboratories.

Veterinary Instruments
 & Disposables –
Revenues in the retail market.

Animal Care & Other product sales rose 32%this category decreased 4% in fiscal 2016, with2020 compared to fiscal 2019. Veterinary instruments sales were down 7% for the increaseyear, primarily the result of a new distribution agreement with a large manufacturer20% decline in needles and supplier of dairy equipment, and strong sales of the Company’s line of thyroid replacement therapy for companion animals. Also contributing to growth3% decline in the Animal Care product category were increased sales of wound care products, as a key active ingredient which had been on backorder for much of fiscal 2015, became available in fiscal 2016, and veterinary antibiotics,syringes, due to lower demand from our largest distributors. Partially offsetting these decreases, protective wear and consumables increased 24% for the year, on the strength of a competitor exiting the business. During$956,000 increase in gloves in the fourth quarter of fiscal 2016,2020, the Company was notified that a competitor had been granted approval on a new drug application for a competitive thyroid replacementresult of demand caused by the

COVID-19
pandemic.
Animal Care
 & Other –
Sales of these products decreased 5% in fiscal 2020 compared to fiscal 2019. Antibiotics and injectable vitamin products were down 20% and 15%, respectively, due primarily to inventory destocking at distributors. Sales of our biologics product effectively giving them exclusive rights to sell the product. As a result, the Company is unable to sell its productline, marketed primarily into the domesticequine market, effective July 2016, until it is granted similar regulatory approval;declined 17%, and our equine supplements were also down 20%, due to lower demand from end customers in this approval is expectedmarket. Sales of wound care products rose 9% to partially offset these losses.
Rodenticides, Insecticides
 & Disinfectants –
Sales in this category increased 4% in fiscal 2019. Sales of this product in fiscal 2016 were $6.2 million.

The Company’s line of Rodenticides, Insecticides & Disinfectants rose 17% in fiscal 2016,2020, compared to the prior year, led byyear. The increase was due primarily to a 58%$2.6 million increase in sales of rodenticides. This increase wascleaners and disinfectants for the year, driven in large part by growth in hand sanitizers, disinfectants, and disinfecting wipes in the result of an expansion offourth quarter resulting from the Company’s contract manufacturing business with a large marketer of rodenticides to

COVID-19
pandemic. Revenues for water disinfection in animal protein production environments rose 8% over fiscal 2019. Rodenticide sales increased 1% over the commercial and residential markets. Additionally, the Company successfully introduced a number of new products intoprior year, as strong growth in the retail agricultural market and also benefitted from the continued vole outbreak in the northwestern U.S. Cleaners and disinfectant revenues declined 9% compared to fiscal 2015, primarily due to lower sales to international customers as the strength of the U.S. dollar made the Company’s products less competitive internationally; poor economic conditions in a number of the Company’s key international markets also adversely impacted sales. The Company’s line of insecticides rose 3% in fiscal 2016, as incremental revenues from new product launches werewas almost entirely offset by lower sales of existing productsto agricultural markets in the northwest U.S., due to timinglower rodent pressure. Insecticide revenues declined 2% for the year.
26

Genomics Services –
Sales in this category increased 14% in fiscal 2020, aided by the acquisition of ordersLivestock Genetics (September 2018) and backorders causedDelta Genomics (January 2019); organic growth in this category was 12%. Strong growth in the companion animal and commercial beef cattle markets was partially offset by revenue decreases in the U.S. commercial dairy market due to weak economic conditions in that market, resulting from a movement away from dairy milk towards alternative products.
Year Ended May 31, 2019 Compared to Year Ended May 31, 2018
Food Safety:
Natural Toxins, Allergens
 & Drug Residues –
Sales in this category increased 7% in fiscal 2019 compared to the prior year. For the natural toxins and allergens product lines, test kit sales increased 15% and 7%, respectively, for the year. The natural toxin increase was due to new business earned in Brazil for aflatoxin test kits, and higher sales of DON test kits in the U.S. and France, the result of mild outbreaks. These increases were partially offset by a vendor issue.

5% decrease in sales of drug residues test kits, due to lower demand in Europe.

Bacterial
 & General Sanitation –
Sales in this category increased 10% in fiscal 2019 compared to the prior year. Sales of test kits to detect pathogens increased 24%, as we continued to gain new business with our
Listeria
Right Now test kit that launched in fiscal 2018. Sales of our AccuPoint sanitation monitoring product line increased 11%, with samplers up 13%, as we increased our market share. Sales of products to detect spoilage organisms in foods increased 3%.
Culture Media
 & Other –
Sales in this category increased 13% in fiscal 2019 compared to fiscal 2018. Sales of Neogen Culture Media, formerly marketed as the Acumedia and Lab M brands, increased 7%, aided in part by the August 2018 acquisition of Clarus Labs, which consists of the Colitag product and reports in the culture media product line. Excluding new business from the acquisition, sales in the Neogen Culture Media product line increased 4%. This category also includes forensic drug test kits sold within Brazil, which increased significantly as business shifted from labs in the U.S. in the prior year (reported in the Animal Safety segment) to labs in Brazil and increased demand from commercial laboratories in that country.
Rodenticides, Insecticides
 & Disinfectants –
Revenues of products in this category sold through our Food Safety operations increased 7% in fiscal 2019. This category was led by increases in sales of cleaners and disinfectants to customers in Europe, China and India, partially offset by lower sales of insecticides in Brazil due to a large government tender in fiscal 2018 which did not recur in fiscal 2019.
Genomics Services revenues
Sales of genomics services sold through our Food Safety operations increased 27%16% in fiscal 20162019 compared to the same period in the prior year, primarily due to higher sales in the European porcine and bovine markets. We also benefitted from a large,
non-recurring
research project with the Brazilian government, and the commercialization of a new service offering for a type of cattle specific to the Brazilian market.
Animal Safety:
Life Sciences –
Sales in this category decreased 25% in fiscal 2019 compared to the same period in the prior year, as approximately $2.4 million of forensic drug test kit revenues shifted to our operations in Brazil, which are reported in the Food Safety segment. This testing was performed by commercial labs in the U.S. in the prior fiscal year, but has since moved to commercial labs located in Brazil.
Veterinary Instruments
 & Disposables –
Revenues in this category decreased 7% in fiscal 2019 compared to fiscal 2018. Protective wear and consumables decreased 17%, resulting from poor economic conditions in the commercial dairy production market. Veterinary instruments sales were down 4% for the year, however, this product line had a very strong increase in fiscal 2018, with sales up 23% in that period compared to the prior year. A 19% decline in detectable needles was partially offset by strong increases in disposable syringes and aluminum and poly hub needles.
Animal Care
 & Other –
Sales of these products decreased 3% in fiscal 2019. Wound care and injectable vitamin products were down 13% and 6%, respectively, due to inventory destocking at distributors; dairy supplies that we distribute were down 5%, due to poor economic conditions in the commercial dairy production market. Additionally, we spent more on promotional programs and rebates with distributors, which are recorded as contra revenues within this category, in fiscal 2019 than in the prior year. Partially offsetting these losses were a 12% increase in sales of our biologics product line and a 7% increase in supplements and other care products, both due to increased demand from end customers in the companion animal and equine markets.
27

Rodenticides, Insecticides
 & Disinfectants –
Sales in this category decreased 2% in fiscal 2019, compared to the same period in the prior year. IncrementalThe decrease was due primarily to the full year impact of toll manufacturing business withlost in the third quarter of fiscal year 2018. Additionally, rodenticide sales declined due to poor weather conditions causing lower demand and a large poultry producer, earnedweak U.S. animal protein market partially caused by tariff issues.
Genomics Services –
Sales in this category increased 11% in fiscal 2015,2019, aided by the acquisition of Neogen Australasia (September 2017), Livestock Genetics (September 2018) and Delta Genomics (January 2019); organic growth in this category was 7%. Strong growth in the primary driver of the growth. The Company also continued to gain market share in fiscal 2016 with its proprietary chip technology, primarily tobeef cattle and pig producers,companion animal markets was partially offset by revenue decreases in U.S. poultry and grewporcine markets, despite increases in sample volume particularly with its largest customers. In addition, the canine testing service business grew 17% as the Company successfully commercialized new service offerings, developedvolumes, resulting from a shift to lower priced chips and services. Additionally, poor economic conditions in the prior fiscal year.

U.S. commercial dairy production market resulted in lower revenues from that market.

COST OF REVENUES

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Cost of Revenues

  $189,626    13 $168,211    17 $143,389 

(dollars in thousands)
  
2020
   
Increase
  
2019
   
Increase
  
2018
 
Cost of Revenues
  $221,891    0 $222,266    5 $211,658 
Cost of revenues increased 13%was essentially flat in fiscal 20172020 compared to fiscal 2019 and 17%rose 5% in fiscal 2016 in comparison with the prior years.2019 compared to fiscal 2018. This compares with revenue increases of 13%1% in both fiscal years.2020 and 4% in fiscal 2019. Expressed as a percentage of revenues,sales, cost of revenues was 52.4%53.1%, 52.4%53.7% and 50.7%53.2% in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. InGross margins were 46.9%, 46.3%, and 46.8% for fiscal 2017, improvementsyears 2020, 2019, and 2018, respectively.
Fiscal 2020
– Our overall gross margin improved 60 basis points in fiscal 2020, primarily from improved gross margin in the Animal Safety gross margins,segment and improved efficiencies, resulting from lower raw material costsa focus on
manufacturing
cost reductions. These efforts resulted in a slight decrease in cost of revenues compared to the genomics business and increased higher margin forensic kit sales into the commercial laboratory market, and strong growth in sales of higher margin mycotoxin and allergen test kits in theprior fiscal year.
Fiscal 2019
– Both Food Safety and Animal Safety margins decreased in fiscal 2019, primarily due to a product mix shift towards lower margin products within each segment, overcame the lower gross margins resulting from the Quat-Chem and Rogama acquisitions. For fiscal 2016,to a lesser extent, the strength of the U.S. dollar, which adversely impacted revenue with no corresponding declinerose against all of the currencies in productthe countries in which we operate, and resulted in higher cost had the largest impact on the declineof sales in our international operations, which pay for their inventory in U.S. dollars. A higher overall proportion of Food Safety revenues, which have higher than average gross margins, compared to fiscal 2015. In addition, shifts in product mixpartially offset the lower margins within the each segment.
Food Safety segment, in part the result of acquisitions completed in fiscal years 2015 and 2016, towards products which have lower gross margins than the segment average, and a shift in the proportion of Animal Safety revenues to the overall revenue of the Company, resulted in the decline in gross margins.

Gross Margins:

Food Safety gross margins were 55.3%51.4%, 56.7%51.8% and 59.7%52.4% in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. During
Fiscal 2020 –
Food Safety margins decreased 40 basis points in fiscal 2017, the Company purchased the Quat-Chem and Rogama businesses, which generated gross margins2020, primarily due to lower than historical averages for this segment. These acquisitions,sales of higher margin forensic test kits in Brazil, and the full year impactcontinued strength of the prior year acquisitions of Lab MU.S. dollar against currencies in the countries in which we operate; our international operations pay for their inventory primarily in U.S. dollars
, and Deoxi resultedthe weakness in a 140 basis point decline in local currencies adversely impacted gross margins.
Fiscal 2019 –
Food Safety gross margins.margins decreased 60 basis points in fiscal 2019,
primarily the result of a shift in product mix at our international operations; in fiscal 2019, these operations sold a higher proportion of lower margin traditional Animal Safety products such as cleaners and disinfectants. In addition, gross margins were also negatively impacted by the strength of the U.S. dollar relative to the international currencies in which the Company operates, primarilywe operate, particularly in Brazil, Europe, and Mexico, where the real, pound and peso declined in value against the U.S. dollar by 14%15%, 3%, and 12%4%, respectively. These international operations report in through the Food Safety segment. Partially offsetting these negative impacts to gross margins were favorable shiftsIncreases in product mix towards higher margin product lines such as our diagnostic and forensic test kits for mycotoxins and allergens. In fiscal 2016, lower gross margins resulted primarily from the strength in the U.S. dollar, which resulted in lower revenues and gross margins when international sales were converted from local currencies to the dollar. All currencies the Company operates in weakened against the dollar in fiscal 2016, pressuring margins in this segment. Additionally, revenues from the acquisition of Lab M, which were at lower average gross margins than the rest of the segment, standard cost adjustments at Neogen Latinoamerica, and other product mix shifts within the segment, negatively impacted gross margins in Food Safety.

partially offset these decreases.

28

Animal Safety Gross Margins:
Animal Safety gross margins were 40.6%42.3%, 40.1%40.6% and 40.4%41.4% in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. For fiscal 2017, improvements in raw material costs and favorable product mix
Fiscal 2020 –
Animal Safety gross margins increased by 170 basis points, driven by increased sales of higher margin disinfectant products, particularly in the fourth quarter of the year as a result of the
COVID-19
pandemic, which caused heavy demand for our sanitizing products. In addition, a mix shift towards genomics business and strong sales of forensic kits to commercial labs inservices for the U.S. more than offset the loss of high margin revenues from the thyroid replacement product for companion animals which the Company was required to stop selling at the end of fiscal 2016. For fiscal 2016, improved gross margins from the 58% increase in sales of rodenticides,animal markets, which have higher than average gross margins within the segment, were somewhat offset by lower gross margins on revenues from the dairy distribution business initiated in August 2015, lower gross margins at GeneSeek due to the significant increase in poultry business, which has lower than average gross margins within the genomics product line,business, contributed to the improvement.
Fiscal 2019 –
Animal Safety gross margins decreased 80 basis points in fiscal 2019,
primarily the result of lower volumes in higher margin products such as diagnostics, animal care products, instruments and other product mix shifts withinrodenticides. Forensic test kit revenues in Animal Safety declined as a large U.S. commercial laboratory transferred sample testing to its locations in Brazil which we service through our Brazilian Food operation reporting in the Food Safety segment.

We also had strong growth in sales of genomics services in our Australian operations; gross margins in this operation are lower than historical Animal Safety margins due to higher chip costs and lack of scale. Partially offsetting these lower margins were increased margins in the U.S. genomics operations, based primarily on improved input costs and increased sales of higher margin services to the bovine and companion animal markets.

OPERATING EXPENSES

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Sales and Marketing

  $62,424    8 $57,599    11 $51,757 

General and Administrative

   34,214    17  29,189    16  25,233 

Research and Development

   10,385    5  9,890    3  9,577 
  

 

 

    

 

 

    

 

 

 

Total Operating Expense

   107,023    11  96,678    12  86,567 
  

 

 

    

 

 

    

 

 

 

(dollars in thousands)
  
2020
   
Increase
  
2019
   
Increase
  
2018
 
Sales and Marketing
  $69,675   -1%  $70,230     5%  $66,929 
General and Administrative
   44,331     9%   40,791     7%   38,294 
Research and Development
   14,750   15%   12,805   18%   10,855 
  
 
 
     
 
 
     
 
 
 
Total Operating Expense
  $128,756     4%  $123,826     7%  $116,078 
  
 
 
     
 
 
     
 
 
 
Overall operating expenses increased by 11%4% in fiscal 20172020 and 12%7% in fiscal 2016,2019, each compared to the prior year. These increases compare to revenue increases of 13% in1% and 4%, respectively, for each comparative period.

Sales and Marketing:
Sales and marketing expenses increaseddecreased by 8%1% in fiscal 20172020 compared to fiscal 2019 and 11%rose 5% in fiscal 2016, each2019 compared withto the prior year. As a percentage of sales, sales and marketing expense was 17.3%16.7%, 17.9%17.0% and 18.3%16.8% in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. For fiscal 2017, salaries and commissions within the
Fiscal 2020
– The $550,000 decline in sales and marketing function, which is also comprisedexpenses in fiscal 2020 was driven by a $1.3 million, or 7.4%, decline in spending in this category in the fourth quarter of technical service, customer servicethe year, caused by a reduction in business travel, meals and product management personnel, rose 10%, primarilyentertainment, trade shows, and related marketing expenses, as the
COVID-19
global pandemic resulted in strict travel restrictions and reductions in face to face sales activities in many of our markets during the quarter. Partially offsetting these declines were higher compensation and related fringe benefits, the result of increased headcount, increased shipping expenses, and higher regulatory expense due to product registration efforts in our international markets.
Fiscal 2019
– Salaries and commissions increased staffingby 4% in 2019 and drove the 5% increase in revenue, while traveloverall sales and marketing expenses; shipping expenses rose 7%.increased 11%, the result of higher rates and an increase in air shipments. Other significant expense increases were domestic shipping expense, up 11%the result of higher trade show, exhibit and in line with the revenue increase,sponsorship costs, and royalty expense, which rose 35% due to increased sales in fiscal 2017 and aone-time credit in the prior year resulting from a retroactive rate reduction on a royalty agreement. Of the $4.8 million increase in expenses, approximately $2.2 million resulted from the Company’s recent acquisitions. For fiscal 2016, salaries, commissions and travel expenses rose 13%, primarily on increases in staffing and higher revenue. Other significant expenseprovision for bad debts. Partially offsetting these increases were sales promotionslower promotion and allowances, based on higher levels of sales to the Company’s largest distributors, shipping expense, up 13%consulting expenses.
29

General and in line with the revenue increase, and shows and exhibits, which rose 22% on increased Company participation in trade shows.

Administrative:

General and administrative expenses rose 17%9% in fiscal 20172020 compared to fiscal 20162019 and by 16%7% in fiscal 20162019 compared to fiscal 2015. The increases2018. As a percentage of sales, general and administrative expense was 10.6%, 9.8% and 9.6% in fiscal years 20172020, 2019 and 2016, respectively, are primarily2018, respectively.
Fiscal 2020 –
Higher stock-based compensation costs and a significant uptick in legal fees, driven in part by the number of acquisitions completed during the year, resulted in the overall 9% expense increase. In addition, the company continued to invest in information technology infrastructure, network capabilities and
e-commerce
initiatives. This resulted in higher depreciation on
IT-related
hardware and increased license fees on software investments. These increases were somewhat offset by a reduction in outside consulting. General and administrative expenses at five new company locations, the result of acquisitions in the second half of fiscal 2020, totaled $520,000
for the year
.
Fiscal 2019 –
Higher salary and stock-based compensation costs were the primary drivers of the overall 7% expense increase. In addition, higher salaries, due to additional headcount as well as compensation increases. Higherdepreciation and license fees on
IT-related
hardware and software investments, increased training, recruiting and legal and professional fees and additional amortization of intangible assets, due to the Company’s recent acquisitions, also contributed to the increaseincreased expense. These increases were somewhat offset by a $427,000 reduction in each comparative period.    

amortization expense as certain intangible assets from past acquisitions were fully amortized during the year.

Research and Development:
Research and development expenses increased 5% in fiscal 2017 and 3% in fiscal 2016, each compared to the prior year. Higher salaries expense in each fiscal year, resulting from increased headcount, was partially offset by lower levels of consulting and other outside services. As a percentage of revenue, these expenses were 2.9% in fiscal year 2017, 3.1% in fiscal year 2016 and 3.4% in fiscal year 2015; the Company expects to spend 3% to 4% of total revenue on research and development annually.

OPERATING INCOME

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Operating Income

  $64,945    15 $56,386    6 $53,118 

The Company’s operating income increased by 15% in fiscal 2017 compared to fiscal 2016,2020 and by 6%18% in fiscal 2016 compared to fiscal 2015. Expressed as a percentage of revenues, it was 18.0%, 17.6% and 18.8% in fiscal years 2017, 2016 and 2015, respectively.

The 15% increase in operating income for 2017 was due to the 13% increase in revenues and operating expense increases which were less than the revenue growth rate, combined with gross margins which, at 47.6% of sales, were the same as the prior year.

The 6% increase in operating income in fiscal 2016 was due primarily to the 13% increase in revenues and lower rates of increases in operating expenses, partially offset by the 170 basis point reduction in gross margin expressed as a percentage of revenues. The Company controlled its expense growth while incurring additional amortization and other expenses relating to its recent acquisitions.

OTHER INCOME (EXPENSE)

(dollars in thousands)

  2017   Increase   2016  Increase   2015 

Other Income (Expense)

  $1,728    n/a   $(873  n/a   $(1,042

Other Income (Expense) consists principally of royalty income, interest income from investing the Company’s excess cash balances, the impact of foreign currency transactions, adjustments to contingent consideration liabilities relating to acquisitions, and other

miscellaneous items.

Other Income of $1,728,000 in fiscal 2017 primarily consisted of net interest income of $838,000, a $660,000 gain recorded as the result of the settlement of a licensing agreement, $171,000 of royalty income, a net gain of $18,000 resulting from contingent consideration payments made during the year for prior year acquisitions, and a loss of $40,000 on foreign currency translations.

In fiscal 2016, Other Expense primarily consisted of losses on foreign currency translations of $1,338,000, the result of all foreign currencies in which we operate devaluing against the U.S. dollar. In addition, the Company recognized interest income of $322,000,

and royalty income of $217,000.

In fiscal 2015, Other Income (Expense) primarily consisted of losses on foreign currency translations of $1,124,000, the result of the stronger U.S. dollar during the year. In addition, the Company recognized interest income of $228,000, royalty income of $150,000 and net expense of $297,000 resulting from contingent consideration payments made during the year for prior year acquisitions. The contingent consideration adjustments consisted of $241,000 of income for SyrVet, $454,000 of expense for Prima Tech, and $84,000 of expense for Chem-Tech; these adjustments were the difference between the liability recorded at the initial purchase of each business and the actual payment made to the former owners, and were based on the achievement of sales goals for the first 12

months of the Company’s ownership.

PROVISION FOR INCOME TAXES

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Provision for Income Taxes

  $22,700    20 $18,975    3 $18,500 

The effective tax rate was 34.0% of pretax income in fiscal 2017, 34.2% in fiscal 2016 and 35.5% in fiscal 2015. Differences in the tax rate from the 35% U.S. statutory corporate rate were primarily due to increases from international taxes and the provision for state taxes, offset by tax deductions related to domestic manufacturing and credits related to research and development activities. The fiscal 2017 effective tax rate of 34.0% includes benefit from research and development credits, the Company’s domestic manufacturing deduction and reversal of a valuation allowance against net operating losses in Brazil, which the Company is utilizing. The Company is currently under audit by the Internal Revenue Service for fiscal years 2014-2016.

The effective tax rate declined in fiscal 2016 due primarily to amendments filed for the fiscal 2012, 2013 and 2014 federal income tax returns and an adjustment for fiscal 2015 relating to credits claimed for research and development activities. The Company engaged a third party in fiscal 2016 to perform a study of its research and development activities, and credits originally claimed thereon, for these prior annual periods. Based on the results of the study, the Company revised its calculations for its research and development activities for those periods,

resulting in higher tax credits.

NET INCOME AND INCOME PER SHARE

(dollars in thousands-except per share data)

  2017   Increase  2016   Increase  2015 

Net Income Attributable to Neogen

  $43,793    20 $36,564    9 $33,526 

Net Income Per Share-Basic

  $1.16    $0.98    $0.91 

Net Income Per Share-Diluted

  $1.14    $0.97    $0.90 

Net income increased by 20% in fiscal 2017 and increased by 9% in fiscal 2016,2019, each compared to the prior year. As a percentage of revenue, netthese expenses were 3.5% in fiscal year 2020, 3.1% in fiscal year 2019 and 2.7% in fiscal year 2018; we expect to spend approximately 3% of total revenue on research and development annually.

Fiscal 2020 –
The 15% increase in research and development expenses in fiscal 2020 was primarily the result of continued spending with development partners for two new readers, currently anticipated to be launched in the first half of fiscal 2021. Increased compensation expense, resulting from investments in people as we heighten the development capabilities of the group, higher depreciation expense from continued investment in analytical equipment, and an increase in contracted services also contributed to the expense growth.
Fiscal 2019 –
The 18% increase in research and development expenses in fiscal 2019 was primarily the result of development spending for next generation products and increases in expenditures to obtain regulatory approvals for a number of new products. Higher salaries expense, resulting from increased headcount and compensation increases, and increased depreciation expense, resulting from investments in analytical and testing equipment, accounted for the remainder of the increase.
OPERATING INCOME
(dollars in thousands)
  
2020
   
Increase
  
2019
   
Increase
  
2018
 
Operating Income
  $67,523   -1%  $68,094   -3%  $70,194 
Our operating income decreased by 1% in fiscal 2020 compared to fiscal 2019, and by 3% in fiscal 2019 compared to fiscal 2018. Expressed as a percentage of revenues, operating income was 12.1%16.1%, 16.4% and 17.6% in fiscal 2017, 11.4%years 2020, 2019 and 2018, respectively.
Gross margins rose by $4.4 million in fiscal 2016 and 11.8%2020; the increase was more than offset by an overall increase of $4.9 million, or 4.0%, in operating expenses, resulting in a 1% decrease in operating income compared to fiscal 2019.
The 3% decrease in operating income for fiscal 2019 was due primarily to overall operating expense increases of $7.7 million, up 7%, which compared to a gross margin increase of $5.6 million.
30

OTHER INCOME (EXPENSE)
Other Income (Expense) for the previous three fiscal years consisted of the following:
(dollars in thousands)
  
2020
   
2019
   
2018
 
Interest income (net of expense)
  $5,992   $4,683   $2,043 
Foreign currency transactions
   (1,178   (1,279   274 
Royalty income
   1    150    147 
Licenses and settlements
   (38   672    360 
Quat-Chem contingent consideration
   —      422    255 
Deoxi contingent consideration
   —      (10   (42
Other
   5    227    234 
  
 
 
   
 
 
   
 
 
 
Total Other Income
  $4,782   $4,865   $3,271 
  
 
 
   
 
 
   
 
 
 
The increase in interest income in fiscal 2015.

years 2020 and 2019, each compared to the prior year, is the result of higher cash balances and rising interest rates during the two year period. During the second half of the 2020 fiscal year, and particularly in response to the

COVID-19
pandemic, yields on fixed income securities declined significantly, corresponding to a similar decline in the ten year U.S. Treasury bill rate. The loss from foreign currency translations in fiscal 2020 and 2019 is primarily the result of the changes in the value of foreign currencies relative to the U.S. dollar in countries in which we operate; the dollar strengthened against all of these currencies in
each comparative year
.
In fiscal 2020, we recognized $600,000 of expense for an expected settlement of a penalty payable to the U.S. government due to a violation of a sanctions program. This was partially offset by a $483,000 gain resulting from a settlement with the Brazilian government related to sales taxes charged over several years, and proceeds received for a property loss settlement. In fiscal 2019 and 2018, gains were recognized on insurance proceeds received for property loss settlements. Other Income in fiscal 2019 and 2018 included the adjustment of Quat-Chem and Deoxi contingent consideration based on the level of achievement of revenue targets for the acquired businesses in each of those fiscal years.
PROVISION FOR INCOME TAXES
(dollars in thousands)
  
2020
   
Increase
  
2019
   
Increase
  
2018
 
Provision for Income Taxes
  $12,830   0%  $12,783   25%  $10,250 
Income tax expense for fiscal 2020 was $12.8 million, an effective tax rate of 17.7%, compared to income tax expense of $12.8 million in 2019, an effective tax rate of 17.5%. For fiscal 2018, income tax expense of $10.3 million represented an effective tax rate of 14.0%.
The U.S. Tax Act reduced the statutory income tax rate from 35% to 21% in December 2017. During both fiscal 2020 and 2019, we utilized the 21% statutory rate for the entire year to compute our income tax expense, whereas the statutory rate in fiscal 2018 was a blended rate of 29.2%.
Differences from the U. S. statutory rate to our effective rate are primarily due to provisions in the U.S. Tax Act and the exercise of stock options. Please refer to Note 6 to the consolidated financial statements for more information.
NET INCOME AND INCOME PER SHARE
(dollars in thousands, except per share data)
  
2020
   
Increase
   
2019
   
Increase
   
2018
 
Net Income Attributable to Neogen
  $59,475    -1%   $60,176    -5%   $63,145 
Net Income Per Share-Basic
  $1.13     $1.16     $1.23 
Net Income Per Share-Diluted
  $1.13     $1.15     $1.21 
Net income decreased $701,000 in fiscal 2020 compared to fiscal 2019, primarily due to the $654,000 decrease in in
pre-tax
income.
Net income decreased by 5% in fiscal 2019 as compared to fiscal 2018. This is due to the increase in our effective tax rate in fiscal 2019 and, to a lesser extent, a 1% decrease in
pre-tax
income.
31

FUTURE OPERATING RESULTS

Neogen Corporation’s future operating results involve a number of risks and uncertainties. Actual events or results may differ materially from those discussed in this report. Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed below as well as those discussed elsewhere in this report. Management’s ability to grow the business in the future depends upon itsour ability to successfully implement various strategies, including:

developing, manufacturing and marketing new products with new features and capabilities;capabilities, and having those new products successfully accepted in the marketplace;

expanding the Company’sour markets by fostering increased use of Companyour products by customers;

maintaining or increasing gross and net operating margins in changing cost environments;

strengthening operations and sales and marketing activities in geographies outside of the U.S.;

developing and implementing new technology development strategies; and

identifying and completing acquisitions that enhance existing product categories or create new products or services.

FINANCIAL CONDITION AND LIQUIDITY

On May 31, 2017, the Company2020, we had $77.6$66.3 million in cash and cash equivalents, $66.1$277.4 million in marketable securities, and working capital of $257.0$488.9 million. For the year ended May 31, 2017,2020, cash generated from operating activities was $60.3$85.9 million, compared to $35.3$63.8 million generated in fiscal 2016;2019; proceeds from stock option exercises provided an additional $21.1$29.4 million of cash. For the same period, additions to property, equipment and equipmentother
non-current
assets were $24.1 million and business acquisitions used cash of $14.6 million and $34.0 million, respectively. The Company has$13.2 million. We have a financing agreement with a bank providing for an unsecured revolving line of credit of $15.0 million, which expires on September 30, 2019.2021. There were no advances against this line of credit during fiscal years 2017, 20162020, 2019 and 2015,2018, and no balance outstanding at May 31, 20172020 and 2016. The Company does have an outstanding borrowing of $1.2 million at its pesticide business in Brazil, which originated prior to the Company’s purchase of the business. The terms of the borrowing allow for repayment of the principal only upon export shipment of the associated inventory, which the Company believes will occur in the 2018 fiscal year.

Accounts2019.

Net accounts receivable at May 31, 20172020 were $68.6$84.7 million, compared to $67.6$82.6 million at May 31, 2016,2019; the increase is primarily due to the increase in revenues. Daysthe days sales outstanding
 (DSO),
a measurement of the time it takes to collect receivables, decreased fromwhich was 68 days at May 31, 2020 compared to 61 days at May 31, 20162019. We have been carefully monitoring our customer receivables as the
COVID-19
pandemic has spread across our global markets; to 60 days at May 31, 2017. Alldate, although there has been some slowdown in collections, we have not experienced an appreciable increase in bad debt write offs. We did provide an additional $100,000 in our allowance for bad debts to account for potential write offs related to
COVID-19,
based in part on the increase in DSO,
and will continue to actively manage our customer accounts are actively managed and no losses in excess of amounts reserved are currently expected.

adjust the allowance account as circumstances change.

Inventory balances were $73.1$95.1 million at May 31, 2017,2020, an increase of $8.7$9.1 million, or 14%11%, compared to $64.4$86.0 million at May 31, 2016. Approximately $2.22019. During both fiscal 2019 and fiscal 2020, we have increased inventory levels of products that are sold into our European markets, to enhance our ability to serve these markets in the event of a disorderly Brexit. While Brexit is now official, there is a transition period which ends on December 31, 2020, and we will continue to monitor and adjust our inventory levels as necessary. In 2020, we increased our inventory levels by $4.3 million in the U.S., in part to ensure that we have adequate supplies of critical raw and finished products in the increase was from the acquisitions of Quat-Chem and Rogama, completed during fiscal 2017. The Companyevent our supply chain is adversely impacted by
COVID-19.
We have also increased inventory levels at a number of its other international locations by approximately $1.3 million due to acquisitions. Notwithstanding these increases, all operations participate in programs to support the revenue growth and to ensureimprove inventory turns, while ensuring adequate safety stocksstock to minimize backorders. The Company continues to identify and rationalize redundant product offerings resulting from recent acquisitions.

Neogen has been consistently profitable and has generated strong cash flow from operations during each of the past three fiscal years 2015, 2016 and 2017.years. However, the Company’sour cash on hand and current borrowing capacity may not be sufficient to meet the Company’sour cash requirements to commercialize products currently under development or its potentialour future plans to acquire additional businesses, technology and products that fit within the Company’sour strategic plan. Accordingly, the Companywe may be required, or may choose, to issue equity securities or enter into other financing arrangements for a portion of itsour future capital needs.

The Company is

We are subject to certain legal and other proceedings in the normal course of business that have not had, and, in the opinion of management, are not expected to have, a material effect on itsour results of operations or financial position.

32

CONTRACTUAL OBLIGATIONS

The Company has

As of May 31, 2020, we have the following contractual obligations due by period:

(dollars in thousands)

  Total   Less than
1 year
   1-3 years   3-5 years   More than
5 years
 

Long-Term Debt

  $1,195   $1,195   $—     $—     $—   

Operating Leases

   1,150    591    381    155    23 

Unconditional Purchase Obligations (1)

   48,831    43,402    5,429    —      —   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
  $51,176   $45,188   $5,810   $155   $23 

       
Less than
           
More than
 
(dollars in thousands)
  
Total
   
1 year
   
1-3 years
   
3-5 years
   
5 years
 
Long-Term Debt
  $—     $—     $—     $—     $—   
Operating Leases
   2,094    1,080    973    41     
Unconditional Purchase Obligations (1)
   55,180    48,681    6,499         
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  $57,283   $49,763   $7,478   $42   $—   
(1)
Unconditional purchase obligations are primarily purchase orders for future inventory and capital equipment purchases.

NEW ACCOUNTING PRONOUNCEMENTS

See discussion of any New Accounting Pronouncements in Note 1 to Consolidated Financial Statements.

consolidated financial statements.

33

ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company has

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. The Company’sOur primary interest rate risk is due to potential fluctuations of interest rates for variable rate borrowings and short-term investments.

Foreign exchange risk exposure arises because the Company marketswe market and sells itssell our products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. The Company’sOur operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, the euro, the Mexican peso, the Brazilian real, the Chinese yuan, the Australian dollar and to a lesser extent, the Indian rupee, the Canadian dollar, the Argentine peso, the Uruguayan peso and the Canadian dollar;Chilean peso; there is also exposure to a change in exchange rate between the British pound sterling and the euro. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenuesinvoiced amounts can be positively or negatively affected by changes in exchange rates in the course of collection. The Company uses derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the United States,U.S., located in the United Kingdom,Scotland, England, Italy, Brazil, Mexico, Argentina, Uruguay, Chile, China, India, Canada and CanadaAustralia where the functional currency is the British pound sterling, Brazilian real, Mexican peso, Argentine peso, Uruguayan peso, Chilean peso, Chinese yuan, Indian rupee, Canadian dollar and CanadianAustralian dollar, respectively, and also transacts business throughout Europe in the euro. The Company’sOur investments in foreign subsidiaries are considered to be long-term.

As discussed in ITEM 1A. RISK FACTORS, our financial condition and results of operations could be adversely affected by currency fluctuations.
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

The response to this item is submitted in a separate section of this report starting on page
F-1.

ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE—NONE

ITEM 9A.
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of the Company’sour management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’sour disclosure controls and procedures (as defined in Rule
13a-15
(e) under the Securities Exchange Act of 1934) as of May 31, 2017.2020. Based on and as of the time of such evaluation, the Company’sour management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, concluded that the Company’sour disclosure controls and procedures were effective as of the end of the period covered by this report to ensure that information required to be disclosed in the reports that are filed or submitted under the Securities and Exchange Act of 1934 is appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure the information required to be disclosed in the reports that are filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules
13-a-15(f)
and
15d-15(f).
Under the supervision and with the participation of the Company’sour management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, an evaluation was conducted as to the effectiveness of internal control over financial reporting as of May 31, 2017,2020, based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, management concluded that internal control over financial reporting was effective as of May 31, 2017.2020. The effectiveness of internal control over financial reporting as of May 31, 2017,2020 has been audited by BDO USA, LLP, an independent registered public accounting firm, as stated in its attestation report, which is included on the following page and is incorporated into this Item 9A by reference.

Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting were identified as having occurred during the year ended May 31, 20172020 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

34

Report of Independent Registered Public Accounting Firm

Stockholders
and Board of Directors and Stockholders

Neogen Corporation and Subsidiaries

Lansing, Michigan

Opinion on Internal Control over Financial Reporting
We have audited Neogen Corporation and Subsidiaries’Corporation’s (the Company’s) internal control over financial reporting as of May 31, 2017,2020, based on criteria established in
Internal Control – Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Neogen CorporationIn our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of May 31, 2020, based on the COSO criteria
.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of May 31, 2020 and Subsidiaries’2019, the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended May 31, 2020, and the related notes and our report dated July 30, 2020 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Item 9A,Item “9A, Management’s Report on Internal Control Overover Financial Reporting.”Reporting”. Our responsibility is to express an opinion on the company’sCompany’s internal control over financial reporting based on our audit.

We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Neogen Corporation

/s/ BDO USA, LLP
Grand Rapids, Michigan
July 30, 2020
BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and Subsidiaries maintained, in all material respects, effective internal control over financial reporting as of May 31, 2017, based on the COSO criteria.

We also have audited, in accordance with the standardsforms part of the Public Company Accounting Oversight Board (United States),international BDO network of independent member firms.

BDO is the consolidated balance sheets of Neogen Corporationbrand name for the BDO network and Subsidiaries as of May 31, 2017 and 2016, and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the three years in the period ended May 31, 2017, and our report dated July 28, 2017 expressed an unqualified opinion thereon.

/s/ BDO USA, LLP

Grand Rapids, Michigan

July 28, 2017

Member Firms.

35

ITEM 9B.
OTHER INFORMATION – NONE

PART III

ITEM 10.
DIRECTORS, AND EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE

Information regarding the Company and certain corporate governance matters appearing under the captions “Election of Directors”,Directors,” “Audit Committee”,Committee,” and “Miscellaneous-Section 16(a) Beneficial Ownership Reporting Compliance” is incorporated by reference to Neogen’s 20172020 proxy statement to be filed within 120 days of May 31, 2017.

The Company has2020.

We have adopted a Code of Conduct that applies to all of itsour directors, officers and employees. The Company has made a copy of thisThis Code of Conduct is available on itsour website at http:
https://www.neogen.com/pdf/CodeOfConduct.pdf.

OFFICERS AND OTHER KEY INDIVIDUALS OF THE REGISTRANT

globalassets/pdfs/corporate-governance-sec-and-investor-information/codeofconduct.pdf

Information About Our Executive Officers
The officers of Neogen are elected by and serve at the discretion of the Board of Directors. The names and titles of the Company’sour officers as of May 31, 2020 are set forth below.

Name
  
Position with the Company
  
Year Joined

the Company
 

John E. Adent

  
President & Chief Executive Officer
   2017 

Stewart W. Bauck, D.V.M., Ph.D.

  
Vice President, Agrigenomics
   2012 

Edward L. Bradley

Joseph A. Corbett
  Vice President, Food Safety1995

Richard E. Calk

President & Chief Operating Officer2014

Joseph A. Corbett

Vice President, Animal Safety Sales & Operations
   1993 

James L. Herbert

Robert S. Donofrio, Ph.D.
  Executive Chairman of the Board
Vice President, Food Safety Research & Development
   19822016 

Melissa K. Herbert

Shane M. Fitzwater
  
Vice President, Support ServicesAnimal Safety Operations
2018
Jerome L. Hagedorn
Vice President, Food Safety Operations
2018
Jason W. Lilly, Ph.D.
Vice President, International Business
   2005 

Daniel D. Kephart, Ph.D.

Julie A. Mann*
  
Vice President & Chief ScienceHuman Resources Officer
   2017 

Kenneth V. Kodilla

Terri A. Morrical
  Vice President, Manufacturing2003

Jason W. Lilly, Ph.D., MBA

Vice President, Corporate Development2005

Terri A. Morrical

Vice President, Animal Safety
   1992 

Marylinn Munson
Vice President, Agrigenomics
2020
Steven J. Quinlan

  
Vice President & Chief Financial Officer
   2011 

Jennifer A. Rice, D.V.M., Ph.D.

Vice President & Senior Research Director2008

Dwight E. Schroedter

Vice President, Animal Safety Manufacturing1995

Melissa K. Herbert, Vice President, Support Services, is the daughter of James L. Herbert, Executive Chairman of the Board.

* Ms. Mann was promoted to this position on June 1, 2020.
Information concerning the officers of Neogen follows:

John E. Adent, age 49,52, joined Neogen as Chief Executive Officer on July 17, 2017. Prior to joining Neogen, Mr. Adent served as the Chief Executive Officer of Animal Health International, Inc., formerly known as Lextron, Inc., from 2004 to 2015, also serving as its President during that time. Animal Health International was sold to Patterson Companies, Inc. in 2015, and Mr. Adent served as the Chief Executive Officer of the $3.3 billion Animal Health Division of Patterson Animal Health from that period until his resignation on July 1, 2017. Mr. Adent began his career with management responsibilities for Ralston Purina Company, developing animal feed manufacturing and sales operations in China and the Philippines. When Ralston Purina spun off that business to Agribrands, he continued his management role in the European division in Spain and Hungary, serving as managing director of the Hungarian operations. He left Ralston Purina in 2004.

Dr. Stewart W. Bauck, age 59,62, joined Neogen in 2012 as the Company’sour Director of Beef Cattle Genomics, and became General Manager of Neogen’s GeneSeek subsidiarygenomics operation in Lincoln, NE in 2013. In December 2016, Dr. Bauck was named Neogen’s Vice President, of Agrigenomics, responsible for GeneSeek’sthe operation and execution of the company’sour genomics strategy. Effective June 1, 2020, Dr. Bauck transitioned into a part-time role of Senior Director, Special Projects, assisting in commercial development opportunities in Canada. Prior to joining Neogen, Dr. Bauck spent 15 years with Merial, Inc., where he created and launched the Igenity livestock production business. Igenity was acquired by Neogen from Merial in May 2012. Dr. Bauck’s experience also includes various responsibilities in technical services and management for Merck AgVet, and, earlier in his career, he owned and operated his own private veterinary practice with a major emphasis on food-producing animals.

Edward L. Bradley, age 57, joined the Company in February 1995 as part of its acquisition of AMPCOR Diagnostics, Inc, where he served as Vice President of Sales and Marketing. In June 1996, he was named a Vice President of Neogen. In June 2006, Mr. Bradley was named Vice President, Food Safety. He has responsibility for all of Food Safety, with the exception of Neogen Europe and research and development. From 1988 to 1995, Mr. Bradley served in several sales and marketing capacities for Mallinckrodt Animal Health, including the position of National Sales Manager in its Food Animal Products Division. Prior to joining Mallinckrodt, he held several sales and marketing positions for Stauffer Chemical Company.

Richard E. Calk Jr., age 54, joined the Company as President and Chief Operating Officer in December 2014. He is responsible for all of the operations of the Company. He joined the Company after gaining extensive experience in a variety of senior leadership positions at food ingredient companies CP Kelco, Roquette America, and DSM Food Specialties. Mr. Calk has specialized in leading the resurgence of various companies’ brands by helping to modify simple food commodities to become value-added specialty ingredients to be used in foods and other products, and then expanding the global reach of those value-added ingredients. His experience includes establishing new operations throughout Asia, Europe, North and South America.

36

Joseph A. Corbett, age 48,51, joined Neogen in December 1993 as a sales representative in the Animal Safety operation based in Lexington, Kentucky. Prior to joining Neogen, he worked for the Marriott Corporation in sales and operations. He has served in various sales, marketing and operational roles in the Neogen Animal Safety group. Most recently, Mr. Corbett was Senior Director of Sales & Operations, Animal Safety.segment. He was named Vice President, Animal Safety Sales and Operations in October 2014, responsible for all Animal Safety revenues, excluding GeneSeekGenomics and Life SciencesSciences.
Dr. Robert S. Donofrio, age 47, joined Neogen in February 2016 as Director of Microbiology Research and operations at the Lexington distribution centers.

James L. Herbert, age 77, is Executive ChairmanDevelopment, and was promoted to Director of the Board of Directors of the Company. He had been the Chief Executive Officer and Chairman of the Board since 2006; he resigned as Chief Executive Officer on July 17, 2017, when John Adent was named to that role. Prior to 2006, he had been President and a Director since he founded the Company in June 1982. Mr. Herbert previously held the position of Corporate Vice President of DeKalb Ag Research, a major agricultural genetics and energy company. He has management experience in animal biologics, specialized chemical research, medical instruments, aquaculture, animal nutrition, and poultry and livestock breeding and production.

Melissa K. Herbert, age 53, joined the Company in August 2005 as a sales representative in the Company’s Food Safety DivisionResearch and Development in Lansing, Michigan.December 2016. In 2011, Ms. Herbert was named Manager of Industry Affairs, with oversight of regulatory issues for both the Food and Animal Safety divisions, and in June 2013, Director of Industry Affairs. SheApril 2018, Dr. Donofrio was named Vice President, Support Services in October 2015. Support Services is comprised of Technical Service, Regulatory AffairsFood Safety Research and Industry Affairs departments.

Dr. Daniel D. Kephart, age 53, joined Neogen in January 2017 as Chief Science Officer — a new position for the Company. Dr. Kephart’s experience and expertise in technology scouting, product design, and instrument integration will help broaden Neogen’s continued rapid growth in the development of solutions for both food and animal safety.Development. Prior to joining Neogen, Kephart served ashe worked for 15 years at NSF International in various positions of increasing responsibility, including Director of Microbiology and Molecular Biology and Director of Applied Research, where he led efforts in grant research and Development Directormethod development with partners in academia, industry and government. At Neogen, Dr. Donofrio is responsible for our food safety research activities in the Agribusiness unit of Thermo Fisher Scientific, as well as Animal HealthU.S., Scotland and Food Safety Development at Life Technologies. His extensive industry experience also includes the management of a team focused on technical applications and customer-facing solutions for Promega Corporation.

Kenneth V. Kodilla,England.

Shane M. Fitzwater, age 60,46, joined Neogen in November 2003April 2018 as Vice President, of Manufacturing. He has responsibilityAnimal Safety Operations. In his role, Mr. Fitzwater is responsible for all manufacturing, inventory management,quality systems, supply chain, shipping and quality systemwarehousing for our Animal Safety operations, excluding Genomics. Prior to joining Neogen, he spent 18 years in positions of increasing responsibility at Ecolab, Inc., including five years as Ecolab’s Vice President of Supply Chain, Global Specialty Sector. Mr. Fitzwater managed Ecolab’s global supply chain for a $750 million business unit with worldwide manufacturing and logistics operations. Before being named a vice president, he spent four years as a director of operations at Ecolab, managing a group of 450 employees and an annual operating budget of $40 million.
Jerome L. Hagedorn, age 54, joined Neogen in April 2018 as Vice President, Food Safety Operations. In the role, Mr. Hagedorn is responsible for the Company’smanufacturing, supply chain, shipping and warehousing, production engineering and quality systems for Neogen’s Food Safety Division in Lansing, Michigan.operations. Prior to joining Neogen, Mr. Kodilla servedHagedorn spent the past eight years as Vice President of Operations at Siemens Healthcare Diagnostics. At Siemens, he was responsible for multiple plant manager for Facet Technologies in Atlanta, Georgia from 2001, as Manufacturing Manager for Becton Dickinson and Difco Laboratories from 1988, and as Quality Manager for Lee Laboratories from 1984. Mr. Kodilla’soperations, including diagnostic instrument manufacturing and regulatory experience includes FDA/ISO regulated Classnew product introduction. Prior to joining Siemens, Mr. Hagedorn held a variety of senior level positions over a 20 year career, including Director of Manufacturing at Bayer Healthcare in Indiana, Director of Lean Manufacturing at Invensys in Ohio, and diagnostic reagents and devices, high volume automated assembly and packaging, materials management and plant operations.

Manager of Automated Manufacturing at Siemens Electronic Components in Mexico.

Dr. Jason W. Lilly, age 43,46, joined the CompanyNeogen in June 2005 as Market Development Manager for Food Safety. In June 2009, he moved to the Corporate Development group. He was named Vice President of Corporate Development in December 2011, responsible for the identification and acquisition of new business opportunities for the Company. In January 2019, Dr. Lilly was named Vice President, International Business, responsible for Neogen’s operations outside of the U.S. and Canada. Prior to joining Neogen, he served in various technical sales and marketing roles at Invitrogen Corporation. Dr. Lilly’s technical knowledge
Julie Mann, age 55, joined Neogen in 2017 as Director of Human Resources and business acumen provideswas promoted to Senior Director of Human Resources in June 2019. On June 1, 2020, Ms. Mann was named Vice President & Chief Human Resources Officer, with responsibilities for people-focused programs and initiatives for Neogen’s more than 1,700 global employees. Ms. Mann has more than 30 years of experience focused on all aspects of strategic human resources including talent acquisition, compensation and benefits, employee development and employee relations. Prior to joining Neogen, Ms. Mann held the Company withpositions of Director, Talent Acquisition at Holland, a strong combination of mergerlogistics company, and acquisition skills.

Director, People Services Consulting at Herman Miller.

Terri A. Morrical, age 52,55, joined Neogen in September 1992 as part of the Company’sour acquisition of WTT, Incorporated. She has directed most aspects of the Company’sour Animal Safety operations since she joined Neogen and currently serves as Vice President in charge of all ofresponsible for the Company’s Animal Safety operationssegment, excluding GeneSeek.Genomics. From 1986 to 1991, Ms. Morrical was Controller for Freeze Point Cold Storage Systems and concurrently served in the same capacity for Powercore, Inc. In 1990, she joined WTT, Incorporated as VP/CFO and then became President, the position she held at the time Neogen acquired the business.

Marylinn Munson, age 56, joined Neogen in May 2020 as Vice President, Agrigenomics. Ms. Munson has held positions with increasing responsibility in sales and operations in the life science, biotechnology and agriculture industries for more than 20 years, with an additional seven years of experience in clinical and research labs. In the five years prior to joining Neogen, Ms. Munson was Board Chair at NorthShore Bio, Sr Partner at TNK Associates, LLC (dba Devil Doc Distributors) and provided consulting services at MPower Network. Her previous positions included VP of Global NGS Informatics at Qiagen, VP of Global Business Development and Sales at Biomatrica, Director of Global Sales Operations and America Sales at Illumina, and Global Market/Business Development Manager at Agilent Technologies.
Steven J. Quinlan, age 54,57, joined Neogen in January 2011 as Vice President and Chief Financial Officer. He was named Secretary in October 2011. He is responsible for all internal and external financial reporting for the Company,Neogen, and also manages the accounting, human resources, information technology communicationscorporate purchasing, treasury and facilities departments.investor relations functions. Mr. Quinlan came to the CompanyNeogen following 19 years at Detrex Corporation (1992-2010), the last eight years serving as Vice President-Finance, CFO and Treasurer. He was on the audit staff at the public accounting firm Price Waterhouse (now PWC) from 1985-1989.

Dr. Jennifer A. Rice, age 56, joined the Company in February 2009 as Senior Scientific Officer. In October 2010, she was named Vice President and Senior Research Director and had responsibility to manage and lead Neogen’s research and development team. Prior to joining Neogen, Dr. Rice served as Animal Health Global Product Development Leader at Dow AgroSciences. From 1996 to 2004, she held Research Director Positions at Biocor Animal Health (2001-2004) and Merial Animal Health (1996-2001). Dr. Rice’s strong background in leading large global research and development teams brought a key management skill to Neogen. Dr. Rice retired from the Company effective November 11, 2016.

Dwight E. Schroedter, age 60, joined Neogen in January 1995 as the Research and Development Manager of the Animal Safety Division based in Lexington, Kentucky. He has served in a variety of technical, operational and sales roles as part of the Animal Safety Division and was named Vice President, Animal Safety Manufacturing in October 2014, overseeing manufacturing operations at the Company’s domestic Animal Safety manufacturing locations, excluding Lansing. Prior to joining Neogen, Mr. Schroedter managed the antibody development laboratory for the Ames Division of Miles, Incorporated.

37

ITEM 11.
EXECUTIVE COMPENSATION

The information required by this Item, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the sections entitled “Compensation Discussion and Analysis”, “Compensation Committee Report” and “Executive Compensation” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2020.
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the section entitled “Security Ownership of Certain Beneficial Owners, Management and Related Stockholder Matters” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2020.
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this Item, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the section entitled “Information about the Board and Corporate Governance Matters” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2020.
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this itemItem, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the section entitled “Proposal 3
Ratification of the appointment of the Company’s independent registered public accounting firm” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2020.

PART IV

ITEM 15.
EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) (1) and (2) and (c). The response to this portion of ITEM 15 is submitted as a separate section of this report.

report starting on page

F-1.
(a) (3) and (b). The Exhibits, listed on the accompanying Exhibit Index on page 36,40, are incorporated herein by reference.

ITEM 16.
FORM
10-K
SUMMARY — NONE
38

Neogen Corporation

Annual Report on Form
10-K

Year Ended May 31, 2017

2020

EXHIBIT INDEX

EXHIBIT NO.

  

DESCRIPTION

  3.1  Restated Articles of Incorporation, as restatedamended on November 23, 2011 (incorporated by reference to Exhibit 3(i) tothe exhibit 3.1 filed with the Registrant’s Quarterly Report on Form10-Q dated November filed December 30, 2011).
  3.2  Certificate of Amendment to Articles of Incorporation filed on October 11, 2010.
  3.3Certificate of Amendment to Articles of Incorporation filed on November 20, 2018 (incorporated by reference to the exhibit filed with the Registrant’s Quarterly Report on Form 10-Q filed December 28, 2018).
  3.4By-Laws, as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form10-Q dated February 29, filed April 14, 2000).
10.1  Neogen Corporation 1997 Stock Option Plan, as amended (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on FormS-8 (No.333-122110) filed January 18, 2005).
10.2Neogen Corporation 2007 Stock Option Plan as amended and restated (incorporated by reference to Exhibit A to the Registrant’s 2011 Proxy Statement August 31, 2011 filed September 1, 2011).
10.310.2  Neogen Corporation 2015 Omnibus Incentive Plan (incorporated by reference to Appendix A to the Registrant’s 2015 Proxy Statement dated and filed August 29,25, 2015).
10.3Neogen Corporation 2018 Omnibus Incentive Plan (incorporated by reference to Appendix A to the Registrant’s 2018 Proxy Statement dated and filed August 28, 2018).
10.4  Amended and Restated Credit Agreement dated as of November 30, 20162018 between Registrant and JPMorgan Chase N.A. (incorporated by reference to Exhibit 10.A to the registrant’s Form8-K filed on December 6, 2016)2018).
21.021  Listing of Subsidiaries
23.123  Consent of Independent Registered Public Accounting Firm BDO USA, LLP
24.124  Power of Attorney
31.1  Section 302 Certification of Principal Executive Officer
31.2  Section 302 Certification of Principal Financial Officer
32  Certification Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS  Inline XBRL Instance Document
101.SCH  Inline XBRL Taxonomy Extension Schema Document
101.CAL  Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF  Inline XBRL Taxonomy Extension Definition Document
101.LAB  Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE  Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

39

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 NEOGEN CORPORATION
By:
/s/ John E. Adent
By:
/s/ Steven J. Quinlan
 /s/ James L. Herbert                             /s/ Steven J. Quinlan                        
John E. Adent, President & Chief 

James L. Herbert, Executive Chairman

of the Board of Directors

 Steven J. Quinlan, Vice President &
 Executive Officer Chief Financial Officer
 (Principal Executive Officer) (Principal Financial & Accounting Officer)

Dated: July 28, 2017

30, 2020

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

     

Title

  

Date

/s/ James L. Herbert

James L. Herbert

Executive Chairman of the Board of Directors (Principal Executive Officer)July 28, 2017

/s/ RichardJohn E. Calk

RichardAdent

John E. Calk

Adent
    President & Chief OperatingExecutive Officer (Principal Executive Officer)  July 28, 201730, 2020

/s/ Steven J. Quinlan

Steven J. Quinlan

    Vice President & Chief Financial Officer (Principal Financial & Accounting Officer)  July 28, 201730, 2020

*

James C. Borel
Chairman of the BoardJuly 30, 2020
*
DirectorJuly 30, 2020
William T. Boehm, Ph.D.      
William T. Boehm
*
    DirectorJuly 30, 2020
Ronald D. Green, Ph.D.  

*

James C. Borel

    DirectorJuly 30, 2020
James L. Herbert  

*

Ronald D. Green

    DirectorJuly 30, 2020
G. Bruce Papesh  

*

G. Bruce Papesh

    DirectorJuly 30, 2020
James P. Tobin  

*

Jack C. Parnell

    Director  July 30, 2020

*

Thomas H. Reed

Director

*

Darci L. Vetter
      
James P. TobinDirector

*By:  /s/ James L. HerbertJohn E. Adent             
 James L. Herbert, John E. Adent,
Attorney-in-fact
                   July 28, 201730, 2020

40

ANNUAL REPORT ON FORM
10-K

ITEM 15 (a)(1)(a)(2) (3), (b) and (c)

LIST OF FINANCIAL STATEMENTS, EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

YEAR ENDED MAY 31, 2017

NEOGEN CORPORATION

LANSING, MICHIGAN

FORM10-K—ITEM 15(a)(1) AND (2) AND 15(c)

LIST OF FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES

YEAR ENDED MAY 31, 2020
NEOGEN CORPORATION
LANSING, MICHIGAN
FORM
10-K—ITEM
15(a)(1) AND (2) AND 15(c)
LIST OF FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES
The following consolidated financial statements of Neogen Corporation and subsidiaries are included below and incorporated in ITEM 8:

Report of Independent Registered Public Accounting Firm

Consolidated Balance Sheets—May 31, 20172020 and 2016

2019

Consolidated Statements of Income—Years ended May 31, 2017, 20162020, 2019 and 2015

2018

Consolidated Statements of Comprehensive Income—Years ended May 31, 2017, 20162020, 2019 and 2015

2018

Consolidated Statements of Stockholders’ Equity— Years ended May 31, 2017, 20162020, 2019 and 2015

2018

Consolidated Statements of Cash Flows— Years ended May 31, 2017, 20162020, 2019 and 2015

2018

Notes to Consolidated Financial Statements

Schedules for which provision is made in the applicable accounting regulation of the United States Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.

FORM10-K – ITEM 15 (a) (3) AND (b)

A list of Exhibits required to be filed as a part of this report is set forth in the Exhibit Index, which immediately follows the signature page, and is incorporated herein by reference.

F-1

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors and Stockholders

Neogen Corporation and Subsidiaries

Lansing, Michigan

Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Neogen Corporation and Subsidiaries (the Company)“Company”) as of May 31, 20172020 and 2016, and2019, the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended May 31, 2017. These2020, and the related notes (collectively referred to as the consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States)statements). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Neogen Corporation and Subsidiariesthe Company at May 31, 20172020 and 2016,2019, and the results of its operations and its cash flows for each of the three years in the period ended May 31, 20172020

,
in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), Neogen Corporation and Subsidiaries’the Company’s internal control over financial reporting as of May 31, 2017,2020, based on criteria established in
Internal Control – Integrated Framework (2013)
 issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)(“COSO”) and our report dated July 28, 201730, 2020 expressed an unqualified opinion thereon.

Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Evaluation of the Accounting for Income Taxes
As described in Notes 1 and 6 to the consolidated financial statements, the Company recorded income tax expense related to US and Foreign tax paying jurisdictions totaling $12.83 million for the year ended May 31, 2020, and deferred income tax liabilities totaling $18.13 million at May 31, 2020. The Company’s accounting for income taxes involves the application of tax regulations in each of the foreign tax paying jurisdictions in which it operates. The determination of income subject to income tax in each tax paying jurisdiction requires management to apply transfer pricing guidelines for certain intercompany transactions. Additionally, the Company is entitled to claim foreign tax credits for taxes paid in international tax paying jurisdictions. Management’s assumptions and allocations used in the determination of the foreign tax credits are based on current interpretations of complex income tax regulations and can have a material effect on the calculation of US income taxes.
F-2

We identified the assumptions and allocations used to calculate foreign taxes and international components of US income taxes to be a critical audit matter. These assumptions and allocations include: (i) interpretation of tax laws in multiple tax paying jurisdictions, (ii) technical merit of tax positions including considerations related to transfer pricing guidelines for certain intercompany transactions, and (iii) allocation methodologies that are subjective in nature. Auditing these assumptions and allocations involved subjective auditor judgment due to the complexity and the extent of specialized knowledge needed.
The primary procedures we performed to address this critical audit matter included:
Assessing the design and testing operating effectiveness of certain controls over the Company’s income tax provision process, including controls over the identification and application of tax laws over earnings from multiple tax jurisdictions and the process to assess the technical merits of tax positions taken.
Evaluating the reasonableness and appropriateness of the data used to develop the assumptions and allocations made by management against relevant evidence obtained in other areas of the audit.
Utilizing professionals with specialized skills and knowledge in taxation to evaluate the Company’s application of the applicable tax laws, the technical merit of tax positions taken, and the reasonableness of the Company’s apportionment methodologies used.
/s/ BDO USA, LLP

We have served as the Company���s auditor since 2014.
Grand Rapids, Michigan

July 28, 2017

30, 2020

F-3

Neogen Corporation and Subsidiaries

Consolidated Balance Sheets – Assets

(in thousands)

   May 31 
   2017   2016 

Assets

    

Current Assets

    

Cash and cash equivalents

  $77,567   $55,257 

Marketable securities

   66,068    52,539 

Accounts receivable, less allowance of $2,000 and $1,500 at May 31, 2017 and 2016, respectively

   68,576    67,652 

Inventories

   73,144    64,371 

Prepaid expenses and other current assets

   7,606    8,407 
  

 

 

   

 

 

 

Total Current Assets

   292,961    248,226 

Property and Equipment

    

Land and improvements

   3,094    2,659 

Building and improvements

   37,917    33,417 

Machinery and equipment

   64,867    56,470 

Furniture and fixtures

   3,333    3,068 

Construction in progress

   2,290    1,057 
  

 

 

   

 

 

 
   111,501    96,671 

Less accumulated depreciation

   49,753    41,988 
  

 

 

   

 

 

 

Net Property and Equipment

   61,748    54,683 

Other Assets

    

Goodwill

   104,759    88,506 

Othernon-amortizable intangible assets

   14,323    9,170 

Amortizable customer-based intangible assets, net of accumulated amortization of $20,846 and $17,277 at May 31, 2017 and 2016, respectively

   35,983    30,909 

Othernon-current assets, net of accumulated amortization of $9,931 and $7,530 at May 31, 2017 and 2016, respectively

   18,635    18,446 
  

 

 

   

 

 

 

Total Other Assets

   173,700    147,031 
  

 

 

   

 

 

 

Total Assets

  $528,409   $449,940 
  

 

 

   

 

 

 

 
May 31
 
 
2020
 
 
2019
 
Assets
      
Current Assets
      
Cash and cash equivalents
 $
66,269
  $
41,688
 
Marketable securities
  
277,404
   
225,836
 
Accounts receivable, net of allowance of $1,350 and $1,700 at May 31, 2020 and 2019, respectively
  
84,681
   
82,582
 
Inventories
  
95,053
   
85,992
 
Prepaid expenses and other current assets
  
13,999
   
13,431
 
         
Total Current Assets
  
537,406
   
449,529
 
         
Property and Equipment
      
Land and improvements
  
5,456
   
5,324
 
Building and improvements
  
48,881
   
46,205
 
Machinery and equipment
  
90,351
   
82,752
 
Furniture and fixtures
  
4,324
   
3,895
 
Construction in progress
  
4,968
   
2,294
 
         
  
153,980
   
140,470
 
Less accumulated depreciation
  
75,309
   
65,623
 
         
Net Property and Equipment
  
78,671
   
74,847
 
         
Other Assets
      
Right of use assets
  
1,952
   
 
Goodwill
  
110,340
   
103,619
 
Other
non-amortizable
intangible assets
  
15,217
   
15,510
 
Amortizable intangible assets, net of accumulated amortization of $44,690 and $40,835
at May 31, 2020 and 2019,
 
respectively
  
51,364
   
52,096
 
  
 
 
   
 
 
 
Other
non-current
assets
  
2,232
   
139
 
         
Total Other Assets
  
181,105
   
171,364
 
         
 
 
 
 
 
 
 
 
 
Total Assets
 $
 
797,182
  $
 
695,740
 
         
See accompanying notes to consolidated financial statements.

F-
4

Neogen Corporation and Subsidiaries

Consolidated Balance Sheets – Liabilities and Stockholders’ Equity

(in thousands, except share and per share)

   May 31 
   2017  2016 

Liabilities and Equity

   

Current Liabilities

   

Accounts payable

  $16,244  $15,800 

Accruals

   

Accrued compensation

   5,002   4,986 

Income taxes

   936   —   

Other accruals

   13,820   7,812 
  

 

 

  

 

 

 

Total Current Liabilities

   36,002   28,598 

Deferred Income Taxes

   17,048   14,758 

OtherNon-Current Liabilities

   3,602   2,423 
  

 

 

  

 

 

 

Total Liabilities

   56,652   45,779 

Commitments and Contingencies (note 7)

   

Equity

   

Preferred stock, $1.00 par value - shares authorized 100,000; none issued and outstanding

   —     —   

Common stock, $0.16 par value - shares authorized 60,000,000; 38,199,367 and 37,567,689 shares issued and outstanding at May 31, 2017 and 2016, respectively

   6,112   6,011 

Additionalpaid-in capital

   176,779   150,000 

Accumulated other comprehensive loss

   (7,203  (3,946

Retained earnings

   295,926   252,133 
  

 

 

  

 

 

 

Total Neogen Corporation and Subsidiaries Stockholders’ Equity

   471,614   404,198 

Non-controlling interest

   143   (37
  

 

 

  

 

 

 

Total Equity

   471,757   404,161 
  

 

 

  

 

 

 
  $528,409   449,940 
  

 

 

  

 

 

 

 
May 31
 
 
2020
 
 
2019
 
Liabilities and Stockholders’ Equity
      
         
Current Liabilities
      
Accounts payable
 $
25,650
  $
19,063
 
Accruals
      
Accrued compensation
  
7,735
   
7,085
 
Income taxes
  
1,456
   
601
 
Other accruals
  
13,648
   
11,502
 
  
 
 
  
 
 
 
Total Current Liabilities
  
48,489
   
38,251
 
Deferred Income Taxes
  
18,125
   
15,618
 
Other
Non-Current
Liabilities
  
5,391
   
3,972
 
  
 
 
  
 
 
 
Total Liabilities
  
72,005
   
57,841
 
Commitments and Contingencies (note 7)
    
Stockholders’ Equity
      
Preferred stock, $1.00 par value — shares authorized 100,000; 0ne issued and outstanding
  
   
 
Common stock, $0.16 par value — shares authorized 120,000,000; 52,945,841 and 52,216,589 shares issued and outstanding at May 31, 2020 and 2019, respectively
  
8,471
   
8,355
 
Additional
paid-in
capital
  
257,693
   
221,937
 
Accumulated other comprehensive loss
  
(19,709
)  
(11,640
)
Retained earnings
  
478,722
   
419,247
 
  
 
 
  
 
 
 
Total Neogen Corporation and Subsidiaries Stockholders’ Equity
  
725,177
   
637,899
 
  
 
 
  
 
 
 
Total Liabilities and Stockholders’ Equity
 $
797,182
  $
695,740
 
         
See accompanying notes to consolidated financial statements.

F-
5

Neogen Corporation and Subsidiaries

Consolidated Statements of Income

(in thousands, except per share)

   Year Ended May 31 
   2017  2016  2015 

Revenues

    

Product revenues

  $306,512  $273,570  $243,909 

Service revenues

   55,082   47,705   39,165 
  

 

 

  

 

 

  

 

 

 

Total Revenues

   361,594   321,275   283,074 
  

 

 

  

 

 

  

 

 

 

Cost of Revenues

    

Cost of product revenues

   156,568   137,766   120,377 

Cost of service revenues

   33,058   30,445   23,012 
  

 

 

  

 

 

  

 

 

 

Total Cost of Revenues

   189,626   168,211   143,389 
  

 

 

  

 

 

  

 

 

 

Gross Margin

   171,968   153,064   139,685 

Operating Expenses

    

Sales and marketing

   62,424   57,599   51,757 

General and administrative

   34,214   29,189   25,233 

Research and development

   10,385   9,890   9,577 
  

 

 

  

 

 

  

 

 

 
   107,023   96,678   86,567 
  

 

 

  

 

 

  

 

 

 

Operating Income

   64,945   56,386   53,118 

Other Income (Expense)

    

Interest income

   838   322   228 

Royalty income

   171   217   150 

Change in purchase consideration

   18   —     (297

Other, net

   701   (1,412  (1,123
  

 

 

  

 

 

  

 

 

 
   1,728   (873  (1,042
  

 

 

  

 

 

  

 

 

 

Income Before Income Taxes

   66,673   55,513   52,076 

Provision for Income Taxes

   22,700   18,975   18,500 
  

 

 

  

 

 

  

 

 

 

Net Income

   43,973   36,538   33,576 

Net (Income) Loss Attributable toNon-controlling Interest

   (180  26   (50
  

 

 

  

 

 

  

 

 

 

Net Income Attributable to Neogen

  $43,793  $36,564  $33,526 
  

 

 

  

 

 

  

 

 

 

Net Income Attributable to Neogen per Share

    

Basic

  $1.16  $0.98  $0.91 
  

 

 

  

 

 

  

 

 

 

Diluted

  $1.14  $0.97  $0.90 
  

 

 

  

 

 

  

 

 

 

 
Year Ended May 31
 
 
2020
 
 
2019
 
 
2018
 
Revenues
         
Product revenues
 $
335,539
  $
339,439
  $
331,288
 
Service revenues
  
82,631
   
74,747
   
66,642
 
             
Total Revenues
  
418,170
   
414,186
   
397,930
 
             
             
Cost of Revenues
         
Cost of product revenues
  
173,566
   
179,660
   
173,725
 
Cost of service revenues
  
48,325
   
42,606
   
37,933
 
             
Total Cost of Revenues
  
221,891
   
222,266
   
211,658
 
             
             
Gross Margin
  
196,279
   
191,920
   
186,272
 
             
Operating Expenses
         
Sales and marketing
  
69,675
   
70,230
   
66,929
 
General and administrative
  
44,331
   
40,791
   
38,294
 
Research and development
  
14,750
   
12,805
   
10,855
 
             
Total Operating Expenses
  
128,756
   
123,826
   
116,078
 
             
Operating Income
  
67,523
   
68,094
   
70,194
 
             
Other Income
         
Interest income, net
  
5,992
   
4,683
   
2,043
 
Royalty income
  
—  
   
150
   
147
 
Other, net
  
(1,210
)  
32
   
1,081
 
             
Total Other Income
  
4,782
   
4,865
   
3,271
 
             
Income Before Income Taxes
  
72,305
   
72,959
   
73,465
 
Provision for Income Taxes
  
12,830
   
12,783
   
10,250
 
             
Net Income
  
59,475
   
60,176
   
63,215
 
Net Income Attributable to
Non-controlling
Interest
  
—  
   
—  
   
(70
)
             
Net Income Attributable to Neogen
 $
59,475
  $
60,176
  $
63,145
 
             
Net Income Attributable to Neogen per Share
         
Basic
 $
1.13
  $
1.16
  $
1.23
 
Diluted
 $
1.13
  $
1.15
  $
1.21
 
Weighted Average Shares Outstanding
     
Basic
   52,550   51,888    51,358 
Diluted
   52,860   52,425    52,149 
See accompanying notes to consolidated financial statements.

F-
6

Neogen Corporation and Subsidiaries

Consolidated Statements of Comprehensive Income

(in thousands, except per share)

   Year Ended May 31 
   2017  2016  2015 

Net Income

Other comprehensive income (loss), net of tax:

  $43,973  $36,538  $33,576 

currency translations

   (3,257  (1,504  (2,813
  

 

 

  

 

 

  

 

 

 

Comprehensive income

   40,716   35,034   30,763 

Comprehensive (income) loss attributable tonon-controlling interest

   (180  26   (50
  

 

 

  

 

 

  

 

 

 

Comprehensive income attributable to Neogen

  $40,536  $35,060  $30,713 
  

 

 

  

 

 

  

 

 

 

thousands)

 
Year Ended May 31
 
 
2020
 
 
2019
 
 
2018
 
Net Income
 $
 
59,475
  $
 
60,176
  $
 
63,215
 
Other comprehensive loss, net of tax: foreign currency translations
  
(8,495
)  
(1,894
)  
(2,543
)
Other comprehensive income, net of tax: unrealized gain on marketable securities
  
426
   
—  
   
—  
 
             
Comprehensive income
  
51,406
   
58,282
   
60,672
 
Comprehensive income attributable to
non-controlling
interest
  
—  
   
—  
   
(70
)
 
             
Comprehensive income attributable to Neogen
 $
51,406
  $
58,282
  $
60,602
 
             
See accompanying notes to consolidated financial statements.

F-
7

Neogen Corporation and Subsidiaries

Consolidated Statements of Stockholders’ Equity

(in thousands, except shares)

              Accumulated           
           Additional  Other      Non-    
           Paid-in  Comprehensive  Retained   Controlling  Total 
   Shares   Amount   Capital  Income (Loss)  Earnings   Interest  Equity 

Balance, May 31, 2014

   36,732,313   $5,877   $118,070  $371  $182,043   $(61 $306,300 

Exercise of options, share-based compensation and $2,475 income tax benefit

   376,364    61    13,115       13,176 

Issuance of shares under employee stock purchase plan

   19,592    3    721       724 

Net income (loss) for 2015

         33,526    50   33,576 

Other comprehensive income (loss)

        (2,813     (2,813
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Balance, May 31, 2015

   37,128,269    5,941    131,906   (2,442  215,569    (11  350,963 

Exercise of options, share-based compensation and $2,945 income tax benefit

   421,143    67    17,311       17,378 

Issuance of shares under employee stock purchase plan

   18,277    3    783       786 

Net income (loss) for 2016

         36,564    (26  36,538 

Other comprehensive income (loss)

        (1,504     (1,504
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Balance, May 31, 2016

   37,567,689    6,011    150,000   (3,946  252,133    (37  404,161 

Exercise of options, share-based compensation and $3,922 income tax benefit

   612,963    98    26,621       26,719 

Issuance of shares under employee stock purchase plan

   18,715    3    922       925 

Purchase of minority interest

       (764      (764

Net income (loss) for 2017

         43,793    180   43,973 

Other comprehensive income (loss)

        (3,257     (3,257
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Balance, May 31, 2017

   38,199,367   $6,112   $176,779  $(7,203 $295,926   $143  $471,757 
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

            
Accumulated
           
   
Common Stock
  
Additional
Paid-in
  
Other
Comprehensive
  
Retained
   
Non-
Controlling
  
Total
 
  
Shares
 
 
Amount
 
 
Capital
 
 
Income (Loss)
 
 
Earnings
 
 
Interest
 
 
Equity
 
Balance,
June
1, 2017
  
50,932,489
  $
8,149
  $
174,742
  $
(7,203
) $
295,926
  $
143
  $
471,757
 
Exercise of options and share-based compensation expense
  
781,116
   
125
   
26,992
   
—  
   
—  
   
—  
   
27,117
 
Issuance of shares under employee stock purchase plan
  
22,127
   
4
   
1,048
   
—  
   
—  
   
—  
   
1,052
 
Purchase of minority interest
  
—  
   
—  
   
(210
)  
—  
   
—  
   
(213
)  
(423
)
Net income for 2018
  
—  
   
—  
   
—  
   
—  
   
63,145
   
70
   
63,215
 
Other comprehensive loss
  
—  
   
—  
   
—  
   
(2,543
)  
—  
   
—  
   
(2,543
)
                             
Balance, May 31, 2018
  
51,735,732
   
8,278
   
202,572
   
(9,746
)  
359,071
   
—  
   
560,175
 
Exercise of options and share-based compensation expense
  
512,527
   
82
   
21,335
   
—  
   
—  
   
—  
   
21,417
 
Issuance of shares under employee stock purchase plan
  
18,330
   
3
   
1,157
   
—  
   
—  
   
—  
   
1,160
 
Shares repurchased
  
(50,000
)  
(8
)  
(3,127
)  
—  
   
—  
   
—  
   
(3,135
)
Net income for 2019
  
—  
   
—  
   
—  
   
—  
   
60,176
   
—  
   
60,176
 
Other comprehensive loss
  
—  
   
—  
   
—  
   
(1,894
)  
—  
   
—  
   
(1,894
)
                             
Balance, May 31, 2019
  
52,216,589
   
8,355
   
221,937
   
(11,640
)  
419,247
   
—  
   
637,899
 
Exercise of options and share-based compensation expense
  
707,674
   
113
   
34,566
   
—  
   
—  
   
—  
   
34,679
 
Issuance of shares under employee stock purchase plan
  
21,578
   
3
   
1,190
   
—  
   
—  
   
—  
   
1,193
 
Net income for 2020
  
—  
   
—  
   
—  
   
—  
   
59,475
   
—  
   
59,475
 
Other comprehensive loss
  
—  
   
—  
   
—  
   
(8,069
)  
—  
   
—  
   
(8,069
)
                             
Balance, May 31, 2020
  
52,945,841
  $
 
8,471
  $
 
257,693
  $
(19,709
) $
 
478,722
  $
—  
  $
 
725,177
 
                             
See accompanying notes to consolidated financial statements.

F-
8

Neogen Corporation and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

   Year Ended May 31 
   2017  2016  2015 

Cash Flows From Operating Activities

    

Net income

  $43,973  $36,538  $33,576 

Adjustments to reconcile net income to net cash provided from operating activities:

    

Depreciation and amortization

   14,691   12,181   10,649 

Deferred income taxes

   (292  1,906   496 

Share-based compensation

   5,261   5,468   4,450 

Excess income tax benefit from exercise of stock options

   (3,922  (2,945  (2,475

Changes in operating assets and liabilities, net of business acquisitions:

    

Accounts receivable

   5,035   (6,002  (7,252

Inventories

   (6,970  (9,427  319 

Prepaid expenses and other assets

   812   (3,836  3,264 

Accounts payable

   (1,691  704   412 

Accruals and other changes

   3,377   744   353 
  

 

 

  

 

 

  

 

 

 

Net Cash From Operating Activities

   60,274   35,331   43,792 

Cash Flows Used in Investing Activities

    

Purchase of property, equipment and othernon-current intangible assets

   (14,578  (14,222  (9,619

Proceeds from the sales of marketable securities

   149,226   147,189   93,662 

Purchase of marketable securities

   (162,755  (151,625  (105,944

Business acquisitions, net of cash acquired

   (34,029  (42,491  (6,554
  

 

 

  

 

 

  

 

 

 

Net Cash Used in Investing Activities

   (62,136  (61,149  (28,455

Cash Flows From Financing Activities

    

Exercise of stock options

   21,148   12,363   8,558 

Excess income tax benefit from the exercise of stock options

   3,922   2,945   2,475 
  

 

 

  

 

 

  

 

 

 

Net Cash From Financing Activities

   25,070   15,308   11,033 

Effect of Exchange Rate on Cash

   (898  (294  (984
  

 

 

  

 

 

  

 

 

 

Net Increase (Decrease) in Cash and Cash Equivalents

   22,310   (10,804  25,386 

Cash and Cash Equivalents, Beginning of Year

   55,257   66,061   40,675 
  

 

 

  

 

 

  

 

 

 

Cash and Cash Equivalents, End of Year

  $77,567  $55,257  $66,061 
  

 

 

  

 

 

  

 

 

 

Supplementary Cash Flow Information

    

Income taxes paid, net of refunds

  $13,865  $13,413  $10,454 

 
Year Ended May 31
 
 
2020
 
 
2019
 
 
2018
 
Cash Flows From Operating Activities
         
Net income
 $
59,475
  $
60,176
  $
63,215
 
Adjustments to reconcile net income to net cash from operating activities:
      
Depreciation and amortization
  
18,396
   
17,624
   
17,058
 
Deferred income taxes
  
1,601
   
1,197
   
(2,996
)
Share-based compensation
  
6,468
   
5,543
   
4,909
 
Changes in operating assets and liabilities, net of business acquisitions:
         
Accounts receivable
  
(2,881
)  
(4,025
)  
(10,233
)
Inventories
  
(10,011
)  
(10,437
)  
(2,647
)
Prepaid expenses and other assets
  
(1,017
)  
(3,569
)  
(2,275
)
Accounts payable
  
6,745
   
(1,461
)  
4,381
 
Accruals and other changes
  
7,102
   
(1,206
)  
(2,281
)
             
Net Cash From Operating Activities
  
85,878
   
63,842
   
69,131
 
             
Cash Flows
For
Investing Activities
         
Purchase of property, equipment and other
non-current
intangible assets
  
(24,052
)  
(14,661
)  
(20,946
)
Proceeds from the sales of marketable securities
  
406,731
   
339,225
   
299,751
 
Purchase of marketable securities
  
(458,300
)  
(437,324
)  
(361,419
)
Business acquisitions, net of cash acquired
  
(13,164
)  
(6,388
)  
(468
)
             
Net Cash
For
Investing Activities
  
(88,785
)  
(119,148
)  
(83,082
)
Cash Flows From Financing Activities
         
Exercise of stock options and other
  
29,405
   
17,034
   
23,261
 
Repurchase of common stock
  
—  
   
(3,135
)  
—  
 
Purchase of
non-controlling
minority interest
  
—  
   
—  
   
(423
)
             
Net Cash From Financing Activities
  
29,405
   
13,899
   
22,838
 
Effect of
Foreign
Exchange Rate on Cash
  
(1,917
)  
21
   
(3,380
)
             
Net
Increase
(Decrease) in Cash and Cash Equivalents
  
24,581
   
(41,386
)  
5,507
 
Cash and Cash Equivalents, Beginning of Year
  
41,688
   
83,074
   
77,567
 
             
Cash and Cash Equivalents, End of Year
 $
66,269
  $
41,688
  $
83,074
 
             
Supplementary Cash Flow Information
         
Income taxes paid, net of refunds
 $
7,364
  $
13,027
  $
14,966
 
See accompanying notes to consolidated financial statements.

F-
9

Neogen Corporation and Subsidiaries

Notes to Consolidated Financial Statements

1.
Summary of Significant Accounting Policies

Nature of Operations

Neogen Corporation develops, manufactures and markets a diverse line of products and services dedicated to food and animal safety.

Basis of Consolidation

The consolidated financial statements include the accounts of Neogen Corporation and its subsidiaries, (collectively, the Company), all of which are whollywholly-owned as of May 31, 2020. Neogen Latinoamérica was 100% owned as of May 31, 2017, with the exception of Neogen Latinoamerica. Neogen Latinoamerica was 90% owned as of2020 and May 31, 2017 and 2016. The Company made an additional capital contribution on December 31, 2013 which increased its ownership interest in2019; Neogen Latinoamerica from 60% to 90%. Neogen do Brasil was 100% and 90% owned as of May 31, 2017 and 2016, respectively. The Company purchased all shares owned by the two minority interest ownersowner on February 28,December 31, 2017, which increased its ownership interest in Neogen do BrasilLatinoamérica from 90% to 100%.Non-controlling interest represents the The
non-controlling owner’s proportionate share in the equity of these subsidiaries; thenon-controlling owner’s
owners’ proportionate share in the income or losses of the subsidiaries is
was
 subtracted from, or added to, CompanyNeogen’s net income to calculate the net income attributable to Neogen Corporation.

All intercompany accounts and transactions have been eliminated in consolidation.

Use

Share and per share amounts reflect the December 29, 2017
4-for-3
stock split as if it took place at the beginning of Estimates

The preparationthe period

s
presented.
Functional Currency
Our functional currency is the U.S. dollar. We translate our non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in other comprehensive income (loss). Gains or losses from foreign currency transactions are included in other income (expense) on our consolidated statement of income.
Recently Adopted Accounting Standards
Leases
On June 1, 2019, the Company adopted ASU
No. 2016-02—
Leases (Topic 842). Refer to the Leases section of Note 1 for further information.
Recent Accounting Pronouncements Not Yet Adopted
Financial Instruments- Credit Losses
In June 2016, the FASB issued ASU No.
2016-13—Measurement
of Credit Losses on Financial Instruments, which changes how companies measure credit losses on most financial statements in conformity with U.S.instruments measured at amortized cost and certain other instruments, such as loans, receivables and
held-to-maturity
debt securities. Rather than generally accepted accounting principlesrecognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires managementcompanies to make estimatesrecognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and assumptionsthe amount of amortized cost that affect the amounts reported incompany expects to collect over the instrument’s contractual life. ASU
2016-13
is effective for fiscal periods beginning after December 15, 2019 and must be adopted as a cumulative effect adjustment to retained earnings. Adoption of this guidance will not have a material impact on our consolidated financial statements due to the Company’s short-term contractual life of receivables and accompanying notes. Actual results could differ from these estimates. Significant estimates impactingminimal expected losses.
Fair Value Measurements
In August 2018, the accompanyingFASB issued ASU
2018-3,
Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements of fair value measurements. ASU
2018-13
is effective for fiscal years beginning after December 15, 2019. Adoption of this guidance will not have an impact on our consolidated financial statements includestatements.
Cloud Computing Implementation Cost
In August 2018, the allowanceFASB issued ASU
2018-15,
Intangible-Goodwill and Other
Internal-Use
Software (Subtopic
350-40):
Customer’s Accounting for uncollectible accounts receivable, inventory valuation and intangible assets.

Implementation Cost Incurred in a Cloud Computing Arrangement That Is a Service Contract, which clarifies the accounting for implementation costs in cloud computing arrangements. ASU

2018-15
is effective for fiscal years beginning after December 15, 2019. Adoption of this guidance will not have an impact on our consolidated financial statements.
F-10

Comprehensive Income

Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting
principles
, are excluded from net income and recognized directly as a component of stockholders’ equity. Accumulated other comprehensive income (loss) consists solely of foreign currency translation adjustments.

adjustments and unrealized gains and losses on our marketable securities.

Fair Value of Financial Instruments
The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.
Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:
Level 1:
Observable inputs such as quoted prices in active markets;
Level 2:
Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
Level 3:
Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Cash and Cash Equivalents
Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90
days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Cash and cash equivalents were
$66,269,000 and $41,688,000 at May 31, 2020 and 2019, respectively.
The carrying value of these assets approximates fair value due to the short maturity of these instruments and is classified as Level 1 in the fair value hierarchy.
Cash held by foreign subsidiaries was $13,060,000 and $8,711,000 at May 31, 2020 and 2019, respectively.
Marketable Securities
The Company has marketable securities held by banks or broker-dealers at May 31, 2020, consisting of short-term domestic certificates of deposit of $16,848,000 and commercial paper and U.S. treasuries rated at least
A-1/P-1
(short-term) and A/A2 (long-term) with original maturities between 91 days and two years of $260,556,000. Total outstanding marketable securities at May 31, 2020 were $277,404,000; there were $225,836,000 in marketable securities outstanding at May 31, 2019.
Changes in market value are monitored and recorded on a monthly basis; in the event of a downgrade in credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security portfolio. These securities are classified as available for sale. The primary objective of management’s short-term investment activity is to preserve capital for the purpose of funding
current
operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the income statement. Adjustments in the fair value of these assets are recorded in other comprehensive income.
F-11

Marketable Securities as of May 31, 2020 and 2019 are listed below by classification and remaining maturities.
  
 
 
Year ended May 31
 
(in thousands)
 
Maturity
 
 
2020
 
  
2019
 
US Treasuries
 
0 – 90 days
  $
—  
  $
2,470
 
 
91 –180 days
   
—  
   
—  
 
 
181 days –1 year
   
2,532
   
2,435
 
 
1 – 2 years
   
—  
   
2,505
 
 
 
 
 
 
 
 
 
 
 
 
 
Commercial Paper
 & Corporate Bonds
 
0 – 90 days
   
133,130
   
84,338
 
 
91 – 180 days
   
73,824
   
47,960
 
 
181 days –1 year
   
43,231
   
34,369
 
 
1 – 2 years
   
7,839
   
34,078
 
 
 
 
 
 
 
 
 
 
 
 
 
Certificates of Deposit
 
0 – 90 days
   
1,003
   
7,732
 
 
91 – 180 days
   
5,184
   
5,000
 
 
181 days –1 year
   
6,069
   
750
 
 
1 – 2 years
   
4,592
   
4,199
 
             
Total Marketable Securities
  $
277,404
  $
225,836
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The components of marketable securities at May 31, 2020 are as follows:
 
  
Amortized
 
  
Unrealized
 
  
Unrealized
 
 
 
 
(in thousands)
  
Cost
 
  
Gains
 
  
Losses
 
 
Fair Value
 
US Treasuries
  
$
2,502
 
  
$
30
 
  
$
—  
 
 
$
2,532
 
Commercial Paper & Corporate Bonds
  
 
257,700
 
  
 
347
 
  
 
(23
 
 
258,024
 
Certificates of Deposit
  
 
16,648
 
  
 
200
 
  
 
—  
 
 
 
16,848
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
Total Marketable Securities
  
$
 276,850
 
  
$
577
 
  
$
(23
 
$
 277,404
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
F-1
2

Use of Estimates
The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. We believe that these estimates have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Though the impact of the
COVID-19
pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. Actual results may differ from these estimates under different assumptions or conditions.
Accounts Receivable and Concentrations of Credit Risk

Financial instruments which potentially subject the CompanyNeogen to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit historyhistories before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts on accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts. No customer accounted for more than 10% of accounts receivable at May 31, 20172020 or 2016,2019, respectively. The activity in the allowance for doubtful accounts was as follows:

   Year ended May 31 
(in thousands)  2017   2016   2015 

Beginning Balance

  $1,500   $1,300   $1,200 

Provision

   645    305    337 

Recoveries

   25    90    92 

Write-offs

   (170   (195   (329
  

 

 

   

 

 

   

 

 

 

Ending Balance

  $2,000   $1,500   $1,300 
  

 

 

   

 

 

   

 

 

 

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.

Fair Value Measurements

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1:

Observable inputs such as quoted prices in active markets;

Level 2:

Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3:

        Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own         assumptions.

Cash and Cash Equivalents

Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents were $77,567,000 and $55,257,000 at May 31, 2017 and 2016, respectively. The carrying value of these assets approximates fair value due to the short maturity of these instruments and meet the Level 1 criteria. Cash held by foreign subsidiaries was $8,132,000 and $5,320,000 at May 31, 2017 and 2016, respectively.

Marketable Securities

The Company has marketable securities held by banks or broker-dealers at May 31, 2017, consisting of short-term domestic certificates of deposit of $25,355,000 and commercial paper rated at leastA-2/P-2 with maturities between 91 days and one year of $40,713,000. Total outstanding marketable securities at May 31, 2017 were $66,068,000; there were $52,539,000 in marketable securities outstanding at May 31, 2016. These securities are classified as available for sale. The primary objective of the Company’s short-term investment activity is to preserve capital for the purpose of funding operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities are recorded at fair value (that approximates cost) based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within Other Income on the income statement.

   
Year ended May 31
 
(in thousands)
  
2020
   
2019
   
2018
 
Beginning Balance
 $
1,700
  $
1,550
  $
2,000
 
Provision
  
393
   
263
   
152
 
Recoveries
  
49
   
38
   
40
 
Write-offs
  
(792
)  
(151
)  
(642
)
             
Ending Balance
 $
 
1,350
  $
 
1,700
  $
 
1,550
 
             
Inventories

Inventories are stated at the lower of cost or net realizable value, determined on the
first-in,
first-out method, or market.
method. The components of inventories were as follows:

   Year ended May 31 
(in thousands)  2017   2016 

Raw Materials

  $33,190   $29,501 

Work-in-process

   4,831    4,498 

Finished goods

   35,123    30,372 
  

 

 

   

 

 

 
  $73,144   $64,371 
  

 

 

   

 

 

 

 
Year ended May 31
 
(in thousands)
 
2020
 
  
2019
 
Raw Materials
 $
45,058
  $
41,594
 
Work-in-process
  
6,887
   
5,581
 
Finished goods
  
43,108
   
38,817
 
         
 $
 
95,053
  $
 
85,992
 
         
The Company’s inventories are analyzed for slow moving, expired and obsolete items no less frequently thanon a quarterly basis and the valuation allowance is adjusted as required.required within cost of sales expense. The valuation allowance for inventory
was $2,000,000 $
2,850,000
and $1,550,000 $
2,250,000
at May 
31 2017
,
2020
and 2016,
2019
, respectively.

F-13

Property and Equipment

Property and equipment is stated at cost. Expenditures for major improvements are capitalized while repairs and maintenance are charged to expense.
expense
 as incurred
.
Depreciation is provided on the straight-line method over the estimated useful lives of the respective assets, which are generally
seven
to
39
years for buildings and improvements and
three
to
ten
years for furniture, fixtures, machinery and equipment. Depreciation expense was $8,783,000, $7,452,000 $
11,907,000
, $
11,315,000
and $6,318,000 $
10,315,000
in fiscal years 2017, 2016
2020
,
2019
and 2015,
2018
, respectively.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants
not-to-compete
and patents. Amortizable intangible assets are amortized on either an accelerated or a straight-line basis, generally over 5 to 25 years. The CompanyManagement reviews the carrying amounts of goodwill and other
non-amortizable
intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired by
.
In evaluating goodwill for impairment, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the goodwill impairment test. In contrast, we can opt to bypass the qualitative assessment for any reporting unit in any period and proceed directly to assessing the fair value of all of our reporting units and compare the fair value of the reporting unit to carrying value to determine if any impairment is necessary. Doing so does not preclude us from performing the qualitative assessment in any subsequent period. In the fourth quarter of fiscal 2020, we elected to bypass the qualitative approach that allows the assessment of qualitative factors to determine whether it is more likely than not that the fair value of a quantitative assessment. reporting unit is less than its carrying amount and instead proceeded directly to assessing the fair value of all of our reporting units and comparing the fair values of the reporting units to the carrying values to determine if any impairment is necessary
.
If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable earnings multiples of peer companies, such assets are reduced to their estimated fair value and a charge is made to operations.
NaN goodwill impairments were identified during the years ended May 31, 2020, 2019 and 2018, respectively.
The remaining weighted-average amortization period for customer-based intangibles was 9 years and other intangibles are 11 and 1210 years respectively, at May 31, 20172020 and May 31, 2016.

2019, respectively.

Long-lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset are less than the carrying value of the asset. In such an event, fair value is determined using discounted cash flows, and if lower than the carrying value, impairment is recognized through a charge to operations.

NaN impairments of long-lived assets were identified during the years ended May 31, 2020, 2019 and 2018, respectively.
Reclassifications

Certain immaterial amounts in the fiscal 20162019 and 20152018 financial statements have been reclassified to conform towith the fiscal 20172020 presentation.

See the Company’s discussion on Accounting Standards Update2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, below for information on reclassifications related to the adoption of this standard as of May 31, 2017.

Stock Options

Equity Compensation Plans
At May 31, 2017,2020, the Company had stock option plans which are described more fully in Note 5.

5 to the consolidated financial statements.

The weighted-average fair value per share of stock options granted during fiscal years 2017, 20162020, 2019 and 2015,2018, estimated on the date of grant using the Black-Scholes option pricing model, was $15.86, $13.11$15.56, $14.91 and $11.91,$14.47, respectively. The fair value of stock options granted was estimated using the following weighted-average assumptions:

   Year ended May 31 
   2017   2016   2015 

Risk-free interest rate

   1.2%    1.2%    1.2% 

Expected dividend yield

   0.0%    0.0%    0.0% 

Expected stock volatility

   35.2%    33.3%    36.2% 

Expected option life

   4.0 years        4.0 years        4.0 years     

 
Year ended May 31
 
 
2020
 
 
2019
 
 
2018
 
Risk-free interest rate
  
1.9%
   
2.6%
   
1.6%
 
Expected dividend yield
  
0.0%
   
0.0%
   
0.0%
 
Expected stock volatility
  
29.4%
   
27.0%
   
27.7%
 
Expected option life
  
3.5
 
years
   
3.5 years
   
4.0 years
 
The risk-free interest rate for periods within the expected life of options granted is based on the United States Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on historical volatility of the Company’s stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data. TheWe include recent historical experience in estimating our forfeitures. As employees terminate, grant tranches expire or as forfeitures are known, estimated expense is adjusted to actual. For options granted in fiscal years 2020, 2019 and 2018, the Company recognizesrecorded charges in general and administrative expense based on the fair value of stock options using the acceleratedstraight-line method over their requisite service periods which the Company has determined to be the vesting periods.

Revenue Recognition

Revenue from products and services is recognized when the product has been shipped or the service performed, the sales price is fixed and determinable, and collection of any receivable is probable. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred and later recognized in the period, that all recognition criteria have been met. Customer credits for sales returns, pricing and other disputes, and other related matters (including volume rebates offered to certain distributors as marketing support) represent approximately 3% of reported net revenue in fiscal years 2017, 2016 and 2015.

Shipping and Handling Costs

Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by the Company are recorded in sales and marketing expense; these expenses totaled $10,185,000, $9,734,000 and $8,648,000 in fiscal years 2017, 2016 and 2015, respectively.

generally five years.

F-14

Income Taxes

The Company accounts

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carry forwardscarryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

The Company’s

Our wholly-owned foreign subsidiaries are comprised of Neogen Europe, Lab M Holdings,Ltd, Quat-Chem Ltd, Abtek (Biologicals) Ltd, Neogen Italia S.r.l., Neogen do Brasil, Rogama Industria e Comercio Ltda, Neogen Latinoamérica, Productos Quimicos Magiar S.A., Neogen Uruguay, Neogen Chile SpA, Neogen
Bio-Scientific
Technology Co (Shanghai), Neogen Food and Animal Security (India), Neogen Canada, Acumedia do Brasil, Deoxi Biotecnologia Ltda, and Rogama Industria e Comercio, Ltda; Neogen owns 90% of Neogen Latinoamerica.Australasia Pty Limited. Based on historical experience, as well as the Company’smanagement’s future plans, earnings from these subsidiaries are expected to be
re-invested
indefinitely for future expansion and working capital needs. Furthermore, the Company’sour domestic operations have historically produced sufficient operating cash flow to mitigate the need to remit foreign earnings. On an annual basis, the Company evaluateswe evaluate the current business environment and whether any new events or other external changes might require a
re-evaluation
of the decision to indefinitely
re-invest
foreign earnings. At MayIt is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “U.S. Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include a federal corporate tax rate reduced from 35% to 21% for tax years beginning after December 31, 2017, unremitted earningsthe transition of U.S. international taxation from a worldwide tax system to a territorial system, and a
one-time
transition tax on the mandatory deemed repatriation of foreign earnings. The U.S. Tax Act also includes a provision to tax global intangible
low-taxed
income (GILTI) of foreign subsidiaries were $35,281,000.

and a deduction for foreign derived intangible income (FDII), both of which became effective for us beginning June 1, 2018. See Note 6 to the consolidated financial statements for further information.

Research and Development Costs

Research and development costs, which consist primarily of compensation costs, administrative expenses and new product development, among other items, are expensed as incurred.

Advertising Costs

Advertising costs are expensed within sales and marketing as incurred and totaled $1,643,000, $1,463,000
$1,454,000, $1,471,000 and $1,371,000$1,411,000 in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively.

F-15

Net Income Attributable to Neogen per Share

Basic net income per share is based on the weighted average number of common shares outstanding during each year. Diluted earnings per share is based on the weighted average number of common shares and dilutive potential common shares outstanding. The Company’sOur dilutive potential common shares outstanding during the years result entirely from dilutive stock options. The following table presents the net income per share calculations:

   Year ended May 31 
(in thousands, except per share)  2017   2016   2015 

Numerator for basic and diluted net income per share - Net Income attributable to Neogen

  $43,793   $36,564   $33,526 
  

 

 

   

 

 

   

 

 

 

Denominator for basic net income per share - Weighted average shares

   37,908    37,402    36,953 

Effect of dilutive stock options

   466    473    491 
  

 

 

   

 

 

   

 

 

 

Denominator for diluted net income per share

   38,374    37,875    37,444 

Net income attributable to Neogen per share

      

Basic

  $1.16   $0.98   $0.91 

Diluted

  $1.14   $0.97   $0.90 

 
Year ended May 31
 
(in thousands, except per share)
 
2020
 
 
2019
 
 
2018
 
Numerator for basic and diluted net income per share - Net Income attributable to Neogen
 $
 
59,475
  $
 
60,176
  $
 
63,145
 
Denominator for basic net income per share - Weighted average shares
  
52,550
   
51,888
   
51,358
 
Effect of dilutive stock options
  
310
   
537
   
791
 
             
Denominator for diluted net income per share
  
52,860
   
52,425
   
52,149
 
Net income attributable to Neogen per share
         
Basic
 $
1.13
  $
1.16
  $
1.23
 
Diluted
 $
1.13
  $
1.15
  $
1.21
 
At May 31, 2017, 2016 and 2015,2020, 28,000 potential shares from option exercises were excluded from the computation of diluted net income per share, as the option exercise prices exceeded the average market price of the common stock exceeded the option exercise price for all outstanding options; therefore, noshares. At May 31, 2019, 5
,
000 potential shares were excluded from the diluted net income per share computation.

New Accounting Pronouncements

In At May 2014, the FASB issued ASU No.2014-09—Revenue from Contracts with Customers. The new standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. In April 2016, the FASB issued Accounting Standards UpdateNo. 2016-10— Revenue from Contracts with Customers (Topic 606), which amends and adds clarity to certain aspects of the guidance set forth in ASU2014-09 related to identifying performance obligations and licensing. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The guidance permits two methods of adoption; a full retrospective method to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the guidance recognized at the date of initial application. The Company has formed a team to evaluate the impact of the adoption of this standard on its consolidated financial statements.

In July 2015, the FASB issued ASU No.2015-11—Inventory: Simplifying the Measurement of Inventory. The update requires inventory not measured using either the last in, first out (LIFO) or the retail inventory methods to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price31, 2018, all potential shares were included in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company will adopt this standard oncomputation.

Leases
On June 1, 20172019, we adopted Topic 842 using the prospective approach and doesdid not expect the adoption will have a material impact on its consolidated financial condition and results of operations.

In September 2015, the FASB issued ASU2015-16—Simplifying the Accounting for Measurement—Period Adjustments. Changesretrospectively apply to the accounting for measurement-period adjustments relate to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill as a result of changes made to the balance sheet amounts of the acquiree. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and instead require the acquiring entity to record these adjustments in the reporting period they are determined. The new standard is effective for public companies for fiscal years beginning after December 15, 2015. The Company has adopted this standard; the adoption has not had a material impact on its consolidated financial condition and results of operations.

The FASB issued ASU No.2015-17—Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes as part of its Simplification Initiative. The amendments eliminate the guidance inprior periods. Topic 740, Income Taxes, that required an entity to separate deferred tax assets and liabilities between current andnon-current amounts in a classified balance sheet. Rather, deferred taxes will be presented asnon-current under the new standard. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 for public companies. Early adoption is permitted. The Company retrospectively adopted ASU2015-17 as of May 31, 2017. On the May 31, 2016 balance sheet,842 requires the Company reclassified $1,775,000 of current deferred tax assets to Deferred Income Taxes, withinNon-current Liabilities. Total assets and total liabilities decreased by $1,775,000.

In February 2016, the FASB issued ASU No.2016-02—Leases to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a

right-of-use
asset representing its right to use the underlying asset for the lease term. Upon adoption of Topic 842, we recognized all leases with terms greater than 12 months in duration on our consolidated balance sheets as
right-of-use
assets and lease liabilities
, each at an approximate balance
of
$
2.0
 million.
Right-of-use
assets are recorded in other assets on our consolidated balance sheets. Current and
non-current
lease liabilities are recorded in other accruals within current liabilities and other
non-current
liabilities, respectively, on our consolidated balance sheets. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessor have not significantly changed from previous U.S. GAAP. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018. Modified retrospective application is permitted with certain practical expedients. Early adoption is permitted. The Company is in the process of evaluating its lessee
We lease various manufacturing, laboratory, warehousing and lessor arrangementsdistribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all of our leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the impact of this amendment on its consolidated financial condition and results of operations. This evaluation includes a review of revenue through leasing arrangements as well as lease expenses, which are primarily through operating lease arrangements at mostpresent value of the Company’s facilities.

In March 2016,lease payments over the FASB issued ASUNo. 2016-09—Compensation-Stock Compensation (Topic 718): Improvementslease term. Our lease terms may include options to Employee Share-Based Payment Accounting to provide guidance that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additionalpaid-in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 with early adoption permitted. The Company will adopt this standard effective June 1, 2017 and currently believes that tax benefits related to share-based payments will result in a lower effective tax rate in fiscal 2018.

In June 2016, the FASB issued ASUNo. 2016-13—Measurement of Credit Losses on Financial Instruments, which changes how companies measure credit losses on most financial instruments measured at amortized cost and certain other instruments, such as loans, receivables andheld-to-maturity debt securities. Rather than generally recognizing credit lossesextend when it is probablereasonably certain that we will exercise that option.

We have made certain assumptions and judgments when applying ASC 842, the loss has been incurred,most significant of which are:
We elected the package of practical expedients available for transition that allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842.
We did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset.
For all asset classes, we elected to not recognize a
right-of-use
asset and lease liability for short-term leases (i.e. leases with a term of 12 months or less).
For all asset classes, we elected to not separate
non-lease
components from lease components to which they relate and have accounted for the combined lease and
non-lease
components as a single lease component.
The determination of the discount rate used in a lease is our incremental borrowing rate that is based on what we would normally pay to borrow on a collateralized basis over a similar term
for
an amount equal to the lease payments.
F-16

Supplemental balance sheet information related to operating leases was as follows:
(in thousands)
May 31,
2020
Right of use
assets
$
1,952
Lease liabilities
current
1,054
Lease liabilities
non-current
913
The weighted average remaining lease term and weighted average discount rate were as follows:
May 31,
2020
Weighted average remaining lease term
2.5 years
Weighted average discount rate
3.2
%
Operating lease expenses are classified as cost of revenues or operating expenses on the revised guidance requires companies to recognize an allowanceconsolidated statements of income. The components of lease expense were as follows:
(in thousands)
  
Year Ended
May 31, 2020
 
Operating leases
 $
  1,207
 
Short term leases
  
166
 
     
Total lease expense
 $
1,373
 
     
Cash paid for credit lossesamounts included in the measurement of lease liabilities for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU2016-13 is effective for fiscal periods beginning after December 15, 2019 and must be adopted as a cumulative effect adjustment to retained earnings. Early adoption is permitted. The Company does not believe the adoption of this guidance will have an impactoperating leases included in cash flows from operations on its consolidated financial statements.

In August 2016, the FASB issued ASUNo. 2016-15—Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force). The amendments in ASU2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows were approximately $1,178,000 for the year ended May 31, 2020. There were 0

non-cash
additions to
right-of-use
assets obtained from new operating lease liabilities for the year ended May 31, 2020.
Undiscounted fut
u
re minimum lease payments as of May 31, 2020 were as follows:
(in thousands)
  
Amount
 
Years ending May 31, 2021
 $
  1,080
 
2022
  
546
 
2023
  
286
 
2024
  
141
 
2025 and thereafter
  
41
 
     
Total lease payments
  
2,094
 
Less: imputed interest
  
(112
)
     
Total lease liabilities
 $
1,982
 
     
At May 31, 2019, under FASB Accounting Standards Codification (FASB ASC) 230, StatementASC 840, Leases, the minimum annual rental payments under our lease agreements were as follows: $1,112,000 in 2020; $810,000 in 2021; $297,000 in 2022; $101,000 in 2023; and none thereafter.
F-17

Revenue Recognition
On June 1, 2018, Neogen adopted ASC Topic 606—Revenue from Contracts with Customers (Topic 606) using the full retrospective approach.
We determine the amount of Cash Flows.revenue to be recognized through application of the following steps:
Identification of the contract with a customer;
Identification of the performance obligations in the contract;
Determination of the transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when or as the Company satisfies the performance obligations.
Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognized revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The amendmentscollectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in ASU2016-15other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.
Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method, for incentives that are effectiveoffered to individual customers, and the expected-value method, for public business entitiesprograms that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.
The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In suc
h
 cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense
when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by
Neogen
are recorded in sales and marketing expense; these expenses totaled $
13,514,000
, $
13,503,000
and $
12,147,000
in fiscal years beginning after December 15, 2017,2020, 2019 and interim periods within those fiscal years. Early adoption2018, respectively. Revenue is permitted, including adoption during an interim period. recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or
reperformance
of service except in the case of quality or warranty issues.
Th
e
se situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.
The Company derives revenue from two primary sources — product revenue and service revenue.
Product revenue consists primarily of shipments of:
Diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;
Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and
Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.
Revenue for Neogen’s products are recognized and invoiced when the product is shipped to the customer.
Service revenue consists primarily of:
Genomic identification and related interpretive bioinformatic services; and
Other commercial laboratory services.
Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.
Payment terms for products and services are generally 30 to 60 days.
F-1
8

The following table presents disaggregated revenue by major product and service categories for the years ended May 31, 2020, 2019 and 2018:
   
Year Ended
 
       
Increase/
       
Increase/
     
(dollars in thousands)
  
May 31, 2020
   
(Decrease)
   
May 31, 2019
   
(Decrease)
   
May 31, 2018
 
Food Safety:
          
Natural Toxins, Allergens & Drug Residues
 $
76,207
   
(3
)%
 $
78,373
   
7
% $
72,962
 
Bacterial & General Sanitation
  
41,780
   
(0
)%  
41,966
   
10
%  
38,156
 
Culture Media & Other
  
47,847
   
(4
)%  
49,857
   
13
%  
44,271
 
Rodenticides, Insecticides & Disinfectants
  
28,890
   
13
%  
25,584
   
7
%  
23,821
 
Genomics Services
  
17,967
   
2
%  
17,694
   
16
%  
15,267
 
                     
  
212,691
   
(0
)%  
213,474
   
10
%  
194,477
 
Animal Safety:
               
Life Sciences
  
6,322
   
(20
)%  
7,858
   
(25
)%  
10,411
 
Veterinary Instruments & Disposables
  
42,941
   
(4
)%  
44,582
   
(7
)%  
47,749
 
Animal Care & Other
  
28,389
   
(5
)%  
29,941
   
(3
)%  
30,930
 
Rodenticides, Insecticides & Disinfectants
  
68,815
   
4
%  
66,389
   
(2
)%  
67,646
 
Genomics Services
  
59,012
   
14
%  
51,942
   
11
%  
46,717
 
                     
  
205,479
   
2
%  
200,712
   
(1
)%  
203,453
 
                     
Total Revenue
 $
  418,170
   
1
% $
  414,186
   
4
% $
  397,930
 
                     
See Note 9 to the consolidated financial statements for disaggregated revenues by
geographical
location.
Revision of Previously Issued Financial Statements
The Company has not yet adopted this updatehistorically classified certain variable consideration components resulting from volume rebates, distributor support, and is currently evaluating the impactother marketing discounts as cost of ASUNo. 2016-15 onrevenues or sales and marketing expense in its consolidated financial statements.

In January 2017,statements of income. These amounts should have been classified as contra revenue in product or service revenues. We had determined in prior periods that the FASBmisstatements were clearly immaterial, individually and in the aggregate, to each of the reporting periods affected. The Company began properly classifying these items as contra revenues beginning in the fiscal year ended May 31, 2019 and revised the financials for fiscal year 2018 to conform to the current period presentation. These immaterial adjustments had no impact on Neogen’s operating income, income before taxes, net income or reported earnings per share, and no change to stockholders’ equity.

Presented below are the effects of the revisions on the line items within our previously issued ASU2017-04—Intangibles—Goodwill and Other (Topic 350). ASU2017-04 simplifies the subsequent measurementconsolidated statements of goodwill by removing the second step of thetwo-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognizedincome for the amount by whichyear ended May 31, 2018. Revised consolidated statements of income related to these periods are presented in this Form 10-K.​​​​​​​
F-
20

 
Year Ended
May 31, 2018
 
   
As
Previously
Reported
   
Adjustments
  
As Revised
 
(in thousands)
 
 
 
 
 
 
Revenues
         
Product revenues
 $
  335,554
  $
  (4,266
) $
  331,288
 
Service revenues
  
66,698
   
(56
)  
66,642
 
             
Total revenues
  
402,252
   
(4,322
)  
397,930
 
Cost of revenues
         
Cost of product revenues
  
174,067
   
(342
)  
173,725
 
Cost of service revenues
  
37,933
   
—  
   
37,933
 
             
Total cost of revenues
  
212,000
   
(342
)  
211,658
 
             
Gross margin
  
190,252
   
(3,980
)  
186,272
 
Operating expenses
         
Sales and marketing
  
70,909
   
(3,980
)  
66,929
 
             
Total operating expenses
  
120,058
   
(3,980
)  
116,078
 
             
Operating income
  
70,194
   
—  
   
70,194
 
             
The revisions had no impact our audited consolidated statement of equity or audited consolidated statement of cash flows for the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company has adopted this amendment; the adoption has not had an impact on its consolidated financial statements.

2. Goodwill and Other Intangible Assets

year ended May 31, 2018.

2.Goodwill and Other Intangible Assets
Management has completed the annual impairment analysis of goodwill and intangible assets with indefinite lives using a quantitative assessment as of the first day of the fourth quarter of fiscal years 2017, 20162020, 2019 and 2015,2018, respectively, and determined that recorded amounts were not impaired and that no write-down was necessary.

The following table
summarizes
goodwill by reportable segment:

(in thousands)  Food Safety   Animal Safety   Total 

Balance, May 31, 2015

  $18,806   $51,313   $70,119 

Goodwill acquired and/or adjusted

   8,083    10,304    18,387 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2016

  $26,889   $61,617   $88,506 

Goodwill acquired and/or adjusted (1)

   19,031    (2,778   16,253 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2017

  $45,920   $58,839   $104,759 
  

 

 

   

 

 

   

 

 

 

(in thousands)
 
Food Safety
 
 
Animal Safety
 
 
Total
 
Balance, May 31, 2018
 $
  40,001
  $
  59,557
  $
99,558
 
Goodwill acquired
  
3,796
   
1,196
   
4,992
 
Goodwill and/or currency adjustments (1)
  
(1,244
)  
313
   
(931
)
             
Balance, May 31, 2019
 $
42,553
  $
61,066
  $
103,619
 
Goodwill acquired
  
6,254
   
2,095
   
8,349
 
Goodwill and/or currency adjustments
 
(1)
  
(1,592
)  
(36
)  
(1,628
)
             
Balance, May 31, 2020
 $
47,215
  $
63,125
  $
110,340
 
             
(1)
Represents
Includes final purchase price allocation adjustmentadjustments and currency adjustments for goodwill recorded at international locations.

At May 31, 2017,2020,
non-amortizable
intangible assets included licenses of $569,000, trademarks of $12,530,000$13,424,000 and other intangibles of $1,224,000. At May 31, 2016,2019,
non-amortizable
intangible assets included licenses of $569,000, trademarks of $7,377,000$13,717,000 and other intangibles of $1,224,000.

F-21

Amortizable intangible assets consisted of the following and are included in customer-based intangible
intangibles
and other
non-current
assets within the consolidated balance sheets:

(in thousands)  Gross
Carrying
Amount
   Less
Accumulated
Amortization
   Net
Carrying
Amount
 

Licenses

  $5,989   $2,011   $3,978 

Covenants not to compete

   1,208    309    899 

Patents

   9,304    4,601    4,703 

Customer-based intangibles

   56,829    20,846    35,983 

Other products and service-related intangibles

   12,065    3,010    9,055 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2017

  $85,395   $30,777   $54,618 
  

 

 

   

 

 

   

 

 

 

Licenses

  $5,189   $1,782   $3,407 

Covenants not to compete

   491    193    298 

Patents

   8,040    3,631    4,409 

Customer-based intangibles

   48,186    17,277    30,909 

Other products and service-related intangibles

   12,256    1,924    10,332 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2016

  $74,162   $24,807   $49,355 
  

 

 

   

 

 

   

 

 

 

(in thousands)
 
Gross
Carrying
Amount
 
 
Less
Accumulated
Amortization
 
 
Net
Carrying
Amount
 
Licenses
 $
10,346
  $
3,330
  $
7,016
 
Covenants not to compete
  
706
   
407
   
299
 
Patents
  
8,509
   
4,118
   
4,391
 
Customer-based intangibles
  
59,847
   
29,898
   
29,949
 
Other products and service-related intangibles
  
16,646
   
6,937
   
9,709
 
             
Balance, May 31, 2020
 $
96,054
  $
44,690
  $
51,364
 
             
Licenses
 $
9,813
  $
3,182
  $
6,631
 
Covenants not to compete
  
862
   
542
   
320
 
Patents
  
8,158
   
3,570
   
4,588
 
Customer-based intangibles
  
57,634
   
28,017
   
29,617
 
Other products and service-related intangibles
  
16,464
   
5,524
   
10,940
 
             
Balance, May 31, 2019
 $
92,931
  $
40,835
  $
52,096
 
             
Amortization expense for intangibles totaled $5,908,000, $4,730,000$6,489,000, $6,309,000 and $4,331,000$6,743,000 in fiscal years 2017, 2016,2020, 2019, and 2015,2018, respectively. The estimated amortization expense for each of the five succeeding fiscal years is as follows: $5,951,000 in 2018, $5,558,000 in 2019, $5,253,000 in 2020, $4,977,000$6,573,000 in 2021, $6,445,000 in 2022, $6,006,000 in 2023, $5,700,000 in 2024 and $4,646,000$5,370,000 in 2022.2025. The amortizable intangible assets useful lives are 2 to 20 years for licenses, 53 to 13 years for covenants not to compete, 5 to 25 years for patents, 5 to 20 years for customer-based intangibles and 25 to 20 years for other product and service-related intangibles, which primarily consist of product formulations. All definite-lived intangibles are amortized on a straight linestraight-line basis with the exception of definite-lived customer-based intangibles and product and service-related intangibles, which are amortized on either a straight-line or an accelerated basis.

3.
Business Combinations

The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions described below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

Fiscal 2015

2018

On OctoberSeptember 1, 2014,2017, the Company acquired allthe assets of The University of Queensland Animal Genetics Laboratory, an animal genomics laboratory located near Brisbane, Australia. This acquisition is intended to accelerate the stockgrowth of BioLumix, Inc., a manufacturerNeogen’s animal genomics business in Australia and marketer of automated systems for the detection of microbial contaminants located in Ann Arbor, Michigan.New Zealand. Consideration for the purchase was $4,514,000$2,063,000; $468,000 was initially paid in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $499,000, other receivable of $178,000, inventory of $421,000 prepaid assets of $48,000, property and equipment of $159,000, current liabilities of $155,000,non-current liabilities of $780,000, intangible assets of $2,090,000 (with an estimated life of5-15 years) andcash with the remainder to goodwill(non-deductible for tax purposes). These values are Level 3 fair value measurements. This business has been relocated to Lansing, Michigan and integrated withdue in annual installments over the Company’s operations there, reporting within the Food Safety segment.

On December 8, 2014, the Company acquired the food safety and veterinary genomic assets of its Chinese distributor Beijing Anapure BioScientific Co., Ltd. Consideration for the purchase was $2,040,000 in cash.next five years. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $525,000, property and$19,000, equipment of $64,000,$419,000,

non-current
liabilities of $1,629,000, intangible assets of $422,000$902,000 (with an estimated life of
5-15
years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business has been integrated into the Company’s subsidiary in China and reports within the Food Safety segment.

Fiscal 2016

On June 1, 2015, the Company acquired the assets of Sterling Test House, a commercial food testing laboratory based in India.

Consideration for the purchase was $1,118,000 in cash and approximately $102,000 of a contingent consideration liability, due in installments on the first two anniversary dates, based on an excess sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $43,000, inventory of

$14,000, property and equipment of $141,000, contingent consideration accrual of $102,000, intangible assets of $345,000 (with an estimated life of5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Food Safety segment. In July 2016, the Company paid the former owner $70,000 for contingent consideration based on the achievement of sales targets, and reduced the recorded liability by a corresponding amount. In May 2016, the Company revised the remaining contingent consideration accrual to Other Income because sales targets for the applicable periods were not achieved.

On August 26, 2015, the Company acquired all of the stock of Lab M Holdings, a developer, manufacturer and supplier of microbiological culture media and diagnostic systems located in the United Kingdom. Consideration for the purchase was $12,436,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included cash of $285,000, accounts receivable of $975,000, inventory of $1,169,000, property and equipment of $3,337,000, other current assets of $309,000, current liabilities of $948,000,non-current deferred tax liability of $784,000, intangible assets of $3,611,000 (with an estimated life of5-15 years) and the remainder to goodwill

(non-deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Food Safety segment.

On December 22, 2015, the Company acquired the rodenticide assets of Virbac Corporation, the North American affiliate of the France-based Virbac group, a global animal health company. The acquired assets include a rodenticide active ingredient that complements Neogen’s existing active ingredients, and more than 40 regulatory approvals for a variety of formulations in the United States, Canada and Mexico. The acquired assets also include a large retail and OEM customer base. Consideration for the purchase was $3,525,000 in cash and up to $300,000 of contingent consideration. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $317,000, property and equipment of $60,000, current liabilities of $300,000, intangible assets of $1,759,000 (with an estimated life of5-15 years),non-amortizable trademarks of $200,000 and the remainder to goodwill (deductible

for tax purposes). These values are Level 3 fair value measurements. The products are manufactured at the Company’s production facilitybusiness, renamed Neogen Australasia, continues to operate in Randolph, Wisconsin, and reportits current location, reporting within the Animal Safety
segment. In fiscal 2016,
F-22

Fiscal 2019
On August 1, 2018, the Company paid the former owner $300,000acquired
all of contingent consideration based on the achievement of specific objectives, and reduced the recorded liability by a corresponding amount.

On April 26, 2016, the Company acquired

the stock of Deoxi Biotecnologia Ltda.Clarus Labs, Inc., an animal genomics laboratory located in Aracatuba, Brazil. Thisa manufacturer of water testing products. Neogen has distributed Clarus’ Colitag water test to the food and beverage industries since 2004; this acquisition is intendedhas given the Company the ability to help accelerate the growth of Neogen’s animal genomics services in Brazil.sell this product to new markets. Consideration for the purchase was $1,549,000$4,204,000 in cash and up to $2,552,000$1,256,000 of contingent consideration, due at the end of each ofsemiannually for the first twofive years, based on an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $132,000, inventory of $89,000, other current assets of $9,000, property$32,000, machinery and equipment of $232,000, current liabilities$120,000, accounts payable of $266,000,$53,000, contingent consideration accrual of $453,000,$1,256,000,
non-current
deferred tax liability of $184,000 $544,000,
non-amortizable trademarks of $193,000,
intangible assets of $350,000$878,000, intangible assets of $1,487,000 (with an estimated life of5-10
5-15
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. Since February 2019, $270,000 has been paid to the former owners as contingent consideration from the accrual. Manufacturing of these products was moved to the Company’s Lansing, Michigan location in October 2018, reporting within the Food Safety segment.
On September 4, 2018, the Company acquired the assets of Livestock Genetic Services, LLC, a Virginia-based company that specializes in genetic evaluations and data management for cattle breeding organizations. Livestock Genetic Services had been a long-time strategic partner of Neogen and the acquisition enhanced the Company’s
in-house
genetic evaluation capabilities. Consideration for the purchase was $1,100,000 in cash, with $700,000 paid at closing and $400,000 payable to the former owner on September 1, 2019, and up to $585,000 of contingent consideration, payable over the next three years. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included office equipment of $15,000, contingent consideration accrual of $385,000, intangible assets of $942,000 (with an estimated life of
5-15
years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and is managed by Neogen do Brasil, reporting withinIn September 2019, the Food Safety segment. In June 2017, the Companyformer owner was paid the former owners $393,000$400,000 installment of the purchase price owed and was also paid $107,000 in contingent consideration based on the achievement of sales targets and charged $14,000 to Other Income; $60,000 remains accrued for contingent considerationin the first year. Services provided by this operation are now performed at the end ofCompany’s Lincoln, Nebraska location, reporting within the second year.

Animal Safety segment.

On MayJanuary 1, 2016,2019, the Company acquired the stockassets of Preserve InternationalEdmonton, Alberta based Delta Genomics Centre, an animal genomics laboratory in Canada. Delta’s laboratory operations were renamed Neogen Canada and its sister company, Tetradyne LLC, manufacturers and marketersthe acquisition was intended to accelerate growth of cleaners, disinfectants and associated products to the swine, poultry, food processing and dairy markets. Preserve and Tetradyne have manufacturing locationsCompany’s animal genomics business in Memphis, Tennessee and Turlock, California.Canada. Consideration for the purchase was $24,245,000$1,485,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,629,000, inventory of $1,964,000, other current assets of $269,000, land, property$38,000, machinery and equipment of $1,625,000, current liabilities$371,000, unearned revenue liability of $987,000,non-current liabilities of $660,000,$125,000, intangible assets of $11,950,000$532,000 (with an estimated life of5-15 years),non-amortizable trademarks of $2,600,000, and the remainder 5 to goodwill (partially deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current locations and reports within the Animal Safety segment.

Fiscal 2017

On December 1, 2016, the Company acquired the stock of Quat-Chem Ltd., a chemical company that manufactures biosecurity products, based in Rochdale, England. Consideration for the purchase was $21,606,000 in cash and up to $3,778,000 of contingent consideration, due at the end of each of the first two years, based on an excess net sales formula. The preliminary purchase price allocation included accounts receivable of $4,684,000, inventory of $1,243,000, land, property and equipment of $2,715,000, accounts payable of $2,197,000, deferred tax liability of $1,133,000, contingent consideration accrual of $1,105,000, other current liabilities of $604,000,non-amortizable intangible assets of $1,637,000, intangible assets of $5,682,000 (with an estimated life of5-15 years) and the remainder to goodwill(non-deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and is managed by Neogen Europe, reporting within the Food Safety segment.

On December 27, 2016, the Company acquired the stock of Rogama Industria e Comercio, Ltda., a company that develops and manufactures rodenticides and insecticides, based near Sao Paulo, Brazil. Consideration for the purchase was $12,423,000 in cash and up to $2,069,000 of contingent consideration, due at the end of each of the first two years, based on an excess net sales formula. The preliminary purchase price allocation included accounts receivable of $1,863,000, inventory of $1,026,000, property and equipment of $1,840,000, current liabilities of $2,177,000, contingent consideration accrual of $430,000,non-current deferred tax liability of $1,307,000,non-amortizable intangible assets of $591,000, intangible assets of $3,252,000 (with an estimated life of5-1510 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. Services provided by this operation continue to be performed in Edmonton, reporting within the Animal Safety segment.

Fiscal 2020
On January 1, 2020, the Company acquired
all of
the stock of Productos Quimicos Magiar, a distributor of Neogen’s Food Safety products for the past 20 years, located in Argentina.
This businessacquisition gives Neogen a direct sales presence in Argentina.
Consideration for the purchase was $3,776,000 in net cash, with $3,237,000 paid at closing and $540,000 payable to the former owner on January 1, 2022, and up to $979,000 of contingent consideration, payable in one year, based upon an excess net sales formula. The
preliminary
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $603,000, inventory of $446,000, machinery and equipment of $36,000, other current assets of $221,000, accounts payable of $383,000, other current liabilities of $312,000, contingent consideration accrual of $640,000,
non-current
deferred tax liabilities of $441,000, intangible assets of $1,471,000 (with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This operation continues to operate infrom its current location and is managed by Neogen do Brasil,in Buenos Aires, Argentina, reporting within the Food Safety segment.

It is managed through Neogen’s Latin America operation.
On January 1, 2020, the Company acquired
 all
 of
 the stock of Productos Quimicos Magiar, a distributor of Neogen’s Food Safety products for the past
20 years, located in Uruguay.
This acquisition gives Neogen a direct sales presence in Uruguay.
Consideration for the purchase was $1,488,000 in net cash, with $1,278,000 paid at closing and $210,000 payable to the former owner on January 1, 2022, and up to $241,000 in contingent consideration, payable in one year, based upon an excess net sales formula. The
preliminary
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $280,000, inventory of $174,000, machinery and equipment of
$16,000, other current assets of $68,000, accounts payable of $204,000, other current
liabilities of $11,000, contingent consideration accrual of
F-23

$159,000,
non-current
deferred tax liabilities of $99,000, intangible assets of $398,000 (with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This operation continues to operate from its current location in Montevideo, Uruguay, reporting within the Food Safety segment. It is managed through Neogen’s Latin America operation.
On January 9, 2020, the Company acquired the stock of Diessechem Srl, a distributor of food and feed diagnostics for the past 27 years, located
in
Italy.
This acquisition gives Neogen a direct sales presence in Italy.
Consideration for the purchase was $3,455,000 in net cash. The
preliminary
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $780,000, inventory of $5,000, other current assets of $160,000, accounts payable of $140,000, other current liabilities of $305,000,
non-current
deferred tax liabilities of $294,000, intangible assets of $1,225,000 (with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This operation continues to operate from its current location in Milan, Italy, reporting within the Food Safety segment. It is managed through Neogen’s Scotland operation.
On January 31, 2020, the Company acquired the stock of Abtek Biologicals Limited, a manufacturer and supplier of culture media supplements and microbiology technologies. This acquisition enhances the Company’s culture media product line offering for the worldwide industrial microbiology markets. Consideration for the purchase was $1,401,000 in net cash, with $1,282,000 paid at closing and $119,000 payable to the former owner on January 31, 2021. The
preliminary
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $135,000, inventory of $207,000, machinery and equipment of $105,000, prepayments of $6,000, accounts payable of $118,000, other current liabilities of $34,000,
non-current
deferred tax liabilities of $92,000, intangible assets of $484,000 (with an estimated life of
5-10
years) and the remainder to goodwill
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This manufacturing operation continues to operate from its current location in Liverpool, England, reporting within the Food Safety segment. It is managed through Neogen’s Scotland operation.
On February 28, 2020, the Company acquired the assets of Cell BioSciences, an Australian distributor of food safety and industrial microbiology products. This acquisition gave Neogen a direct sales presence across Australasia for its entire product portfolio. Consideration for the purchase was $3,768,000 in cash, with $3,596,000 paid at closing and $172,000 payable in one year. The
preliminary
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $420,000, unearned revenue liability of $13,000, intangible assets of $1,338,000 (with an estimated life of 3 to 10 years) and the remainder to goodwill
(non-deductible
for tax purposes). The business operates in Gatton, Australia, reporting within the Australian operations in the Animal Safety segment.
On March 26, 2020, the Company acquired the assets of Chile-based Magiar Chilena, a distributor of food, animal and plant diagnostics, including Neogen products.
This acquisition gives Neogen a direct sales presence in Chile.
Consideration for the purchase was $400,000 in cash, with $350,000 paid at closing and $50,000 payable to the former owner on March 26, 2021. The
preliminary
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $164,000, machinery and equipment of $53,000, and intangible assets of $183,000 (with an estimated life of
5-10
years). The business is operated from its current location in Santiago, Chile, reporting within the Food Safety segment. It is managed through Neogen’s Latin America operation.
For each acquisition listed above, the revenues and net income were not considered material and were therefore not disclosed.
4.Long-Term Debt

The Company has a financing agreement with a bank providing for ana $15,000,000 unsecured revolving line of credit, which was amendedexpires on November 30, 2016 to increase the line from $12,000,000 to $15,000,000, and extend the maturity from September 1, 2017 to September 30, 2019.2021. There were no0 advances against the line of credit during fiscal years 20162020 and 2017;2019; there was no0 balance outstanding at May 31, 2017.2020. Interest on any borrowings is at LIBOR plus 100 basis points (rate under the terms of the agreement was 2.04%1.24% at May 31, 2017)2020). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which
EBITDA; the Company believes it was in compliance with these covenants at May 31, 2017.

2020.

F-24

5.Equity Compensation Plans

Qualified

Incentive and
non-qualified
options to purchase shares of common stock may behave been granted to directors, officers and employees of the CompanyNeogen under the terms of the Company’s stock option plans. These options arewere granted at an exercise price of not less than the fair market value of the stock on the date of grant. Remaining shares available for grant under stock option plans were 1,894,000, 2,457,0003,501,000, 3,997,000 and 306,0001,913,000 at May 31, 2017, 20162020, 2019 and 2015,2018, respectively. Options vest ratably over three and five year-year periods and the contractual terms are generally five or ten years.

(options in thousands)  Options   Weighted-Average
Exercise Price
   Weighted-Average
Grant Date Fair  Value
 

Outstanding at May 31, 2014 (577 exercisable)

   1,869    25.69    7.62 

Granted

   536    39.79    11.91 

Exercised

   (380   16.69    5.17 

Forfeited

   (37   33.55    9.45 
  

 

 

     

Outstanding at May 31, 2015 (639 exercisable)

   1,988    31.04    9.20 

Granted

   549    46.98    13.11 

Exercised

   (427   23.47    7.15 

Forfeited

   (29   38.57    11.14 
  

 

 

     

Outstanding at May 31, 2016 (656 exercisable)

   2,081    36.71    10.63 

Granted

   621    54.24    15.86 

Exercised

   (620   30.42    9.03 

Forfeited

   (58   42.72    12.22 
  

 

 

     

Outstanding at May 31, 2017 (496 exercisable)

   2,024    43.84    12.68 
  

 

 

     

(options in thousands)
  
Options
   
Weighted-Average

Exercise Price
   
Weighted-Average
Grant Date Fair Value
 
Outstanding at May 31, 2017 (661 exercisable)
  
2,699
  $
  32.88
  $
9.51
 
Granted
  
829
   
59.37
   
14.47
 
Exercised
  
(821
)  
28.18
   
8.20
 
Forfeited
  
(208
)  
39.57
   
11.12
 
             
Outstanding at May 31, 2018 (508 exercisable)
  
2,499
   
42.63
   
11.44
 
Granted
  
527
   
62.92
   
14.91
 
Exercised
  
(513
)  
31.28
   
8.92
 
Forfeited
  
(128
)  
47.08
   
12.42
 
             
Outstanding at May 31, 2019 (617 exercisable)
  
2,385
   
49.37
   
12.70
 
Granted
  
562
   
63.91
   
15.56
 
Exercised
  
(719
)  
40.24
   
11.05
 
Forfeited
  
(66
)  
57.44
   
14.20
 
             
Outstanding at May 31, 2020 (486 exercisable)
  
2,162
   
55.96
   
13.95
 
             
The following is a summary of stock options outstanding at May 31, 2017:

(options in thousands)        
   Options Outstanding   Options Exercisable 

Range of Exercise Price

  Number   Average
Contractual Life
(in years)
   Weighted-Average
Exercise Price
   Number   Weighted-Average
Exercise Price
 

$  11.02 - $36.26

   491    1.8   $31.22    268   $29.16 

$  36.27 - $40.87

   382    2.8    39.57    113    39.54 

$  40.88 - $49.68

   536    4.1    46.52    115    45.12 

$  49.69 - $54.55

   576    4.7    53.94    —      —   

$  54.56 - $65.71

   39    7.7    58.74    —      —   
  

 

 

       

 

 

   
   2,024    3.5    43.84    496    35.23 

2020:

(options in thousands)
  
Options Outstanding
   
Options Exercisable
 
       
Average
             
       
Contractual Life
   
Weighted-Average
       
Weighted-Average
 
Range of Exercise Price
  
Number
   
(in years)
   
Exercise Price
   
Number
   
Exercise Price
 
$16.82 - $40.91
  
507
   
1.4
  $
  37.26
   
208
  $
  34.94
 
$40.92 - $61.56
  
605
   
2.6
   
58.59
   
183
   
57.43
 
$61.57 - $62.88
  
465
   
3.5
   
62.70
   
85
   
62.70
 
$62.89 - $64.05
  
539
   
4.4
   
63.90
   
—  
   
 
$64.06 - $68.96
  
46
   
3.6
   
66.48
   
10
   
67.98
 
                     
  
2,162
   
3.0
   
55.96
   
486
   
48.94
 
The weighted average exercise price of shares that were exercisable at May 31, 20172020 and 20162019 was $35.23$48.94 and $29.69,$40.68, respectively.

Compensation expense related to share-based awards was $5,261,000, $5,468,000$6,468,000, $5,543,000 and $4,450,000$4,909,000 in fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. Remaining compensation cost to be expensed in future periods for
non-vested
options was $10,999,000$16,949,000 at May 31, 2017,2020, with a weighted average expense recognition period of 3.33.2 years.

 
Year Ended
 
(in thousands)
 
May 31
, 2020
 
 
May 31
, 2019
 
 
May 31
, 2018
 
Aggregate intrinsic value of options outstanding
 $
  32,988
  $
  22,798
  $
  82,649
 
Aggregate intrinsic value of options exercisable
  
10,814
   
10,222
   
22,572
 
Aggregate intrinsic value of options exercised
  
19,597
   
21,382
   
25,844
 
F-2
4

The aggregate intrinsic value of options outstanding and options exercisable was $39,388,000 and $13,929,000, respectively, at May 31, 2017, $26,344,000 and $12,912,000 respectively, at May 31, 2016 and $31,204,000 and $14,201,000 respectively, at May 31, 2015. The aggregate intrinsic value of options exercised during the year was $18,067,000 in fiscal 2017, $12,980,000 in fiscal 2016 and $10,690,000 in fiscal 2015.

Common stock totaling 8,725 of the 337,500 originally authorized shares are reserved for issuance under the terms of the 2002 Employee Stock Purchase Plan. An additional 375,000 shares are also reserved for issuance under the terms of the 2011 Employee Stock Purchase Plan. The plans giveCompany offers eligible employees the

option
to purchase common stock at a 5% discount to the lower of the market value of the stock at the beginning or end of each participation period;period under the terms of the 2011 Employee Stock Purchase Plan; the discount is recorded in general and administrative expense. Total individual purchases in any year are limited to 10% of compensation. Shares purchased by employees through this program were 18,715, 18,277 and 19,59221,578 in fiscal years 2017, 20162020, 18,330 in fiscal 2019 and 2015, respectively.

22,127 in fiscal 2018.

Common
stock totaling 343,817 of the 712,500 authorized shares are reserved for issuance under the plan.
6.Income Taxes

Income before income taxes by source consists of the following amounts:

   Year ended May 31 
(in thousands)  2017   2016   2015 

U.S.

  $55,171   $50,662   $45,156 

Foreign

   11,502    4,851    6,920 
  

 

 

   

 

 

   

 

 

 
  $66,673   $55,513   $52,076 
  

 

 

   

 

 

   

 

 

 

 
Year ended May 31
 
(in thousands)
 
2020
 
 
2019
 
 
2018
 
U.S.
 $
62,329
  $
58,479
  $
62,310
 
Foreign
  
9,976
   
14,480
   
11,155
 
             
 $
72,305
  $
72,959
  $
73,465
 
             
The provision for income taxes consistedconsists of the following:

   Year ended May 31 
(in thousands)  2017   2016   2015 

Current:

      

U.S. Taxes

  $20,259   $14,630   $15,269 

Foreign

   2,514    1,756    1,364 

Deferred

   (73   2,589    1,867 
  

 

 

   

 

 

   

 

 

 
  $22,700   $18,975   $18,500 
  

 

 

   

 

 

   

 

 

 

 
Year ended May 31
 
(in thousands)
 
2020
 
 
2019
 
 
2018
 
Current
         
Domestic
         
Federal
 $
6,886
  $
7,173
  $
  9,715
 
Uncertain tax provision
  
269
   
13
   
(963
)
State
  
1,262
   
1,265
   
1,377
 
Foreign
  
2,475
   
3,758
   
3,066
 
Deferred
         
Domestic
         
Federal
  
1,964
   
1,031
   
(1,981
)
State
  
195
   
98
   
(355
)
Foreign
  
(221
)  
(555
)  
(609
)
 
             
Provision for Income Taxes
 $
12,830
  $
12,783
  $
10,250
 
             
F-26

The reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax expense is as follows:

   Year ended May 31 
(in thousands)  2017   2016   2015 

Tax at U.S. statutory rate

  $23,336   $19,429   $18,227 

Section 199 domestic production deduction

   (1,057   (1,143   (1,067

Foreign rate differential

   (1,247   (699   (949

Subpart F income

   996    1,049    1,396 

Tax credits and other

   (300   337    39 

Provision for state income taxes, net of federal benefit

   972    779    854 

Amended U.S. Federal tax returns FY12, FY13 & FY14

   —      (777   —   
  

 

 

   

 

 

   

 

 

 
  $22,700   $18,975   $18,500 
  

 

 

   

 

 

   

 

 

 

 
Year ended May 31
 
(in thousands)
 
2020
 
 
2019
 
 
2018
 
Tax at U.S. statutory rate
 $
15,184
  $
15,321
  $
21,459
 
Permanent differences
  
360
   
(56
)   
Section 199 domestic production deduction
  
—  
   
—  
   
(1,167
)
Global intangible
low-taxed
income (GILTI)
  
438
   
840
   
—  
 
Foreign derived intangible income deduction (FDII)
  
(1,120
)  
(1,531
)  
—  
 
Foreign rate differential
  
(182
)  
495
   
(461
)
Subpart F income
  
634
   
842
   
816
 
Tax benefits on stock-based compensation
  
(1,998
)  
(2,586
)  
(4,816
)
Changes in tax contingencies - Increase/(Release)
  
269
   
13
   
(1,035
)
Provision for state income taxes, net of federal benefit
  
1,412
   
1,251
   
975
 
Remeasurement of deferred taxes
  
—  
   
—  
   
(6,022
)
Transition tax on foreign earnings and profits
  
—  
   
—  
   
1,223
 
Tax
c
redits
  
(1,417
)  
(1,726
)  
(1,151
)
Other
   (750   (80   429 
             
Tax Expense
 $
12,830
  $
12,783
  $
10,250
 
             
On June 1, 2017, the Company adopted ASU No.
2016-09—Compensation-Stock
Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies the accounting for share-based payments to employees. The guidance requires the recognition of the income effects of awards in the income statement when the awards vest or are settled, thus eliminating additional
paid-in
capital pools. The guidance also allows for a policy election to account for forfeitures as they occur, rather than on an estimated basis, and requires that excess tax benefits be classified as an operating activity on the Statement of Cash Flows. The adoption of this ASU decreased income tax expense by $2.0 million in fiscal 2020, by $2.6 million in fiscal 2019 and by $4.8 million in fiscal 2018.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the U.S. Tax Act) was signed into law, making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a territorial system, and a
one-time
transition tax on the mandatory deemed repatriation of foreign earnings. The U.S. Tax Act also includes a provision to tax global intangible
low-taxed
income (GILTI) of foreign subsidiaries and a deduction for foreign derived intangible income (FDII), both of which became effective for the Company beginning June 1, 2018.
In fiscal 2018, the Company recorded a net benefit of $4.8 million related to the U.S. Tax Act, due to the impact of the reduction in the tax rate on deferred tax assets and liabilities of $6.0 million, partially offset by $1.2 million of
one-time
transition tax on the deemed repatriation of foreign earnings. In fiscal 2019, the Company finalized its calculation of these amounts and recorded immaterial adjustments to income tax expense; the Company also recorded expense of $840,000 related to GILTI and a tax benefit of $1.5 million related to FDII.
Foreign tax credits, primarily offsetting taxes associated with Subpart F and GILTI income, were $945,000, $1,296,000 and $791,000 in fiscal years 2020, 2019 and 2018, respectively. The Company’s U.S.
research and development credits
were $472,000, $430,000 and $422,000 in fiscal years 2020, 2019 and 2018, respectively.
F-2
6

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’sour deferred income tax liabilities and assets are as follows:

   Year ended May 31 
(in thousands)  2017   2016 

Deferred income tax liabilities

    

Indefinite and long-lived assets

  $(23,177  $(19,296

Prepaid expenses

   (640   (824

Brazil valuation allowance

   —      (542
  

 

 

   

 

 

 
   (23,817   (20,662

Deferred income tax assets

    

Stock Options

   2,604    2,786 

Inventories and accounts receivable

   2,603    2,076 

Tax loss carryforwards

   436    813 

Accrued expenses and other

   1,126    229 
  

 

 

   

 

 

 
   6,769    5,904 
  

 

 

   

 

 

 

Net deferred income tax liabilities

  $(17,048  $(14,758
  

 

 

   

 

 

 

 
Year ended May 31
 
(in thousands)
 
2020
 
 
2019
 
Deferred income tax liabilities
      
Indefinite and long-lived assets
 $
(20,867
) $
(18,963
)
Prepaid expenses
  
(795
)  
(586
)
         
  
(21,662
)  
(19,549
)
Deferred income tax assets
      
Stock
o
ptions
  
1,479
   
1,497
 
Inventories and accounts receivable
  
1,336
   
1,315
 
Tax loss carryforwards
  
484
   
417
 
Accrued expenses and other
  
657
   
1,109
 
Less: Valuation
a
llowance
  
(419
)  
(407
)
         
  
3,537
   
3,931
 
         
Net deferred income tax liabilities
 $
(18,125
) $
(15,618
)
         
The Company had no accrualhas the following net operating loss carryforwards:
 
As of
 
 
 
Jurisdiction
 
May 31, 2020
 
 
Expiry
 
U.S.
 $
408
   
2037 to indefinite
 
Foreign
  
1,354
   
2024 to 2039
 
         
 $
  1,762
    
         
We are subject to income taxes in the U.S. (federal and state) and in num
e
rous foreign jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for unrecognizedincome taxes. During the ordinary course of business, there are transactions and calculations for which the ultimate tax benefits at both May 31, 2017determination is uncertain. We establish reserves for
tax-related
uncertainties based on estimates of whether, and 2016. Should the accrual of any interest or penalties relativeextent to unrecognized tax benefits be necessary, such accrualswhich, additional taxes will be reflected withindue. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.
The reconciliation of our tax accounts.
uncertainties
is as follows:
 
Year ended May 31
 
(in thousands)
 
2020
 
 
2019
 
 
2018
 
Beginning balance
 $
611
  $
598
  $
1,633
 
Increase/(decrease) related to prior periods
  
56
   
(106
)  
(1,157
)
 
Increase to current period
  
213
   
119
   
122
 
             
Ending balance
 $
880
  $
611
  $
598
 
             
The Company is under auditno longer subject to examination by the Internal Revenue Service for tax years 2014-2016.

fiscal year 2016 and preceding years.

F-
27

7.Commitments and Contingencies

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company expensescurrently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. We expense these annual costs of remediation, which have ranged from $38,000
$
38,000
to $57,000 $
131,000
per year over the past
five years.years
. The Company’s estimated liability for these costs is $916,000 was $
916,000
at both May 
31 2017
,
2020
and 2016,
2019
, measured on an
undiscounted
basis over an estimated period of
15
years; $54,000 $
100,000
of the liability is recorded within current liabilities and the remainder is recorded within other
non-current
liabilities in the consolidated balance sheet.

In fiscal

2019
, the Company performed an updated Corrective Measures Study (CMS) on the site, per a request from the Wisconsin Department of Natural Resources (WDNR), and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. At this time, the outcome in terms of approach and future costs is unknown, but a change in the current remediation strategy, depending on the alternative selected, could require an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded.
The Company has agreements with unrelated third parties that provide for the payment of license fees and royalties on the sale of certain products. Royalty expense, recorded in sales and marketing, under the terms of these agreements was $2,659,000, $1,969,000$2,524,000, $2,795,000 and $2,189,000$2,876,000 for fiscal years 2017, 20162020, 2019 and 2015,2018, respectively. Some of these agreements provide for guaranteed minimum royalty payments to be paid each fiscal year by the Company for certain technologies. Future minimum royalty payments are as follows: 2018—$625,000, 2019—$659,000, 2020—$666,000, 2021—$674,000182,000, 2022—$110,000, 2023—$105,000, 2024—$105,000 and 2022—2025—$597,000.

The Company leases105,000.

We lease office and manufacturing facilities, vehicles and equipment under
non-cancelable
operating leases. Rent expense for fiscal years 2017, 20162020, 2019 and 20152018 was $729,000, $662,000
$
1,373,000
, $
1,633,000
and $736,000, $
1,083,000
,
respectively. Future fiscal year minimum rental payments for these leases over their remaining terms are as follows: 2018—$591,000, 2019—$292,000, 2020—$88,000, 2021 – $87,000 and 2022 later—$91,000.

The Company is subject to certain legal and other proceedings in the
normal
course of business that, in the opinion of management, shouldare not expected to have a material effect on its future results of operations or financial position.

8.
Defined Contribution Benefit
Plan

The Company maintains a defined contribution 401(k) benefit plan covering substantially all
domestic
employees. Employees are permitted to defer compensation up to IRS limits, with the CompanyNeogen matching 100% of the first 3% of deferred compensation and 50% of the next 2% deferred. The Company’s
of deferred compensation. Neogen’s expense under this plan was $1,259,000, $1,188,000,
$
1,535,000
, $
1,361,000
, and $1,051,000 $
1,325,000
in fiscal years 2017, 2016
2020
,
2019
and 2015,
2018
, respectively.

9.Segment Information

The Company has two2 reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants, and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Neogen’s international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s Food Safetysales and marketing of our food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer the Company’s complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, this operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.
The accounting policies of each of the segments are the same as those described in Note 1.

F-
28

Segment information is as follows:

(in thousands)  Food Safety   Animal Safety   Corporate and
Eliminations (1)
  Total 

Fiscal 2017

       

Product revenues to external customers

  $155,795   $150,717   $—    $306,512 

Service revenues to external customers

   15,530    39,552    —     55,082 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total revenues to external customers

   171,325    190,269    —     361,594 

Operating income (loss)

   33,971    34,841    (3,867  64,945 

Depreciation and amortization

   7,088    7,603    —     14,691 

Total Assets

   190,895    210,927    126,587   528,409 

Expenditures for long-lived assets

   10,332    4,246    —     14,578 

Fiscal 2016

       

Product revenues to external customers

  $133,743   $139,827   $—    $273,570 

Service revenues to external customers

   12,678    35,027    —     47,705 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total revenues to external customers

   146,421    174,854    —     321,275 

Operating income (loss)

   28,984    30,978    (3,576  56,386 

Depreciation and amortization

   5,609    6,572    —     12,181 

Total Assets

   143,303    215,374    91,263   449,940 

Expenditures for long-lived assets

   9,192    5,030    —     14,222 

Fiscal 2015

       

Product revenues to external customers

  $119,990   $123,919   $—    $243,909 

Service revenues to external customers

   11,489    27,676    —     39,165 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total revenues to external customers

   131,479    151,595    —     283,074 

Operating income (loss)

   30,265    26,034    (3,181  53,118 

Depreciation and amortization

   4,620    6,029    —     10,649 

Total Assets

   110,655    179,082    102,444   392,181 

Expenditures for long-lived assets

   4,216    5,403    —     9,619 

(in thousands)
 
Food Safety
 
 
Animal Safety
 
 
Corporate and
Eliminations (1)
 
 
Total
 
Fiscal 2020
            
Product revenues to external customers
 $
189,893
  $
  145,646
  $
—  
  $
335,539
 
Service revenues to external customers
  
22,798
   
59,833
   
—  
   
82,631
 
                 
Total revenues to external customers
  
212,691
   
205,479
   
—  
   
418,170
 
Operating income (loss)
  
33,526
   
39,051
   
(5,054
)  
67,523
 
Depreciation and amortization
  
10,173
   
8,223
   
—  
   
18,396
 
Total Assets
  
222,331
   
231,178
   
343,673
   
797,182
 
Expenditures for long-lived assets
  
15,867
   
8,185
   
—  
   
24,052
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal 2019
            
Product revenues to external customers
 $
190,675
  $
148,764
  $
—  
  $
339,439
 
Service revenues to external customers
  
22,799
   
51,948
   
—  
   
74,747
 
                 
Total revenues to external customers
  
213,474
   
200,712
   
—  
   
414,186
 
Operating income (loss)
  
39,020
   
33,875
   
(4,801
)  
68,094
 
Depreciation and amortization
  
9,525
   
8,099
   
—  
   
17,624
 
Total Assets
  
206,267
   
221,950
   
267,523
   
695,740
 
Expenditures for long-lived assets
  
8,916
   
5,745
   
—  
   
14,661
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal 2018
            
Product revenues to external customers
 $
174,553
  $
156,735
  $
—  
  $
331,288
 
Service revenues to external customers
  
19,924
   
46,718
   
—  
   
66,642
 
                 
Total revenues to external customers
  
194,477
   
203,453
   
—  
   
397,930
 
Operating income (loss)
  
34,561
   
39,529
   
(3,896
)  
70,194
 
Depreciation and amortization
  
9,083
   
7,975
   
—  
   
17,058
 
Total Assets
  
186,570
   
220,629
   
210,810
   
618,009
 
Expenditures for long-lived assets  10,538   10,408   —     20,946 
(1)Includes corporate assets, including cash and cash equivalents, marketable securities, current and deferred tax accounts, and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions and
non-controlling
interests.

Revenues to customers located outside the United States amounted to $129,322,000 or 35.8% of consolidated revenues in fiscal 2017, $107,680,000 or 33.5% in fiscal 2016 and $103,867,000 or 36.7% in fiscal 2015 and were derived primarily in various countries throughout Europe, Canada, South and Central America and Asia. No customer represented revenues in excess of 10% of consolidated net sales in any of the three years.

F-30

The United States based operations represent 76% offollowing table presents the Company’s long-lived assets as of May 31, 2017 and 89% as May 31, 2016.

revenue disaggregated by geographical location:

 
Year ended May 31
 
(in thousands)
 
2020
 
 
2019
 
Domestic
 $
253,458
  $
248,304
 
International
  
164,712
   
165,882
 
         
Total revenue
  
418,170
   
414,186
 
         
10.
Stock RepurchaseRepurchases

In December 2008,October 2018, the Company’s Board of Directors passed a resolution terminating the Company’s prior stock buyback program, which had been approved in December 2008, and authorized a new program to purchase, subject to market conditions, up to 1,125,000
3,000,000 shares of the Company’s common stock. As of May 31, 2017, 112,026 cumulative In December 2018, the Company purchased 50,000
shares have been purchasedunder the new program in negotiated and open market transactions for a total price, including commissions, of approximately $923,000. There were no purchases in fiscal years 2017, 2016 or 2015.
 $
3,134,727
.
Shares purchasedacquired under the program were retired.

A total of 2,950,000 shares of common stock remain available for repurchase under this program as of May 31, 2020.
11.Summary of Quarterly Data (Unaudited)

  Quarter Ended 
 
Quarter Ended
 
(in thousands, except per share)  August
2016
   November
2016
   February
2017
   May
2017
 
  
August
2019
 
  
November
2019
 
  
February
2020
 
  
May 2020
 

Total Revenue

  $83,645   $90,717   $88,385   $98,847  $
101,424
  $
107,803
  $
99,869
  $
109,074
 

Gross Margin

   40,479    43,591    40,880    47,018   
48,194
   
51,026
   
45,330
   
51,729
 

Net income

   9,934    11,171    10,377    12,491   
14,652
   
16,276
   
12,200
   
16,347
 

Net income attributable to Neogen

   9,881    11,151    10,287    12,474 

Basic net income per share

   0.26    0.29    0.27    0.34  $
0.28
  $
0.31
  $
0.23
  $
0.31
 

Diluted net income per share

   0.26    0.29    0.27    0.32  $
0.28
  $
0.31
  $
0.23
  $
0.31
 
   
  Quarter Ended 
 
Quarter Ended
 
(in thousands, except per share)  August
2015
   November
2015
   February
2016
   May
2016
 
  
August
2018
 
  
November
2018
 
  
February
2019
 
  
May 2019
 

Total Revenue

  $74,860   $79,610   $76,725   $90,080  $
99,626
  $
107,098
  $
97,700
  $
109,762
 

Gross Margin

   37,792    38,224    35,196    41,852   
46,729
   
50,033
   
44,628
   
50,530
 

Net income

   9,289    9,142    8,289    9,818   
15,237
   
16,051
   
13,073
   
15,815
 

Net income attributable to Neogen

   9,323    9,073    8,311    9,857 

Basic net income per share

   0.25    0.24    0.22    0.27  $
0.29
  $
0.31
  $
0.25
  $
0.31
 

Diluted net income per share

   0.25    0.24    0.22    0.26  $
0.29
  $
0.31
  $
0.25
  $
0.30
 
Quarterly net income per share is based on weighted-average shares outstanding and potentially dilutive stock options for the specific period and as a result, will not necessarily aggregate to total net income per share as computed for the year as disclosed in the consolidated statements of income.

F-21

F-
30